Cover Page for Protocol 
 
Sponsor name:  [CONTACT_3454] A/S 
NCT number [STUDY_ID_REMOVED] 
Sponsor trial ID: NN9924-4222 
Official title of study: Effi cacy and long-term safety of oral semaglutide versus 
sitagliptin in subjec ts with type 2 diabetes 
Document date: 21-November-[ADDRESS_694602] of contents
Protocol ....................................................... ............................................................... .........................
Attachment I and II............................................ ............................................................... .................
Appendix A - Calcitonin monitoring .............................. ............................................................... ...
Appendix B - Adverse events requiring additional data collection ................................................
Protocol amendment 1 - Global ................................... ............................................................... ......
Protocol amendment 2 - Global ................................... ............................................................... ......
Protocol amendment 1 - FR....................................... ............................................................... .........
Protocol amendment 2 - FR....................................... ............................................................... .........
Protocol amendment 3 - FR....................................... ............................................................... .........CONFIDENTIALDate: Novo Nordisk
Version:
Status:Oral semaglutide
Trial ID: NN9924-4222Clinical Trial Report
Appendix 16.1.121 November 2018
1.0
Final
16.1.1 Protocol and protocol amendmentsCONFIDENTIAL
Redacted protocol 
Lncludes redaction of personal identifiable DQGFRPSDQ\
FRQILGHQWLDO information. 
. 
Protocol
CONFIDENTIALDate: [ADDRESS_694603] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 1 of 119
Protocol
Trial ID: NN9924-4222
PI[INVESTIGATOR_15597] 3 - vs. DPP-4 inhibitor
Efficacy and long-term safety of oral semaglutide versus sitagliptin
in subjects with type 2 diabetes
Trial phase: 3a
Protocol originator
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol
CONFIDENTIALDate: [ADDRESS_694604] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694605] of abbreviations.......................................................................................................... ...............................7
1 Summary....................................................................................................................... ...........................10
2 Flow chart .................................................................................................................... ............................13
3 Background information and rationale for the trial............................................................................ 17
3.1 Background information...................................................................................................... ........17
3.1.1 Type 2 diabetes mellitus ............................................................................................17
3.1.2 Glucagon-like peptide-1 ............................................................................................17
3.1.3 Oral semaglutide........................................................................................................183.1.4 Non-clinical data........................................................................................................1 8
[IP_ADDRESS] Semaglutide.........................................................................................18
[IP_ADDRESS] SNAC ..................................................................................................19
3.1.5 Clinical data oral semaglutide....................................................................................20
[IP_ADDRESS] Pharmacokinetics ................................................................................[IP_ADDRESS] Efficacy ...............................................................................................21
[IP_ADDRESS] Safety...................................................................................................21
3.1.6 Sitagliptin............................................................................................................... ....22
3.2 Rationale for the trial ..................................................................................................... ..............22
4 Objective(s) and endpoint(s) .................................................................................................. ................23
4.1 Objective(s)................................................................................................................ ..................23
4.1.1 Primary objective.......................................................................................................23
4.1.2 Secondary objectives .................................................................................................23
4.2 Endpoint(s)................................................................................................................. ..................23
4.2.1 Primary endpoint........................................................................................................23
4.2.2 Secondary endpoints..................................................................................................23
[IP_ADDRESS] Confirmatory seconda ry endpoints .....................................................23
[IP_ADDRESS] Supportive seconda ry endpoints..........................................................[ADDRESS_694606] ..........................................................................28
5.5 Rationale for treatment ..................................................................................................... ...........28
6 Trial population.............................................................................................................. .........................29
6.1 Number of subjects ........................................................................................................... ...........29
6.2 Inclusion criteria .......................................................................................................... ................29CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694607] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694608] administration........................................................36
8.1.4 End-of-treatment (visit 16) and Follow-up (visit 17).................................................[ADDRESS_694609] and Follow-up (visits 16A and 17A)......[ADDRESS_694610] circumference ..................................................................................................428.3.5 Patient reported outcomes questionnaires..................................................................42
8.4 Assessments for safety...................................................................................................... ...........43
8.4.1 Physical examination .................................................................................................43
8.4.2 Vital signs ............................................................................................................... ...43
8.4.3 Eye examination ........................................................................................................448.4.4 Electrocardiogram – 12 –lead ....................................................................................[ADDRESS_694611] compliance.......................................................................................................... ............54CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694612] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 4 of 119
9 Trial supplies ................................................................................................................ ...........................55
9.1 Trial products.............................................................................................................. .................55
9.2 Labelling ................................................................................................................... ...................55
9.3 Storage ..................................................................................................................... ....................56
9.4 Drug accountability a nd destruction ......................................................................................... ...56
9.5 Auxiliary supplies.......................................................................................................... ..............57
10 Interactive web re sponse system.............................................................................................. ..............58
11 Randomisation procedure and b reaking of blinded codes ..................................................................59
11.1 Breaking of blinded codes .................................................................................................. .........59
12 Adverse events, technical comp laints and pregnancies .......................................................................60
12.1 Definitions ................................................................................................................ ...................60
12.2 Reporting of adverse events................................................................................................ .........64
12.3 Follow-up of adverse events ................................................................................................ ........67
12.4 Technical complaints and tec hnical complaint samples ..............................................................68
12.4.1 Reporting of technical complaints .............................................................................68
12.4.2 Collection, storage and shipment of technical complaint samples ............................68
12.5 Pregnancies in female subjects ............................................................................................. .......69
12.6 Precautions and/or overdose ................................................................................................ ........70
12.7 Committees related to safety............................................................................................... .........71
12.7.1 Novo Nordisk sa fety committee ................................................................................71
12.7.2 Event adjudication committee....................................................................................71
13 Case report forms............................................................................................................ ........................74
13.1 Corrections to cas e report forms........................................................................................... .......74
13.2 Case report form flow...................................................................................................... ............74
14 Monitoring procedures ........................................................................................................ ...................76
15 Data management.............................................................................................................. ......................77
16 Computerised systems......................................................................................................... ....................78
17 Statistical considerations ................................................................................................... .....................79
17.1 Sample size calculation.................................................................................................... ............81
17.2 Definition of analysis sets................................................................................................ ............84
17.3 Primary endpoint........................................................................................................... ...............86
17.3.1 Primary analysis for the primary estimand ................................................................86
17.3.2 Primary analysis for th e secondary estimand.............................................................87
17.3.3 Sensitivity analyses....................................................................................................8 8
[IP_ADDRESS] Pattern mixture models........................................................................89
[IP_ADDRESS] Other sensitivity analysis ....................................................................9017.3.3.3 Assessment of sensitivity analyses......................................................90
17.4 Secondary endpoints........................................................................................................ ............90
17.4.1 Confirmatory sec ondary endpoints............................................................................90
17.4.2 Supportive seconda ry endpoints ................................................................................91
[IP_ADDRESS] Efficacy endpoints...............................................................................91
[IP_ADDRESS] Safety endpoints ..................................................................................93
17.5 Pharmacokinetic modelling .................................................................................................. .......96
17.6 Health economics and/or p atient reported outcomes ...................................................................97CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694613] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 5 of 119
18 Ethics ....................................................................................................................... .................................98
18.1 Benefit-risk assessment of the trial....................................................................................... .......98
18.1.1 Risks and precautions ................................................................................................98
[IP_ADDRESS] Oral Semaglutide.................................................................................9818.1.1.[ADDRESS_694614] during trial ........................................................................................ .....101
18.5 Premature termination of the trial and/or trial site.....................................................................10 2
19 Protocol compliance.......................................................................................................... ....................103
20 Audits and inspections ....................................................................................................... ...................104
21 Critical documents ........................................................................................................... .....................105
22 Responsibilities ............................................................................................................. .........................107
23 Reports and publications..................................................................................................... .................108
23.1 Communication of results................................................................................................... .......108
23.1.1 Authorship ............................................................................................................... 109
23.1.2 Site-specific publication(s) by [CONTACT_1697](s) .........................................................109
23.2 Investigator access to data and review of results .......................................................................109
24 Retention of clinical trial docume ntation and human biospecimens................................................110
24.1 Retention of clinical trial documentation.................................................................................. .110
24.2 Retention of human  biospecimens............................................................................................ .110
25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities............112
26 Indemnity statement .......................................................................................................... ...................113
27 References ................................................................................................................... ...........................115
Attachment I –Global list of key staff and relevant departments and suppliers 
Attachment II –Country list of key staff and relevant departments
Appendix A –Calcitonin monitoring
Appendix B –Adverse events requiring additional data collectionCONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694615] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 6 of 119
Table of Figures
Page
Figure 5–1 Trial design......................................................................................................... ....................26
Figure 12–1 Initial reporting of AEs............................................................................................ ...............66
Figure 17–1 Graphical illustration of the closed testing procedure ............................................................83
Figure 17–2 ADA classification of hypoglycaemia................................................................................. ...96
Table of Tables
Page
Table 5–1 Treatment of subjects................................................................................................. .............27
Table 9–1 Investigati onal medicinal products.................................................................................... .....55
Table 9–2 Storage conditions for investigational medicinal products.....................................................56
Table 12–[ADDRESS_694616] to event 
adjudication ................................................................................................................... .........65
Table 12–2 Adverse events for adjudication ...................................................................................... .......72
Table 17–1 Assumptions for sample size calculation.............................................................................. ..82
Table 17–2 Powers for i ndividual hypotheses..................................................................................... ......82CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694617] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694618] aspartate aminotransferaseAUC area under the curveBG blood glucoseBMI body mass indexCK creatine kinaseCKD-EPI [INVESTIGATOR_534931]-drug interactionDPP-4i dipeptidyl peptidase 4 inhibitorDUN dispensing unit numberEAC event adjudication committee
ECG electrocardiogram
eCRF electronic case report form
eGFRestimated glomerular filtration rate (CDISC term is 
GFR, estimated)
EMA European Medicines AgencyFAS full analysis setCONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694619] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694620] visitFU follow-upGCP Good Clinical Practice
GI gastrointestinal
GLP-1 glucagon-like peptide-1GLP-1 RA glucagon-like-peptide-1 receptor agonistHbA
1c glycosylated haemoglobin
HDL high density lipoproteinIB Investigator’s BrochureICH International Conference on HarmonisationIEC independent ethics committeeIMP investigational medicinal productIWQoL-Lite Impact of Weight on Quality of Life questionnaireIRB institutional review boardIWRS interactive web response systemLDL low density lipoproteinLSFV last subject first visitLSLV last subject last visitMAR missing at randomMEN 2 Multiple Endocrine Neoplasia Type 2MI myocardial infarctionMTC Medullary Thyroid CarcinomaMMRM Mixed Model for Repeated MeasurementsNIMP non-investigational medicinal productNYHA [LOCATION_001] Heart AssociationOAD oral antidiabetic drugP phone contact[CONTACT_345960]: [ADDRESS_694621] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 9 of 119
PG plasma glucose
PK pharmacokineticsPP per protocolPRO patient reported outcomeSAE serious adverse event
SAP statistical analysis plan
SAS safety analysis sets.c. subcutaneous(ly)SF-36v2™ Short Form-[ADDRESS_694622] characteristicsSNAC sodium N-(8-(2-hydroxybenzoyl) amino) caprylateSU sulfonylureaS[LOCATION_003]R suspected unexpected serious adverse reactionT2DM type 2 diabetes mellitusTEAE treatment emergent adverse eventsTIA transient ischemic attackTMM Trial Materials ManualUNL upper normal levelUTN Universal Trial NumberV visitVLDL very low density lipoprotein CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694623] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 10 of 119
1 Summary
Objectives and endpoints:
Primary objective
To compare the effect of once-daily dosing of three dose levels (3 mg, 7 mg and 14 mg) of oral 
semaglutide versus sitagliptin 100 mg once-daily, both in combination with metformin with or 
without sulfonylurea (SU), on glycaemic control in subjects with type 2 diabetes mellitus (T2DM).
Secondary objectives
To compare the effect of once-daily dosing of three dose levels (3 mg, 7 mg and 14 mg) of oral 
semaglutide versus sitagliptin 100 mg once-daily, both in combination with metformin with or 
without SU, on body weight in subjects with T2DM.
To compare the long-term safety and tolerability  of once-daily dosing of three dose levels (3 mg, 
7 mg and 14 mg) of oral semaglutide versus sitagliptin 100 mg once-daily, both in combination 
with metformin with or without SU, in subjects with T2DM.
Primary endpoint
Change from baseline to week 26 in HbA 1c
Key secondary endpointsChange from baseline to week 26 in
!Body weight (kg)
!Fasting plasma glucose (FPG)
Subjects who after 26 weeks of treatment achieve (yes/no):
!HbA
1c< 7.0% (53 mmol/mol), American Diabetes Association (ADA) target
This endpoint will also be evaluated after week 52 and after week 78.
Change from baseline to week 52 and to week 78 in:
!HbA 1c
!Body weight (kg)
!FPG
Number of treatment emergent adverse events (TEAEs) during exposure to trial product, assessed 
up to approximately 83 weeks
Number of treatment emergent severe or blood glucose (BG) confirmed symptomatic 
hypoglycaemic epi[INVESTIGATOR_36184], assessed up to approximately 83 weeksCONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694624] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 11 of 119
Trial design:
The trial is a 78 week, randomised, double-blind, double-dummy, active-controlled, parallel-group, 
multi-centre, multi-national, four-armed trial.
Subjects with T2DM inadequately controlled with metformin or metformin + sulfonylurea (SU) 
will be randomised in a 1:1:1:[ADDRESS_694625] will be approximately 85 weeks. The trial includes a 2 
week screening period, followed by a 78 week randomised treatment period and a follow-up period 
of 5 weeks. 
Trial population:
It is planned to randomise 1860 subjects.
Key inclusion criteria
!Male or female, age ≥ 18 years at the time of signing informed consent.
For Japan only: Male or female, age ≥ 20 years at the time of signing informed consent.
!Diagnosed with T2DM ≥ 90 days prior to day of screening.
!HbA 1c7.0-10.5 % (53-91 mmol/mol) (both inclusive).
!Stable daily dose of metformin ( ≥[ADDRESS_694626]) alone or in combination with SU ( ≥ half of the maximum approved dose 
according to local label or maximum tolerated dose as documented in subject medical record) 
within 90 days prior to the day of screening.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694627] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 12 of 119
Key exclusion criteria
!Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using adequate contraceptive methods (adequate contraceptive measures as 
required by [CONTACT_17993]). 
For certain specific countries: Additional specific requirements apply.
!Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN 2) or Medullary 
Thyroid Carcinoma (MTC).
!History of pancreatitis (acute or chronic).
!History of major surgical procedures involving the stomach potentially affecting absorption of 
trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric by[CONTACT_4897]).
!Any of the following: myocardial infarction, stroke or hospi[INVESTIGATOR_513386]/or 
transient ischaemic attack within the past 180 days prior to the day of screening.
!Subjects presently classified as being in [LOCATION_001] Heart Association (NYHA) Class IV.
!Planned coronary, carotid or peripheral artery revascularisation known on the day of screening.
!Renal impairment defined as estimated Glomerular Filtration Rate (eGFR)
< 60 mL/min/1.73 m2 as per Chronic Kidney Disease Epi[INVESTIGATOR_10444] (CKD-EPI).
!History or presence of malignant neoplasms within the last 5 years (except basal and squamous 
cell skin cancer and in-situ carcinomas).
Key assessments:
Efficacy:
!HbA 1c
!FPG
!Body weight
Safety:
!Adverse events
!Hypoglycaemic epi[INVESTIGATOR_36177]:
The following trial products will be supplied by [CONTACT_3454] A/S, Denmark: 
!Semaglutide, 3 mg tablet
!Semaglutide, 7 mg tablet
!Semaglutide, 14 mg tablet
!Semaglutide placebo tablet (Placebo I)
!Sitagliptin (Januvia®), 100 mg tablet
!Sitagliptin placebo tablet (Placebo II)CONFIDENTIAL
Protocol UTN: U1111-1168-4339 Date: [ADDRESS_694628] 2015 Status: Final Novo Nordisk
Trial ID: NN9924-[ADDRESS_694629] no.: 2015-001351-71 Version: 2.0 Page: 13 of 119
2 Flow chart
Trial PeriodsScreening1Randomisation
TreatmentEnd-of-treatment 
(EoT)Follow-up2EoT premature 
discontinuation3Follow-up 
premature 
discontinuation3
Visit (V), Phone (P) V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 V17 V16A V17A
Timing of visit (weeks)Up 
to -[ADDRESS_694630] (last 
dose)
Visit window (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +[ADDRESS_694631] RELATED
INFO/ASSESSMENTS
Informed consent x
In/exclusion criteria x x
Concomitant medication x x x x x x x x x x x x x x x x x x x
Demography x
Tobacco use x
Concomitant illness and 
medical historyx
History of diabetes x
History of
cardiovascular disease x
History of gallbladder 
diseasex
History of 
gastrointestinal diseasex
Randomisation x
Withdrawal criteria x x x x x x x x x x x x x x x
Protocol UTN: U1111-1168-4339 Date: [ADDRESS_694632] 2015 Status: Final Novo Nordisk
Trial ID: NN9924-[ADDRESS_694633] no.: 2015-001351-71 Version: 2.0 Page: 14 of 119
Trial PeriodsScreening1Randomisation
TreatmentEnd-of-treatment 
(EoT)Follow-up2EoT premature 
discontinuation3Follow-up 
premature 
discontinuation3
Visit (V), Phone (P) V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 V17 V16A V17A
Timing of visit (weeks)Up 
to -[ADDRESS_694634] (last 
dose)
Visit window (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +[ADDRESS_694635] circumference x x x x x x x x
7-point profile x x x x x
PRO questionnaires x x x x x
SAFETY
Eye examination5x
Physical examination x x x x
Electrocardiogram x x x x x x x
Vital signs x x x x x x x x x x x x x x x x x
Pregnancy test6x x x x x x x x x x x x x x x x x x
Calcitonin x x x x x x x x x x
Biochemistry7x x x x x x x x x x x x x
Haematology x x x x x x x x x x x x
Protocol UTN: U1111-1168-4339 Date: [ADDRESS_694636] 2015 Status: Final Novo Nordisk
Trial ID: NN9924-[ADDRESS_694637] no.: 2015-001351-71 Version: 2.0 Page: 15 of 119
Trial PeriodsScreening1Randomisation
TreatmentEnd-of-treatment 
(EoT)Follow-up2EoT premature 
discontinuation3Follow-up 
premature 
discontinuation3
Visit (V), Phone (P) V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 V17 V16A V17A
Timing of visit (weeks)Up 
to -[ADDRESS_694638] (last 
dose)
Visit window (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +[ADDRESS_694639] in 
BG meter usex
Dispense and/or collect 
diaryx x x x x x x x x x x x x x x x x x
Attend visit fasting10x x x x x x x x x x x
Protocol UTN: U1111-1168-4339 Date: [ADDRESS_694640] 2015 Status: Final Novo Nordisk
Trial ID: NN9924-[ADDRESS_694641] no.: 2015-001351-71 Version: 2.0 Page: [ADDRESS_694642] not exc eed 2 weeks prior to randomisation (V2).
X2Subjects, who have discontinued trial product prematurely, are not required to attend V17 (Follow-up).
X3V16A and V17A are only applicable for subjects who have discontinued trial product prematurely.
X4 PK sampling is only applicable for a subset of the subjects.
No PK sampling should be done for visits occurring after V17A (subjects who have discontinued trial product prematurely).
X5 Dilated fundoscopy/fundus photography performed within [ADDRESS_694643] examination.
X6 For women of child bearing potential: Urine pregnancy test should also be performed at any time during the trial if a menstrual  period is missed and/or according to local 
regulations/law.
X7At V1 only Creatinine and eGFR will be assessed as part of Biochemistry. 
X8 At randomisation, the antibody sampling must be done pre-dose. 
No antibody sampling should be done for visits occurring after V17A (subjects who have discontinued trial product prematurely).
X9Adverse events reporting, includes adverse events from the first trial-related activity after the subject has signed the informe d consent at V1.
X10Fasting for blood sampling is defined as having consumed only water within the last 8 hours prior to visit.
Protocol
CONFIDENTIALDate: [ADDRESS_694644] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 17 of 119
3 Background information and rationale for the trial
The trial will be conducted in compliance with this protocol, International Conference on 
Harmonisation (ICH) Good Clinical Practice (GCP)1and applicable regulatory requirements and in 
accordance with the Declaration of Helsinki2.
For Mexico only: The above will include the following responsibilities for the head of the 
Institution/Health Care Establishment, Ethics, Research and, when applicable, Biosafety Committees and sponsor within their scope of responsibility: 
a) Investigation follow-up;
b) Damages to health arising from the investigation development; as well as those arising from 
interruption or advanced suspension of treatment due to non-attributable reasons to the Subject;
c) Timely compliance of the terms in which the authorization of a research for health in human 
beings had been issued;
d) To present in a timely manner the information required by [CONTACT_135534].
In this document, the term investigator refers to the individual responsible for the overall conduct of 
the clinical trial at a trial site.
3.1 Background information
3.1.1 Type 2 diabetes mellitus 
T2DM is a progressive metabolic disease primarily characterised by [CONTACT_36269]. 
The pathogenesis is heterogeneous involving environmental, lifestyle and genetic factors leading to 
chronic hyperglycaemia caused by [CONTACT_111394], impaired insulin secretion 
due to abnormal beta-cell function and abnormal glucose metabolism in the liver.
3
Optimal glycaemic control is the treatment goal in subjects with T2DM, in order to prevent long-term complications associated with chronic hyperglycaemia
4. Despi[INVESTIGATOR_36178]-diabetic drugs, a significant proportion of subjects with T2DM do not achieve the recommended targets for glycaemic control.
5,6
3.1.2 Glucagon-like peptide-1
Glucagon-like peptide-1 (GLP-1) is an incretin  hormone with a glucose-dependent stimulatory 
effect on insulin- and inhibitory effect on glucagon secretion from the pancreatic islets.7,8Subjects 
with T2DM have a decreased incretin effect.9-12However, the insulinotropic action of GLP-1 and 
thus, the ability to lower BG levels, is preserved when GLP-1 is administered at supra physiological 
levels.13In addition, supra physiological levels of GLP-1 induces reduction in body weight14. GLP-
1 is a physiological regulator of appetite and food intake and GLP-1receptors are present in several areas of the brain involved in appetite regulation
15,16. Physiologically, GLP-1 also has a pronounced CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694645] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694646] on gastric emptying; however this effect seems to diminish upon chronic exposure
14-16. These mechanisms of action make GLP-[ADDRESS_694647] (GLP-1 RA) structurally similar to liraglutide 
(Victoza®), a once-daily GLP-1 RA developed by [CONTACT_237176] T2DM. Compared to human native GLP-1, which has a very short half-life, the 
semaglutide molecule has three minor but important modifications ensuring protraction of its 
action: amino acid substitutions at position 8 (alanine to alfa-aminoisobuztyric acid, a synthetic 
amino acid) and position 34 (lysine to arginine) and acylation of the peptide backbone with a spacer 
and C-18 fatty di-acid chain to lysine in position 26.20The fatty di-acid side chain and the spacer 
mediate strong binding to albumin, thereby [CONTACT_36272]. The amino acid substitution at position 8 makes semaglutide less susceptible to degradation by [CONTACT_36273]-4 (DPP-4). 
The change in position [ADDRESS_694648] only one lysine in the 
sequence where to a spacer can be attached.
Semaglutide is in development for oral once-daily treatment of T2DM. As the bioavailability of 
GLP-1 RAs is very low when administered orally, semaglutide has been co-formulated with the 
absorption enhancing excipi[INVESTIGATOR_36179] N-(8-(2-hydroxybenzoyl) amino) caprylate (SNAC) in order 
to increase bioavailability based on the  concept developed by  
. When semaglutide is co-formulated with SNAC, SNAC has the capacity to 
augment the absorption of semaglutide across the gastrointestinal (GI) epi[INVESTIGATOR_2130]. The absorption 
enhancement by [CONTACT_534953], size and time-dependent and is believed to take place in close 
proximity of the tablet in the stomach. The absorption process is hampered if dosed with food, 
liquid or in the presence of significant stomach content. Throughout this document oral semaglutide 
will refer to the drug product, that is, semaglutide co-formulated with 300 mg SNAC. 
Novo Nordisk is currently also developi[INVESTIGATOR_237145]-weekly subcutaneous (s.c.) 
administration in subjects with T2DM. 
3.1.4 Non-clinical data
[IP_ADDRESS] Semaglutide
The non-clinical programme for semaglutide was designed according to the ICH M3 guideline to 
support the clinical development. The standard non-clinical data package required to support phase 
[ADDRESS_694649] been completed. Semaglutide was generally well 
tolerated in animals (mice, rats and cynomolgus monkeys). Two potential safety issues have been 
identified and these are detailed below.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694650] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 19 of 119
Thyroid C-cell tumours in rodents
Treatment-related non-genotoxic proliferative changes in the thyroid C-cells of mice and rats were 
observed in 2-year carcinogenicity studies with semaglutide; thyroid hyperplasia was preceded by 
[CONTACT_36275]. C-cell changes have not been observed in long-term studies in non-
human primate. The observed pattern of effects in mice and rats and lack of these effects in the non-
human primate and in man suggest that the mechanism by [CONTACT_36276] C-
cells in rodents is the same as has been demonstrated for other GLP-1 RAs, including liraglutide. 
According to this mechanism, C-cell hyperplasia is mediated by [CONTACT_17978]-1 receptor and is not 
associated with RET (re-arranged during transfection) gene activation and rodents appear to be 
particularly sensitive, whereas humans are not. The relevance for human subjects is currently 
unknown, but considered to be low21.
Embryo−foetal development toxicity
Semaglutide caused embryo-foetal development toxicity in the rat through a GLP-[ADDRESS_694651] an inverted yolk sac placenta which makes this 
mechanism unlikely to be of relevance to humans and cynomolgus monkeys. In the developmental 
toxicity studies in cynomolgus monkey, a marked pharmacology mediated maternal body weight 
loss coincided with increased early foetal loss; however, there was no indication of a teratogenic 
potential of semaglutide in this species. These data suggest an important species-dependent 
mechanism, whereby [CONTACT_237178].
A review of results from the non-clinical studies can be found in the investigator’s brochure (IB) for 
Semaglutide (subcutaneous administration), edition 1022and the IB for Oral administration of 
semaglutide (NN9924), edition 623, or any updates of these documents.
[IP_ADDRESS] SNAC
SNAC was developed as an absorption enhancing excipi[INVESTIGATOR_36180]. The 
non-clinical programme to support clinical phase 3 development and marketing authorisation 
application (MAA) submission has been conducted including a 26-week carcinogenicity study in 
transgenic rasH2 mice and a 2-year carcinogenicity study in Sprague-Dawley rats.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694652] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 20 of 119
The carcinogenicity studies demonstrated that SNAC was not carcinogenic to the transgenic rasH2 
mouse or the Sprague-Dawley rat. The doses tested covered plasma exposures (AUC) of 2-fold in 
the mouse and up to 44-fold in the rat when compared to the mean human exposure following a 
clinical dose of 300 mg SNAC/day.
A review of results from the non-clinical studies can be found in the IB for Oral administration of 
semaglutide (NN9924), edition 623, or any updates hereof.
3.1.5 Clinical data oral semaglutide
A comprehensive clinical pharmacology programme including 12 trials has been completed, as well 
as a 26-week phase 2 dose-finding trial involving more than 600 subjects with T2DM.
For details on the individual trials, please see the IB for Oral administration of semaglutide 
(NN9924) edition 623, or any updates hereof.
[IP_ADDRESS] Pharmacokinetics
In single dose trials, oral semaglutide has demonstrated a long mean terminal half-life (t ½) ranging 
from 153 to 161 hours (~1 week) and a median time to reach maximum observed concentration 
(tmax) ranging from 1 to 2 hours in healthy subjects. 
In multiple-dose pharmacokinetics (PK) trials, the exposure to oral semaglutide increased with 
increasing dose. Overall, the pharmacokinetic properties of semaglutide appeared similar in healthy 
subjects and in subjects with T2DM.
Exposure of semaglutide exhibits a substantially greater dose-to-dose variation following oral 
administration compared to s.c. administration. However, when administered orally once-daily the 
PK properties of semaglutide, i.e. low clearance and long half-life, will limit the variation in steady 
state plasma exposure.
Data obtained following investigation of different dosing conditions for oral semaglutide have 
demonstrated that subjects should take the oral semaglutide tablet in the morning in a fasting state 
and at least [ADDRESS_694653] meal of the day. The tablet can be taken with up to half a 
glass of water (approximately 120mL/4 fluid oz).
Drug-drug interaction (DDI) investigations have explored the effect of oral semaglutide on the 
exposure to lisinopril, warfarin, metformin and digoxin as well as the effect of omeprazole on oral 
semaglutide and SNAC. It was demonstrated that oral semaglutide did not change the exposure to lisinopril, warfarin or digoxin, but increased the exposure to metformin when taken simultaneously. 
The increase in exposure to metformin may be related to delayed gastric emptying caused by 
[CONTACT_237216]-1 RAs. Based on the wide therapeutic index of metformin, 
the increased exposure to metformin was however not considered clinically relevant. Further, it was CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694654] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694655] was not statistically significant 
or considered clinically relevant.  In subjects with mild to end-stage renal impairment, the exposure 
to semaglutide appeared similar in subjects with normal and impaired renal function, whereas the 
AUC for SNAC was greater in subjects with impaired renal function than in subjects with normal 
renal function. The C maxof SNAC appeared similar in subjects with normal and impaired renal 
function. The renal clearance of all SNAC metabolites was decreased in subjects with renal 
impairment. 
In subjects with mild to severe hepatic impairment, the exposure to semaglutide appeared to be 
unaffected by [CONTACT_36277], whereas the exposure to SNAC (in terms of both 
AUC and C max) was increased for subjects with hepatic impairment as compared to subjects with 
normal hepatic function.
All tablets of oral semaglutide contain 300 mg of SNAC. SNAC is rapi[INVESTIGATOR_19627] a median 
tmaxranging from 0.35 −0.5 hours in healthy subjects and from 0.52 −1.43 hours in subjects with 
T2DM. It is extensively metabolized and no accumulation of SNAC has been observed in clinical 
trials. 
[IP_ADDRESS] Efficacy
The efficacy of oral semaglutide in adult subjects with T2DM was investigated in a 26-week phase 
2 dose-finding trial. In this trial, placebo or one of the following doses of oral semaglutide were 
administered once daily: 2.5, 5, 10, 20 and 40 mg.
Results from the trial showed that oral semaglutide effectively lowered HbA 1cand body weight. 
Placebo-adjusted reductions in HbA 1cwere dose-dependent and statistically significant for all oral 
semaglutide treatment arms at week 26 (range: -0.40% to -1.59%). Placebo-adjusted reductions in 
body weight were dose-dependent and statistically significant for oral semaglutide treatment doses 
of 10 mg and above at week 26 (range: -3.61 to -6.98 kg). 
[IP_ADDRESS] Safety
In the clinical trials completed so far, no unexpected safety findings have been identified for oral 
semaglutide administered up to 40 mg once daily. Consistent with other GLP-1 RAs, commonadverse events (AEs) included nausea and vomiting, most of them of mild to moderate severity. In 
line with findings for other GLP-1 RAs, an increase in heart rate and serum levels of lipase and 
amylase has also been observed in subjects exposed to oral semaglutide.
In addition to the 13 completed clinical trials with oral semaglutide, SNAC has been investigated in 
the programme of orally administrated heparin in combination with SNAC (heparin/SNAC). The 
heparin/SNAC programme ( .) included 29 phase 1 trials (SNAC doses 
ranged from 0.172-10.5 g). In three of these trials SNAC alone was investigated (to a maximum CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694656] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 22 of 119
dose of 10.5 g). The studies covered formulation development, food effect, hepatic and renal 
impairment, age-effect and drug-drug interaction. The programme also included a total of three 
phase 2 and 3 trials in which the effects of orally delivered heparin solution (with >1.5 g SNAC 
three times a day) was investigated. The overall safety profile of oral semaglutide and 
heparin/SNAC indicates that SNAC is safe and well-tolerated.
For further details please see the IB for Oral administration of semaglutide (NN9924) edition 623, or 
any updates hereof.
3.1.6 Sitagliptin
The selected active comparator in this trial is sitagliptin, an oral antidiabetic drug (OAD) of the 
DPP-4 inhibitor (DPP-4i) class suitable for once-daily oral administration. Sitagliptin was 
developed by [CONTACT_44873] & Co and has been marketed since 2006 under the trade name [CONTACT_534973]®. By 
[CONTACT_534954]-4, which breaks down GLP-1 and gastric inhibitory polypeptide 
(GIP), secretion of insulin is increased and release of glucagon is suppressed. 
Further information can be obtained in the locally approved Januvia® label24.
For an assessment of benefits and risks of the trial, see Section 18.1.
3.2 Rationale for the trial
The rationale for the present trial is to compare the efficacy and safety of once-daily dosing with 
three dose levels (3 mg, 7 mg and 14 mg) of oral semaglutide with sitagliptin 100 mg once-daily in 
subjects with T2DM. Furthermore, the trial will ensure that long-term safety data are collected from 
subjects with T2DM exposed to oral semaglutide for a minimum of 18 months, as recommended by 
U.S. Food and Drug Administration (FDA)24.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694657] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 23 of 119
4 Objective(s) and endpoint(s)
4.1 Objective(s)
4.1.[ADDRESS_694658] of once-daily dosing of three dose levels (3 mg, 7 mg and 14 mg) of oral 
semaglutide versus sitagliptin [ADDRESS_694659] of once-daily dosing of three dose levels (3 mg, 7 mg and 14 mg) of oral 
semaglutide versus sitagliptin 100 mg once-daily, both in combination with metformin with or 
without SU, on body weight in subjects with T2DM.
To compare the long-term safety and tolerability of once-daily dosing of three dose levels (3 mg, 7 
mg and 14 mg) of oral semaglutide versus sitagliptin 100 mg once-daily, both in combination with 
metformin with or without SU, in subjects with T2DM.
4.2 Endpoint(s)
4.2.1 Primary endpoint
Change from baseline to week 26 in HbA 1c
4.2.2 Secondary endpoints
[IP_ADDRESS] Confirmatory secondary endpoints
Change from baseline to week 26 in body weight (kg)CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694660] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 24 of 119
[IP_ADDRESS] Supportive secondary endpoints
Supportive secondary efficacy endpoints
Change from baseline to week 52 and to week 78 in:
!HbA 1c*
!Body weight (kg)*
Change from baseline to week 26, to week 52 and to week 78 in:
!Body weight (%)
!FPG*
!Self-measured plasma glucose (SMPG), [ADDRESS_694661] prandial increment (over all meals)
!Body mass index (BMI)
!Waist circumference
!Fasting lipid profile (total cholesterol, low density lipoprotein (LDL) cholesterol, very low 
density lipoprotein (VLDL) cholesterol, high-density lipoprotein (HDL) cholesterol, 
triglycerides, free fatty acids)
!Patient reported outcomes
oShort Form-36 version 2 (SF-36v2™) (acute version) health survey 
oImpact of Weight on Quality of Life (IWQoL-Lite) Clinical Trial Version
oControl of Eating questionnaire (CoEQ)
Subjects who after 26 weeks of treatment achieve (yes/no):
!HbA 1c< 7.0 % (53 mmol/mol) ADA target*
!HbA 1c≤6.5 % (48 mmol/mol) American Association of Clinical Endocrinologists (AACE) 
target
!HbA 1creduction ≥1%
!Weight loss ≥3%
!Weight loss ≥5%
!Weight loss ≥10 %
!HbA 1c < 7.0 % (53 mmol/mol) without hypoglycaemia (treatment emergent severe or BG
confirmed symptomatic hypoglycaemia) and no weight gain
!HbA 1creduction ≥1 % and weight loss ≥3%
The above eight endpoints will be evaluated after week 52 and after week 78 as well.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694662] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 25 of 119
Time to event endpoint
!Time to rescue medication
This endpoint will be evaluated after week 26, after week 52 and after week 78.
Supportive secondary safety endpoints
!Number of TEAEs during exposure to trial product, assessed up to approximately 83 weeks*
!Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_534932], assessed up to approximately 83 weeks*
!Treatment emergent severe or BG confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_36237], assessed up to approximately 83 weeks (yes/no) 
Change from baseline to week 78 in:
!Haematology
!Biochemistry
!Calcitonin
!Pulse
!Systolic blood pressure
!Diastolic blood pressure
!Electrocardiogram (ECG) category
!Physical examination
Occurrence of anti-semaglutide antibodies (yes/no):
!Anti-semaglutide binding antibodies
!Anti-semaglutide neutralising antibodies 
!Anti-semaglutide binding antibodies cross reacting with native GLP-1
!Anti-semaglutide neutralising antibodies cross reacting with native GLP-1 
Anti-semaglutide binding antibody levels
Endpoints to be included in PK meta-analyses across phase 3a trials with oral semaglutide
PK-concentrations
!Semaglutide plasma concentration in a subset of the subjects (approximately 50%) for 
population PK analyses
* Key supportive secondary endpoint prospectively selected for disclosure (e.g. clinicaltrials.gov 
and EudraCT)CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694663] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 26 of 119
5 Trial design
5.1 Type of trial
The trial is a 78 week, randomised, double-blind, double-dummy, active-controlled, parallel-group, 
multi-centre, multi-national trial with four arms comparing efficacy and safety of oral semaglutide 
3 mg, 7 mg and 14 mg once-daily with sitagliptin 100 mg once-daily. Subjects with T2DM 
inadequately controlled on metformin alone or in combination with SU will be randomised in a 
1:1:1:1-manner to receive either:
!oral semaglutide 3 mg and sitagliptin placebo
!oral semaglutide 7 mg and sitagliptin placebo
!oral semaglutide 14 mg and sitagliptin placebo
!sitagliptin 100 mg and oral semaglutide placebo
Randomisation will be stratified according to anti-diabetic pre-trial background medication 
(metformin or metformin + SU) to ensure even distribution of the four treatment arms within strata.
To maintain the blinding of the trial, the treatment will consist of two tablets daily as the sitagliptin 
tablet is not visually identical to the oral semaglutide tablets (see Section 9.1).
Total trial duration for the individual subject will be approximately 85 weeks. The trial includes a 
2 week screening period, followed by a 78 week randomised treatment period and a follow-up 
period of 5 weeks.
A schematic diagram of the trial design is shown in Figure 5–1 .
Figure 5–[ADDRESS_694664] been chosen in accordance with trial objectives and to avoid bias in the trial. The primary 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694665] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 27 of 119
efficacy endpoint will be evaluated at week 26 (see Section 17). No interim analysis will be done 
and the blinding will remain throughout the trial in order to assess long-term safety and tolerability 
in an un-biased manner (see Section 17). Supportive secondary efficacy endpoints are also included 
at week 52 and week 78.
5.3 Treatment of subjects
Treatment of subjects is summarised in Table 5–1 .
Oral semaglutide treatment arms
All subjects randomised to semaglutide will initiate treatment with 3 mg once daily. Subjects 
randomised to maintenance doses of 7 mg or 14 mg will follow a fixed dose-escalation regimen 
with 4 weeks between the dose escalation steps. The maintenance dose of 7 mg once daily will be 
reached after 4 weeks on 3 mg once daily. The maintenance dose of 14 mg once daily will be 
reached after 4 weeks on 3 mg once daily, followed by 4 weeks on 7 mg once daily. In addition, all 
subjects randomised to oral semaglutide will receive sitagliptin placebo once daily. 
Sitagliptin treatment arm
Subjects randomised to sitagliptin will receive 100 mg once daily without dose escalation. In 
addition, all subjects randomised to sitagliptin will receive oral semaglutide placebo once daily. 
Table 5–[ADDRESS_694666] visit in each period V1 V2 V4 V5 V16
Duration of each perioda 2 weeks 4 weeks 4 weeks 70 weeks 5 weeks
Treatment arm
oral semaglutide 3 mg
+ sitagliptin placeboScreening 3 mg + placebo 3 mg + placebo 3 mg + placebo Follow-up
oral semaglutide 7 mg 
+ sitagliptin placeboScreening 3 mg + placebo 7 mg + placebo 7 mg + placebo Follow-up 
oral semaglutide 14 mg 
+ sitagliptin placeboScreening 3 mg + placebo 7 mg + placebo 14 mg + placebo Follow-up 
sitagliptin 100 mg 
+ oral semaglutide placeboScreening 100 mg + placebo 100 mg + placebo 100 mg + placebo Follow-up 
ª Please see Section [ADDRESS_694667] meal of the 
day. Trial products can be taken with up to half a glass of water (approximately 120 ml/4 fluid oz). 
The tablets must be taken whole: do not break or chew (see Table 9–2 ). Furthermore, other oral 
medication can be taken 30 minutes after trial products.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694668] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 28 of 119
5.3.2 Background medication
After inclusion (V1), subjects must continue anti-diabetic pre-trial background medication (i.e. 
metformin alone or in combination with SU) throughout the entire trial. The background medication 
must be maintained at the stable, pre-trial dose and at the same frequency during the whole 
treatment period unless rescue medication is needed (see Section 6.4) or if the subject has 
unacceptable hypoglycaemia on a background of SU in which case the dose of SU can be reduced.
In addition, all background medication:
!is considered to be non-investigational medicinal product (NIMP)
!will not be provided by [CONTACT_3454] A/S
!should be used in accordance with standard of care or local label in the individual country 
!must not exceed the maximum approved dose in the individual country
 
5.[ADDRESS_694669] at 
the discretion of the investigator (for Brazil only: or it will be made available according to local 
regulations ). After discontinuation of trial product, GLP-1 RAs are not allowed before completion 
of the follow-up visit (see Section 8.1.4 and 8.1.5 ) which is to take place [ADDRESS_694670] (to avoid interference with the antibody analysis).
As this trial is a phase 3a trial, oral semaglutide will not be available for prescription until after 
marketing authorisation.
5.[ADDRESS_694671] sufficient data on efficacy and safety in accordance with the trial 
objectives.
Sitagliptin has been chosen as comparator since it is an established OAD within the DPP-4i drug 
class.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694672] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 29 of 119
6 Trial population
6.1 Number of subjects 
Number of subjects planned to be screened: 3100
Number of subjects planned to be randomised: [ADDRESS_694673]: 1674
For Japan only: 200 Japanese subjects planned to be randomised with an approximate equal 
distribution across the 4 treatment arms.For Mexico only: [ADDRESS_694674] be answered “yes”. 
1. Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability for 
the trial. 
2. Male or female, age ≥ 18 years at the time of signing informed consent.
For Japan only: Male or female, age ≥ 20 years at the time of signing informed consent.
3. Diagnosed with type 2 diabetes mellitus ≥90 days prior to day of screening.
4. HbA 1c7.0-10.5% (53-91 mmol/mol) (both inclusive).
5. Stable daily dose of metformin ( ≥[ADDRESS_694675]) alone or in combination with SU ( ≥ half of the maximum approved dose 
according to local label or maximum tolerated dose as documented in the subject medical 
record) within [ADDRESS_694676] be answered "no".
1. Known or suspected hypersensitivity to trial product(s) or related products. 
2. Previous participation in this trial. Participation is defined as signed informed consent.
3. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using adequate contraceptive methods (adequate contraceptive measures as 
required by [CONTACT_17993]).
For [LOCATION_013] only: Only highly effective methods of birth control are accepted (i.e. one that CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694677] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 30 of 119
results in less than 1% per year failure rate when used consistently and correctly such as 
implants, injectables, combined oral contraceptives, some intrauterine device), or sexual 
abstinence or vasectomised partner.
For [LOCATION_008] only: Adequate contraceptive measures are defined as established use of 
oral, intravaginal, transdermal combined estrogen and progestogen hormonal methods of 
contraception; oral, injected or implanted progestogen only hormonal methods of 
contraception; placement of an intrauterine device or intrauterine hormone releasing system, 
bilateral tubal occlusion, barrier methods of contraception (condom or occlusive cap with 
spermicidal foam/gel/film/cream/suppository), female sterilisation, vasectomised partner (where 
partner is sole partner of subject), or true abstinence (when in line with preferred and usual 
lifestyle).
For Brazil only: For women who expressly declare free of the risk of pregnancy, either by [CONTACT_237184], use of 
contraceptive method will not be mandatory.
For Japan only: Adequate contraceptive measures are abstinence (not having sex), diaphragm, 
condom (by [CONTACT_3969]), intrauterine device, sponge, spermicide or oral contraceptives.
4. Receipt of any investigational medicinal product within 90 days before screening.
For Brazil only: Participation in other trials within one year prior to screening visit (visit 1) 
unless there is a direct benefit to the research subject at the investigator´s discretion
5. Any disorder, which in the investigator’s opi[INVESTIGATOR_36174]’s safety or 
compliance with the protocol.
6. Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN 2) or Medullary 
Thyroid Carcinoma (MTC).
7. History of pancreatitis (acute or chronic).
8. History of major surgical procedures involving the stomach potentially affecting absorption of 
trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric by[CONTACT_4897]).
9. Any of the following: myocardial infarction, stroke or hospi[INVESTIGATOR_513386]/or 
transient ischaemic attack within the past 180 days prior to the day of screening. 
10. Subjects presently classified as being in [LOCATION_001] Heart Association (NYHA) Class IV.
11. Planned coronary, carotid or peripheral artery revascularisation known on the day of screening.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694678] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 31 of 119
12. Renal impairment defined as estimated Glomerular Filtration Rate (eGFR) <60 mL/min/1.73 m2 
as per Chronic Kidney Disease Epi[INVESTIGATOR_10444] (CKD-EPI).
13. Treatment with any medication for the indication of diabetes or obesity other than stated in the 
inclusion criteria in a period of 90 days before the day of screening. An exception is short-term 
insulin treatment for acute illness for a total of ≤[ADDRESS_694679] 5 years (except basal and squamous 
cell skin cancer and in-situ carcinomas).
6.[ADDRESS_694680] of treatment on 
glycaemic parameters, rescue criteria will be applied from week 8 and onwards. If any of the FPG 
values (including fasting SMPG) exceed the limits outlined below and no intercurrent cause of the 
hyperglycaemia can be identified, a confirmatory FPG (at central laboratory) should be obtained by 
[CONTACT_36282] a re-test:
!14.4 mmol/L (260 mg/dL) from week 8 to end of week 13
!13.3 mmol/L (240 mg/dL) from week 14 to end of week 25
!11.1 mmol/L (200 mg/dL) from week [ADDRESS_694681] should be offered 
rescue medication (i.e. intensification of existing anti-diabetic background medication and/or 
initiation of new anti-diabetic medication). 
In addition, subject should be offered rescue medication if:
!HbA 1c (at central laboratory) > 8.5% (69.4 mmol/mol) from week 26 to end of trial 
It is important for trial integrity that only subjects actually needing treatment intensification (as 
defined above) are started on rescue medication. Subjects that are started on rescue medication 
should continue to follow the protocol-specified visit schedule. Rescue medication should be 
prescribed as add-on to randomised treatment and according to ADA/European Association for the 
Study of Diabetes guidelines25,26(excluding GLP-RAs, DPP-4 inhibitors and amylin analogues).  
Rescue medication and any changes hereto should be captured on the concomitant medication form in the electronic case report form (eCRF), see Section 8.2.4 . Rescue medication is considered to be 
NIMP and will not be provided by [CONTACT_3454].CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694682] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694683] be discontinued (i.e. a treatment 
discontinuation call must be made in the interactive web response system (IWRS)) and in these 
cases trial product should not be re-initiated. In case the trial product is interrupted due to suspi[INVESTIGATOR_534933], please see Section 8.7.[ADDRESS_694684] if any of the following 
applies:
!pregnancy
!intention of becoming pregnant
!included in the trial in violation of the inclusion and/or exclusion criteria
!participation in another clinical trial with an investigational medicinal product (IMP)
!calcitonin ≥ 100 ng/L
Subjects discontinuing treatment with trial product will not be withdrawn from trial and will be 
followed as described in Section 8.1.[ADDRESS_694685]’s request to withdraw from trial must 
always be respected.
Subjects who agree to attend or provide health status at the planned V16 should not be considered 
withdrawn from the trial.
Subjects should stay in the trial irrespective of lack of adherence to randomised treatment, lack of 
adherence to visit schedule, missing assessments or trial product discontinuation for any reason. 
Only subjects who decline any further contact [CONTACT_135539].
Subjects who consider withdrawing informed consent should be encouraged to have procedures 
performed according to the V16A and V17A visits.
See Section 8.1.6 for procedures to be undertaken in case of withdrawal from trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694686] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694687] included in the trial in violation of the inclusion and/or exclusion criteria must 
discontinue treatment with trial product, but will not be withdrawn from the trial. The subject will 
be followed as described in Section 8.1.5 .
For Mexico only: Should the subject his/her family members parents or legal representative decide 
to withdraw the consent for participation in the trial, the subject will be entitled to receive 
appropriate, free of charge medical care and/or trial drug during the follow up period of the 
protocol when it will be established with certainty that no untoward medical consequences of the 
subject´s participation in the research occurred.
6.[ADDRESS_694688] trial 
population. This will ensure that the trial population will resemble the target population in common 
practice. However, concomitant conditions which could jeopardise the safety of the subjects or 
compliance with the protocol will preclude subjects from participating (see Section 6.3). CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694689] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 34 of 119
7 Milestones
Planned duration of recruitment period FSFV-LSFV 20 weeks
Planned FSFV: 15-Feb-2016
Planned LSLV: 23-Feb-2018
End of trial is defined as LSLV
Recruitment:
The screening and randomisation rate will be followed closely via the IWRS in order to estimate 
when to stop screening. All investigators will be notified immediately when the recruitment period 
ends, after which no further subjects may be screened and the IWRS will be closed for further 
screening.
Trial registration:
Information of the trial will be disclosed at clinicaltrials.gov, novonordisk-trials.com and the 
Clinical Trials Information Japi[INVESTIGATOR_36187].jp. According to the Novo Nordisk Code of 
Conduct for Clinical Trial Disclosure27, it will also be disclosed according to other applicable 
requirements such as those of the International Committee of Medical Journal Editors (ICMJE)28,
the Food and Drug Administration Amendment Act (FDAAA)29, European Commission 
Requirements30,31and other relevant recommendations or regulations. If a subject requests to be 
included in the trial via the Novo Nordisk e-mail contact [CONTACT_36283], Novo Nordisk may 
disclose the investigator’s contact [CONTACT_18026]. As a result of increasing requirements for 
transparency, some countries require public disclosure of investigator names and their affiliations.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694690] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694691] is unable or unwilling to attend all subsequent visit(s) the investigator should at least 
aim to have the subject attend the V8, V12 and the End-of-treatment visit (V16) as these visits
should be performed for all subjects (except subjects who withdraw informed consent, see 
Section 8.1.6 ).
The following sections describe the assessments and procedures. These are also included in the flow 
chart (see Section 2). Informed consent must be obtained before any trial related activity, see 
Section 18.2.
8.1.[ADDRESS_694692] keep a log of staff and a delegation of task(s) list at site. 
Investigator must sign the log of staff and the delegation of task(s) at site prior to the delegation of 
tasks.
At screening, subjects will be provided with a card stating that they are participating in a trial and 
giving contact [CONTACT_49761](es) and telephone number(s) of relevant trial site staff. Subjects should be 
instructed to return the card to the investigator at the last trial visit or to destroy the card after the 
last visit.
A screening session must be made in IWRS. Each subject will be assigned a unique 6-digit subject 
number which will remain the same throughout the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694693] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694694] be reviewed, dated and signed by [CONTACT_36284]/or documented in medical records to assess that the subject is eligible to continue 
in the trial.
Screening failures: For screening failures the screening failure form in the CRF must be completed 
with the reason for not continuing in the trial. Serious adverse events (SAEs) from screening 
failures must be transcribed by [CONTACT_534955]. Follow-up of SAEs must be carried 
out according to Section 12.
A screening failure session must be made in the IWRS. The case book must be signed .
Re-screening is NOT allowed. However, in case any laboratory samples are not available (e.g. 
haemolysed/lost), re-sampling is allowed.
8.1.[ADDRESS_694695] attend several visits in a fasting state (see Section 2). Fasting for blood sampling 
is defined as having consumed only water within the last [ADDRESS_694696] be performed in the IWRS which will allocate the dispensing unit number (DUN) of trial 
product to be dispensed to the subject.
All visit [ADDRESS_694697] (see Section 9) will be dispensed to the subject by [CONTACT_779], hospi[INVESTIGATOR_36188]-of-
treatment visit (see Section 2). The investigator must document that subjects are instructed in the 
dosing requirements at every dispensing visit, please see Section 5.3.[ADDRESS_694698] will be captured in the eCRF.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694699] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 37 of 119
8.1.4 End-of-treatment (visit 16) and Follow-up (visit 17)
Subjects who stay on trial product throughout the trial, must attend the End-of-treatment visit (V16) 
78 weeks after randomisation and the Follow-up visit (V17) [ADDRESS_694700] (+3 days visit window). A completion call must be performed in the IWRS after completion 
of visit 16 (see Section 10).
In case the subject cannot be reached (by [CONTACT_36286]) at the scheduled visit [ADDRESS_694701] (e.g. 
close relatives), relevant physicians, medical records and locator agencies (if allowed according to 
local law) to collect health status. If no health status can be collected, the subject should be 
considered lost to follow up. 
8.1.[ADDRESS_694702] and Follow-up (visits 16A and 17A)
Subjects who discontinue trial product prematurely should attend visit 16A, scheduled to take place 
shortly after discontinuation of trial product. Visit 17A should be scheduled 5 weeks (+3 days visit 
window) after the last date on trial product. A treatment discontinuation session must be performed
in the IWRS at visit 16A (see Section 10).
Subjects should continue with the originally scheduled site contacts after visit 17A and up to visit 
16. If necessary, in order to retain the subject in the trial, site visits can be replaced by [CONTACT_534956] V17A. However, as a minimum, these subjects should be asked to attend the 
scheduled V8 at week 26, V12 at week 52 and End-of-treatment (V16) at week 78.
In case the subject cannot be reached (by [CONTACT_36286]) at the scheduled visit [ADDRESS_694703] (e.g. 
close relatives), relevant physicians, medical records and locator agencies (if allowed according to 
local law) to collect health status. If no health status can be collected, the subject should be 
considered lost to follow up. 
8.1.[ADDRESS_694704] aim to undertake procedures 
similar to those for visit 16A as soon as possible and visit 17A should be scheduled 5 weeks (+3
days visit window) after the last date on trial product, if the subject agrees to it.
The end-of-trial form must be completed and final drug accountability must be performed even if 
the subject is not able to come to the trial site. A treatment discontinuation session must be made in 
the IWRS (see Section 10). The case book must be signed. 
Although a subject is not obliged to give his/her reason(s) for withdrawing from a trial, the 
investigator must make a reasonable effort to ascertain the reason(s), while fully respecting the CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694705] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694706]’s rights. Where the reasons are obtained, the primary reason for not completing the trial 
must be specified on the end-of-trial form in the eCRF.
8.1.7 Investigator assessments
Review of diaries, PROs, laboratory reports,  ECGs and fundoscopy/fundus photography must be 
documented either on the documents and/or in the subject’s medical record.
If clarification of entries or discrepancies in the diary or PROs is needed, the subject must be 
questioned and a conclusion made in the subject’s medical record. Care must be taken not to bias 
the subject.
The documents must be retained at the site as source documentation.
For ECGs, physical examinations and eye examinations the evaluations must follow the categories:
!Normal
!Abnormal
– Was the result clinically significant? (yes/no)
The evaluation should be based on investigators judgement.
For laboratory report values outside the reference range, the investigator must specify whether the 
value is clinically significant or not clinically significant. All laboratory printouts must be signed 
and dated by [CONTACT_36290]. The signed laboratory report is retained at 
the site as source documentation.
In case of abnormal clinically significant findings found as a result of screening procedures 
conducted at visit [ADDRESS_694707]’s medical record and record this in the medical history/concomitant 
illness form in the eCRF. 
The Investigator or his/her delegate must collect and review the PROs and diaries for completeness 
and to ensure that AEs are reported.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694708] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694709] related information 
8.2.1 Demography
Demography will be recorded in the eCRF at screening and consists of:
!date of birth or age (according to local regulation)
!sex
!race (according to local regulation)
!ethnicity (according to local regulation)
8.2.[ADDRESS_694710] stopped 
smoking.
8.2.3 Concomitant illness and medical history
A concomitant illness is any illness that is present at the start of the trial (V1) or found as a result 
of a screening procedure .
Medical history is a medical event that the subject has experienced in the past. Only relevant 
medical history as judged by [CONTACT_41150].
The information collected for concomitant illness and medical history should include diagnosis, 
date of onset and date of resolution or continuation, as applicable.
The following must be recorded in the eCRF (at visit 1) on the disease specific forms only i.e. not 
on the medical history/concomitant illness form:
!Diabetes history/diabetes complications (e.g. date of diagnosis, diabetic retinopathy, diabetic 
neuropathy, diabetic nephropathy)
!History of cardiovascular disease (CVD) (e.g. ischaemic heart disease, myocardial infarction, 
heart failure incl. NYHA class, hypertension, stroke, peripheral arterial disease)
!History of gallbladder disease (e.g. gallstone, cholecystitis, cholecystectomy)
!History of gastrointestinal disease (e.g. gastroesophageal reflux disease, ulcer disease, chronic 
gastritis)
Any change to a concomitant illness should be recorded during the trial. A clinically significant 
worsening of a concomitant illness must be reported as an AE (see Section 12).CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694711] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694712] be recorded at each visit as they occur. 
The information collected for each concomitant medication includes
!trade name [CONTACT_18058]
!indication
!start date and stop date or continuation
!total daily dose (only applicable for antidiabetic medication).
If a change is due to an AE, then this must be reported according to Section 12. If the change 
influences the subject’s eligibility to continue in the trial, the monitor must be informed.
8.3 Assessments for efficacy
8.3.1 Blood samples
Blood samples will be drawn according to flow chart (see Section 2) and will be analysed at the 
central laboratory to determine levels of the following efficacy laboratory parameters:
Glucose metabolism :
!HbA 1c
!FPG
Lipi[INVESTIGATOR_805] (fasting see Section 8.1.2 ):
!Total cholesterol
!LDL-cholesterol
!HDL-cholesterol
!VLDL-cholesterol
!Free fatty acids
!Triglycerides
8.3.2 7 -point self-measured plasma glucose profile
At visit 1, subjects will be provided with a blood glucose meter (BG meter) including lancets, 
plasma-calibrated test strips and control solutions as well as instructions for use. The subjects will 
be instructed in how to use the device, the instruction will be repeated as necessary during the trial. CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694713] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694714] will be instructed to perform a 7-point SMPG profile four times during the trial period 
(see Section 2) using the BG meter provided for the trial. The 7-point SMPG profile should be 
performed on a day where the subject does not anticipate unusual strenuous exercise. The 7-point 
profile should preferably be taken within a week prior to the visit.
Subjects should be instructed in how to record the results of the SMPG values in the diaries. The 
record of each SMPG value should include date, time and value. All data from the diary must be 
transcribed into the eCRF during or following the contact. If obtained via phone and a discrepancy 
is later detected between the diary and the SMPG data obtained at the phone, the values in the eCRF 
should be corrected.
The record of each  SMPG measurement should include the following seven time points:
!before breakfast
![ADDRESS_694715]
!before lunch
!90 minutes after start of lunch
!before dinner
!90 minutes after start of dinner
!at bedtime
8.3.[ADDRESS_694716] be measured and recorded in the eCRF in kilogram or pound (kg or lb), with one 
decimal (with an empty bladder, without shoes and only wearing light clothing). The body weight 
should be assessed on the same calibrated weighing scale equipment throughout the trial, if 
possible.
Height is measured without shoes in centimetres or inches and recorded in the eCRF to nearest 
½ cm or ¼ inch.
BMI will be calculated for the investigators convenience at visit 1 in the eCRF but will not be saved 
in the clinical database. The equation used in the eCRF is listed below:
BMI kg/m2 = body weight (kg)/(Height (m) x Height (m)) or (kg/m2 = [lb/in2 x 703])
All BMI calculations will subsequently take place in the clinical database using measurements of 
height and weight according to flowchart 2.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694717] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694718] 0.5 cm or 
0.2 inches using a non-stretchable measuring tape. The same measuring tape should be used 
throughout the trial (measuring tape will be provided to the sites).
The circumference should be measured when the subject is in a standing position, with an empty 
bladder and wearing light clothing. The subject should be standing, feet together with arms down 
their side and waist accessible. The tape should touch the skin but not compress soft tissue and 
twists in the tape should be avoided. The subject should be asked to breathe normally and the 
measurement should be taken when the subject is breathing out gently.
8.3.5 Patient reported outcomes questionnaires
PRO will be assessed using the questionnaires:
!SF-36v2™ (acute version) health survey37-39
!IWQoL-Lite Clinical Trial Version40,41
!CoEQ42-[ADDRESS_694719] be transferred into the eCRF.
The questionnaires SF-36v2™ and IQWoL-Lite Clinical Trial Version are commonly used PRO 
instruments, also in the T2DM area. The Control of Eating questionnaire has not been developed to 
be used in clinical trials. However, it has previously been included in clinical trials on an item per 
item basis, among others in a T2DM population.
All the questionnaires will be translated to local language before being handed out to the subjects 
participating in the trial. 
SF-36 acute version
SF-36v2™ acute version measures the individual overall health related quality of life on 8 domains; 
Physical functioning, Role functioning, Bodily pain, General health, Vitality, Social functioning, CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694720] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 43 of 119
Role emotional and Mental health. The acute version’s questions are based on a recall period of one 
week. SF-36v2™ contains [ADDRESS_694721] of Weight on Quality of Life questionnaire (IWQoL-Lite) Clinical Trial Version
The IWQoL-Lite for Clinical Trials was adapted from the IWQOL-Lite and measures the health 
related quality of life. The IQWoL- Lite Clinical Trial Version contains 23 items.
Control of Eating Questionnaire (CoEQ)
The CoEQ has its origins in the Food Craving Record. It comprises 21-items designed to assess the 
intensity and type of food cravings, as well as subjective sensations of appetite and mood. For this 
study a version with only 19 items will be included.
8.4 Assessments for safety
8.4.1 Physical examination
A physical examination will be performed by [CONTACT_36291] (see 
Section 2). A physical examination must include:
!General appearance
!Head, ears, eyes, nose, throat, neck
!Thyroid gland
!Respi[INVESTIGATOR_2133]
!Cardiovascular system
!Gastrointestinal system including mouth
!Musculoskeletal system
!Central and peripheral nervous system
!Skin
!Lymph node palpation
8.4.[ADDRESS_694722] be recorded in the eCRF. The actual value of the blood pressure measurement should be 
recorded in the eCRF – without rounding. The same equipment should be used throughout the trial.
Pulse
Pulse (beats per minute) must be recorded in the eCRF at site visits after resting for 5 minutes in a 
sitting position.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694723] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 44 of 119
8.4.3 Eye examination 
Dilated fundoscopy/fundus photography will be performed as per flow chart (see Section 2) by [CONTACT_36292]. Results of the dilated fundoscopy/fundus photography 
will be interpreted by [CONTACT_093] (see Section 8.1.7 ).
If dilated fundoscopy/fundus photography has been performed within [ADDRESS_694724] be available prior to randomisation.
If the dilated fundoscopy/fundus photography is performed before the subject has signed the 
informed consent form, it must be documented in the medical records that the reason for performing 
the procedure was not related to this trial.
8.4.4 Electrocardiogram – 12 –lead
12-lead ECG will be performed as per flowchart (see Section 2) and the assessment must be 
reviewed as described in Section 8.1.[ADDRESS_694725]-baseline ECG is suggestive of new myocardial infarction 
(MI), the investigator will be notified and, unless already done, the investigator should report this as 
AE or SAE at investigator’s discretion (see Section 12.1).
Additional ECG recordings can be performed at the investigator’s site at investigator’s discretion at 
other visits than the planned ECG visits. All these ECGs will undergo central assessment. The 
reason for additional ECG assessments should be documented and an AE should be reported if 
applicable.
All findings suggestive of new MI detected by [CONTACT_135544] (EAC) (see Section 12.7.2 ).
8.4.5 Blood samples
Blood samples will be drawn according to flow chart (see Section 2) and will be analysed at the 
central laboratory to determine levels of the following safety laboratory parameters:CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694726] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 45 of 119
Haematology:
!Haemoglobin
!Haematocrit
!Leucocytes
!Thrombocytes
!Differential count (eosinophils, neutrophils, basophils, lymphocytes and monocytes)
Biochemistry: 
!Alanine aminotransferase (ALT)
!Albumin
!Alkaline phosphatase (ALP)
!Amylase
!Aspartate aminotransferase (AST)
!Bilirubin, total
!Calcium, total
!Creatinine
!eGFR per CKD-EPI32
!Creatine kinase (CK)
!Lipase
!Potassium
!Sodium
!Urea
Hormones:
!Calcitonin
In case any calcitonin value at any time during the trial is ≥10 ng/L, the algorithm in Appendix A
must be followed.
8.4.[ADDRESS_694727] should be performed.
Pregnancy testing will not be required (unless required by [CONTACT_1769]) for women of non-childbearing 
potential defined as, but not limited to, women who have undergone a hysterectomy, bilateral 
oophorectomy or bilateral tubal ligation or who are postmenopausal (i.e. women above the age of CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694728] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694729] 1 year). The basis for non-bearing potential 
should be documented in medical records.
Contraceptive methods
Female subjects of childbearing potential must ensure using adequate contraceptive methods until [ADDRESS_694730].
For [LOCATION_013] only: Only highly effective methods of birth control are accepted (i.e. one that results 
in less than 1% per year failure rate when used consistently and correctly such as implants, 
injectables, combined oral contraceptives, some intrauterine device), or sexual abstinence or 
vasectomised partner.
For [LOCATION_008] only: Adequate contraceptive measures are defined as established use of oral, 
intravaginal, transdermal combined estrogen and progestogen hormonal methods of contraception; 
oral, injected or implanted progestogen only hormonal methods of contraception; placement of an 
intrauterine device or intrauterine hormone releasing system, bilateral tubal occlusion, barrier 
methods of contraception (condom or occlusive cap with spermicidal 
foam/gel/film/cream/suppository), female sterilisation, vasectomised partner (where partner is sole 
partner of subject), or true abstinence (when in line with preferred and usual lifestyle).
For Brazil only: For women who expressly declare free of the risk of pregnancy, either by [CONTACT_237184], use of 
contraceptive method will not be mandatory.
For Japan only: Adequate contraceptive measures are abstinence (not having sex), diaphragm,
condom (by [CONTACT_3969]), intrauterine device, sponge, spermicide or oral contraceptives.For Argentina only: Birth control methods will be reimbursed by [CONTACT_156096] 
S.A.
8.4.7 Antibodies
Blood samples will be drawn for measurement of serum antibodies to semaglutide at selected visits
(see Section 2). Positive anti-semaglutide binding antibody samples will be further characterised for 
cross reactivity to native GLP-1. Samples which are positive for anti-semaglutide neutralising 
antibodies will be further characterised for in vitro neutralising effect towards semaglutide. In 
addition, samples which are positive for antibodies cross-reacting with native GLP-[ADDRESS_694731] 
in the in vitro neutralising antibody assays. The in vitro neutralising assays will be performed by 
[CONTACT_3454].CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694732] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694733] be done pre-dose. 
8.4.8 Hypoglycaemic epi[INVESTIGATOR_36196] (PG) should always be measured and recorded when a hypoglycaemic epi[INVESTIGATOR_36190].
All PG values:
!≤ 3.9 mmol/L (70 mg/dL) or 
!> 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms
should be reported in the diary according to the instructions below throughout the trial from visit [ADDRESS_694734] is recommended to measure PG every 15 
minutes until the SMPG value is > 3.9 mmol/L (70 mg/dL) or symptoms have been resolved in 
accordance to current guidelines33.
An SMPG value ≤ 3.9 mmol/L (70 mg/dL) or hypoglycaemic symptoms must trigger a 
hypoglycaemic epi[INVESTIGATOR_36197]. Repeated SMPG measurements and/or 
symptoms will per default be considered as one hypoglycaemic epis ode until a succeeding SMPG 
value is > 3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved. One hypoglycaemic 
epi[INVESTIGATOR_36198]/or symptoms.
In case of several low SMPG values within the hypoglycaemic epi[INVESTIGATOR_1865], the lowest value is the one 
that will be reported as the SMPG value for the hypoglycaemic epi[INVESTIGATOR_534934]/or symptom.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694735] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694736] should include the following information: 
!Start date and time of the hypoglycaemic epi[INVESTIGATOR_1865].
!Stop date and time of hypoglycaemic epi[INVESTIGATOR_1865] (stop time is the first time the plasma glucose 
value is > 3.9 mmol/L (70 mg/dL and/or symptoms have been resolved)).
If a stop date and time is not reported a h ypoglycaemic epi[INVESTIGATOR_36200] a period of 60 
minutes.
!The plasma glucose level before treating the epi[INVESTIGATOR_1865] (if available) and any follow up 
measurements. 
The lowest value measured during the hypoglycaemic epi[INVESTIGATOR_215511], the remaining values will be kept as source data.
!Whether the epi[INVESTIGATOR_36202] (Yes/No).
A hypoglycaemic epi[INVESTIGATOR_215512]. 
!Whether the subject was able to treat him/herself.
If the severity of a hypoglycaemic epi[INVESTIGATOR_1865] a ggravates, only one hypoglycaemic epi[INVESTIGATOR_534935].
!Date, time and dose of last trial product administration and other anti-diabetic treatments prior 
to the epi[INVESTIGATOR_1865].
!Date and time of last main meal (not including snacks) prior to the epi[INVESTIGATOR_1865].
!Whether the epi[INVESTIGATOR_36205].
!Change in any concomitant illness.
!Any sign of fever or other acute disease.
!Whether the subject was asleep when the epi[INVESTIGATOR_36206].
oIf yes, whether the symptoms of the epi[INVESTIGATOR_36207].
The answer to the question: "Was subject able to treat him/herself?" must be answered "No" for an 
epi[INVESTIGATOR_36208], glucagon, or 
take other corrective actions. PG concentrations may not be available during an event, but 
neurological recovery following the return of PG to normal is considered sufficient evidence that 
the event was induced by a low PG concentration33.
Oral carbohydrates should not be given if the subject is unconscious.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694737] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 49 of 119
If the question "Was the subject able to treat him/herself?" is answered "No", the following 
information should be recorded by [CONTACT_423]:
!Who assisted in the treatment of the hypoglycaemic epi[INVESTIGATOR_1865] (i.e. medical person or non-medical 
person)
!Where the treatment was administered (in clinic/emergency room/ hospi[INVESTIGATOR_36209]. If the 
subject was treated in clinic/emergency room/hospi[INVESTIGATOR_307], whether they were transported in an 
ambulance or not)
!Type of treatment provided by [CONTACT_215559] (i.e. oral carbohydrates, glucagon, IV glucose or 
other)
!Were symptoms alleviated after administration of treatment?
!Factors contributing to the epi[INVESTIGATOR_1865] (i.e. physical activity, missed meal, diet changed, medication 
error (i.e. overdose, mix-up between products), other factors not listed or unknown)
!Did the subject experience seizure?
!Was the subject unconscious/comatose?
!Did the subject experience any of the following symptoms34(layman term used in the diary is 
specified in brackets if different from the protocol term)?
oAutonomic: sweating, trembling, hunger or palpi[INVESTIGATOR_814] (rapid or irregular heart beat)
oNeuroglycopenic: confusion, drowsiness, speech difficulty, visual disturbances, odd 
behaviour, impaired balance or incoordination (reduced ability to coordinate 
movement)
oGeneral malaise: headache or malaise (feeling discomfort/unease)
oOther symptoms?
The Investigator must review the diary at each contact [CONTACT_513452][INVESTIGATOR_1841] (see Section 2for relevant visits). The subject must be questioned whether 
any of the low values were severe i.e. whether the subject was able to self-treat or not. If the subject 
was not able to self-treat it has to be reported as a severe hypoglycaemic epi[INVESTIGATOR_36210] a 
hypoglycaemic epi[INVESTIGATOR_215510].
Low SMPG values for non-severe h ypoglycaemic epi[INVESTIGATOR_36212] a hy poglycae mic epi[INVESTIGATOR_36213] [ADDRESS_694738] be re-trained in how to report  hypoglycaemic epi[INVESTIGATOR_36214] e investigator identifies 
low SMPG values not reported as hypoglycaemic epi[INVESTIGATOR_1841].
If the hypoglycaemic epi[INVESTIGATOR_135520] a safety 
information form (SIF) must also be filled in, see Section 12.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694739] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694740], IgE anti-semaglutide antibodies and PK samples will be 
analysed by a special laboratory and Novo Nordisk A/S (see Sections 8.4.[ADDRESS_694741] be used.
The handling, transportation and storage of biological samples are described in the laboratory 
manual (for central and special laboratory details see Attachment I ).
Samples will be coded in order to keep subject identity anonymous.
Laboratory samples not drawn on the day of the actual visit should preferably be drawn on another 
day within the visit window stated in the flow chart (see Section 2). Please note that a laboratory 
sample pertaining to a specific visit must always be reported to that visit.
For some of the samples drawn during the trial, subjects will be asked to attend the site visits fasting 
(fasting for blood sampling is defined in Section 8.1.2 ).
The central laboratory will provide laboratory results to the investigator on an on-going basis and 
the investigator must review all laboratory results for signs of concomitant illness and AEs and 
report these according to Section 8.7and12). However, anti-semaglutide antibody and semaglutide 
plasma concentration results will not be available to the investigator during the trial. These results 
will be provided to the investigator upon request after the completion of the clinical trial report 
(CTR).
The laboratory provides results to the trial sites in the units preferred by [CONTACT_135545].
The laboratory equipment may provide analyses not requested in the protocol but produced 
automatically in connection with the requested analyses according to specifications in the laboratory 
standard operating procedures. Such data will not be transferred to the trial database, but abnormal 
values will be reported to the investigator. 
For Brazil only: All laboratory results will be communicated to the investigators.
All laboratory samples will be destroyed at the latest at the completion of the CTR, except samples 
obtained for anti-semaglutide antibody analysis. Antibody samples may be retained until drug approval by [CONTACT_401081]/or European Medicines Agency (EMA). The retained antibody samples may 
be used for further characterisation of antibody responses towards drug if required by [CONTACT_534957], see Section 24.2.
For Brazil only: Biological samples from Brazil will be destroyed at the end of the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694742] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694743] attend these visits fasting
(see Section 8.1.2 ).
Low FPGs reported by a laboratory in connection to trial related visits, i.e. FPG results ≤ 3.9 
mmol/L (70 mg/dL), should not be reported as hypoglycaemic epi[INVESTIGATOR_534936] (e.g. a FPG 
result of 2.9 mmol/L (52 mg/dL) should be reported as “low plasma glucose of 2.9 mmol/L (52 
mg/dL)”). See Section 12for reporting of AEs.
8.6 Other assessments
8.6.1 Pharmacokinetics
The blood samples for the population PK will be drawn in a sub population for bioanalysis of
semaglutide plasma concentrations (see Section 2). The sub population will include approximately 
50% of all randomised subjects and the selection of sites to participate will be done in collaboration 
with local Novo Nordisk affiliate. The investigator must record the exact date and time for sampling 
the blood for PK analysis in the eCRF. The date and time of the latest trial product administration 
prior to the visit must be recorded by [CONTACT_534958].
8.6.[ADDRESS_694744] in recording the following data in the diary:
!date and time of first trial product administration
!date and time of last trial product administration prior to visits with PK sampling
!hypoglycaemic epi[INVESTIGATOR_1841]
!changes in concomitant medication
!AEs
!SMPG 7-point profile
8.[ADDRESS_694745] be collected and reported according to the procedures described in Section 12.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694746] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694747] patients with acute pancreatitis experience abdominal pain that is located generally in the 
epi[INVESTIGATOR_135532]. The onset of the pain may be swift reaching maximum 
intensity within 30 min, it is frequently unbearable and characteristically persists for more than 24 
hours without relief.46The pain is often associated with nausea and vomiting. Physical examination 
usually reveals severe upper abdominal tenderness at times associated with guarding. 
In general, both amylase and lipase are elevated during the course of acute pancreatitis. The serum 
lipase may remain elevated slightly longer than amylase. The level of the serum amylase and/or 
lipase does not correlate with the severity of acute pancreatitis.46In general, serum lipase is thought 
to be more sensitive and specific than serum amylase in the diagnosis of acute pancreatitis. 
In case of suspi[INVESTIGATOR_36194], the trial product should promptly be interrupted (NO 
treatment discontinuation call should be made in IWRS before diagnosis of acute pancreatitis is
confirmed). Appropriate additional examinations must be performed, including local measurement 
of amylase and lipase. 
The diagnosis of acute pancreatitis requires two of the following three features47: 
!abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epi[INVESTIGATOR_17961])
!serum lipase activity (and/or amylase activity) at least three times greater than the upper limit of 
normal
!characteristic findings of acute pancreatitis on imaging.
If acute pancreatitis is ruled out, trial product should be re-initiated.If acute pancreatitis is confirmed, appropriate treatment and careful monitoring of the subject 
should be initiated. The subject must be discontinued from trial product (treatment discontinuation 
call), but should remain in the trial (see Section 6.5and 8.1.5 ). The event should be reported as an 
AE requiring additional data collection (see Section 12.1)a n d  Appendix B ) and will undergo 
assessment by [CONTACT_131461] (see Section 12.7.2 ).
8.7.[ADDRESS_694748] but should remain in the trial (see Section 6.5
and 8.1.5 ).
To assist in the diagnostic evaluation it is recommended to draw a blood sample for measurement of 
tryptase (total and/or mature tryptase, local assessment) within 3 hours of onset of the
hypersensitivity reaction, and if this is achieved, a tryptase sample should also be drawn at V17A. CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694749] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694750] but should remain in the trial (see Section 6.5and 8.1.5 ). It is recommended to draw a 
blood sample for local assessment of complement levels (C3 and C4) to assist in the diagnostic 
evaluation. Complement level results should be included in the specific event form when reporting 
the AE.
The event should be reported as an AE requiring additional data collection (see Section 12.1 and 
Appendix B ).
8.7.3 Assessments in case of increased levels of creatine kinase
In case of CK > 10x upper normal level (UNL) prompt repeat testing (at central laboratory) of CK 
should be done. Repeat testing (at central laboratory) should be done regularly until CK levels 
return to normal or baseline state. Additional clinical information should be gathered to seek 
possible cause of the observed CK elevation. 
The event should be reported as an AE requiring additional data collection (see Section 12.1 and 
Appendix B ).
8.7.[ADDRESS_694751] >3x UNL and total bilirubin >2x UNL,
the event must be reported as an SAE (see Section 12.1). 
2. ALT or AST >10x UNL andtotal bilirubin ≤2x UNL, 
the event should be reported as an AE requiring additional data collection(see Section 12.1 and 
Appendix B ).
For both events prompt repeat testing (at central laboratory) including ALT, AST, ALP and total 
bilirubin should be done and discontinuation of trial product considered. Thereafter, repeat testing 
(at central laboratory) of ALT, AST, ALP and total bilirubin should be done regularly until the 
abnormalities return to normal or baseline state. Additional clinical information should be gathered to seek a possible cause of the observed laboratory test abnormalities.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694752] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694753].CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694754] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 55 of 119
9 Trial supplies
Trial supplies comprise trial products and auxiliary supplies. Additional details regarding trial 
supplies can be found in the Trial Materials Manual (TMM). 
Trial products must not be dispensed to any person not included in the trial. 
9.1 Trial products
The following trial products are considered as IMPs and will be provided by [CONTACT_3454] A/S, 
Denmark:
Table 9–[ADDRESS_694755] Strength Dosage form Route of 
administrationContainer/
delivery device 
Semaglutide 3 mg tablet 3 mg
Tablet Oral Dose packa Semaglutide 7 mg tablet 7 mg
Semaglutide 14 mg tablet 14 mg
Placebo I tablet N/A
Sitagliptin (Januvia®) tablet 100 mgTablet Oral Dose packa
Placebo II tablet N/A
aOne dose pack contains one blister pack.
Metformin and SU and rescue medication are considered NIMPs and will not be supplied by [CONTACT_49753]. However, metformin and SU will be reimbursed if required by [CONTACT_42025]’s regulatory 
authority or IRB/IEC.
 
For Japan only: During the treatment period, all anti diabetic medication including pre-trial OADs 
will  be reimbursed by [CONTACT_36297].
Oral semaglutide and the corresponding placebo tablets are white to light yellow oval shaped tablets 
embossed with "M8" on one side. The comparator sitagliptin and the corresponding placebo tablets 
are beige, round, convex tablets engraved with "277" on one side. For both semaglutide and 
sitagliptin, respectively, the active drug and the corresponding placebo tablets are identical with 
regard to visual appearance and all semaglutide tablets are visually identical to each other, 
irrespective of dose levels.
9.2 Labelling
The trial products will be labelled in accordance with Annex 1349, local regulations and trial 
requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694756] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694757] for the trial on an on-going basis 
controlled by [CONTACT_8784]. Trial products will be distributed to the trial sites according to enrolment 
and randomisation.
9.3 Storage 
Storage conditions of the trial products are outlined in Table 9–2 .
Table 9–[ADDRESS_694758] Storage conditions
(not-in-use)In-use conditions
Semaglutide 3 mg tabletDo not store above 30ºC
(86ºF)
Do not freeze
Do not refrigerate
Store in the original packageTake the tablet immediately 
after dispensation from blister card
Take the tablets whole: Do not 
break or chewSemaglutide 7 mg tablet
Semaglutide 14 mg tablet
Placebo I tablet
Sitagliptin (Januvia®) 100 mg tabletDo not store above 30ºC
(86ºF)
Do not freezeDo not refrigerate
Store in the original packageMust not be used if tablets 
appear damaged, if the blister 
pack is broken or unsealed 
before usePlacebo II tablet
The investigator must ensure the availability of proper storage conditions and also record and 
evaluate the temperature. The investigator must  inform Novo Nordisk immediately if any trial 
product has been stored outside specified conditions (e.g. outside temperature range).
Trial product that has been stored improperly must not be dispensed to any subject before it has 
been evaluated and approved for further use by [CONTACT_3454]. The investigator must take 
appropriate action to ensure correct storage.
For Japan only: The head of the study site or the trial product storage manager if assigned by [CONTACT_36298], record and evaluate 
the temperature.
9.4 Drug accountability and destruction
Drug accountability is the responsibility of the investigator.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694759] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694760] (used/partly used or unused including empty packaging material) can be 
stored at room temperature and must be stored separately from non-allocated trial product.
Drug accountability is performed by [CONTACT_36300]. Only dispensed DUNs returned by [CONTACT_423] 
(used/partly used or unused) are accounted for. Drug accountability should be done on tablet level.
Destruction will be done according to local procedures after accountability is finalised and verified 
by [CONTACT_2037]. Destruction of products must be documented and recorded in IWRS including 
destruction confirmation.
9.5 Auxiliary supplies
The following will be provided by [CONTACT_3454] A/S in accordance with the TMM:
• BG meters and BG meter auxiliaries 
For Japan only: The trial sites are allowed to purchase and supply themselves with auxiliary 
supplies, if possible. BG meters must be the same model as supplied by [CONTACT_3454].CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694761] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694762] be restricted to and controlled by [CONTACT_36301]. 
IWRS is used for: 
!Screening
!Screening failure
!Randomisation
!Medication arrival
!Dispensing
!Treatment discontinuation
!Completion
!Code break
!Drug accountability
!Data change
IWRS user manuals will be provided to each trial site. DUNs will be allocated using the IWRS. It is 
important to dispense the exact allocated DUNs to a subject.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694763] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 59 of 119
11 Randomisation procedure and breaking of blinded codes
The trial is a double-blinded trial. A randomisation session will be carried out for all subjects using 
IWRS. 
At the randomisation visit (visit 2) subjects meeting all eligibility criteria will be randomised to one
of four parallel treatment arms as described in Section 5.1.
11.1 Breaking of blinded codes
The IWRS will notify Novo Nordisk (monitor and the Global Safety department) immediately after 
the code is broken.
The code for a particular subject may be broken in a medical emergency if knowing the actual 
treatment would influence the treatment of the subject. Whenever a code is broken the person 
breaking the code must print the Code Break Confirmation Notification generated by [CONTACT_8784], 
record the reason and sign and date the document.
When the code is broken, the treatment allocation will be accessible to the investigator and the 
Novo Nordisk Global Safety department. If IWRS is not accessible at the time of code break the 
IWRS helpdesk should be contact[INVESTIGATOR_530]. Contact [CONTACT_136758] I . If the code has been 
broken the subject should discontinue treatment with trial product but be asked to continue in the 
trial (see Section 8.1.5 ). A treatment discontinuation session must be completed in IWRS.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694764] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 60 of 119
12 Adverse events, technical complaints and pregnancies
12.1 Definitions
Adverse event 
An adverse event (AE) is any untoward medical occurrence in a subject administered a product and 
which does not necessarily have a causal relationship with this treatment.
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with the use of a product, whether or not 
considered related to the product.
An AE includes:
!A clinically significant worsening of a concomitant illness.
!A clinical laboratory adverse event (CLAE): a clinical laboratory abnormality which is 
clinically significant, i.e. an abnormality that suggests a disease and/or organ toxicity and is of a 
severity that requires active management. Active management includes active treatment or 
further investigations, for example change of medicine dose or more frequent follow-up due to 
the abnormality.
The following should notbe reported as AEs:
!Pre-existing conditions, including those found as a result of screening procedures (pre-existing 
conditions should be reported as medical history or concomitant illness).
!Pre-planned procedures unless the condition for which the procedure was planned has worsened 
from the first trial related activity after the subject has signed the informed consent.
!Non-serious hypoglycaemia is an AE, but is reported on a hypoglycaemic epi[INVESTIGATOR_36219], see Section 8.4.8 . 
The following three definitions are used when assessing an AE:
!Severity 
–Mild - no or transient symptoms, no interference with the subject's daily activities.
–Moderate - marked symptoms, moderate interference with the subject's daily activities.
–Severe - considerable interference with the subject's daily activities; unacceptable.
!Causality 
Relationship between an AE and the relevant trial product(s): 
–Probable - Good reason and sufficient documentation to assume a causal relationship.
–Possible - A causal relationship is conceivable and cannot be dismissed.
–Unlikely - The event is most likely related to aetiology other than the trial product.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694765] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 61 of 119
!Final outcome
–Recovered/resolved - The subject has fully recovered, or by [CONTACT_36303]-related activity after the 
subject signed the informed consent.
–Recovering/resolving - The condition is improving and the subject is expected to recover 
from the event. This term is only applicable if the subject has completed the trial or has died 
from another AE.
–Recovered/resolved with sequelae - The subject has recovered from the condition, but 
with lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an 
SAE criterion, the AE must be reported as an SAE.
–Not recovered/not resolved - The condition of the subject has not improved and the 
symptoms are unchanged, or the outcome is not known.
–Fatal - This term is only applicable if the subject died from a condition related to the 
reported AE. Outcomes of other reported AEs in a subject before he/she died should be 
assessed as "recovered/resolved", "recovering/resolving", "recovered/resolved with 
sequelae" or "not recovered/not resolved". An AE with fatal outcome must be reported as an 
SAE.
–Unknown - This term is only applicable if the subject is lost to follow-up.
Serious adverse event
An SAE is an experience that at any dose results in any of the following:
!Death.
!A life-threateningaexperience.
!In-patient hospi[INVESTIGATOR_36220].
!A persistent or significant disability or incapacityc.
!A congenital anomaly or birth defect.
!Important medical events that may not result in death, be life threateninga or require 
hospi[INVESTIGATOR_36221] - based on appropriate medical judgement -
they may jeopardise the subject and may require medical or surgical intervention to prevent one 
of the outcomes listed in the definition of SAEd. 
Suspi[INVESTIGATOR_534937]. 
a. The term "life threatening" in the definition of SAE refers to an event in which the subject was 
at risk of death at the time of the event. It does not refer to an event which hypothetically might 
have caused death if it was more severe.
b. The term "hospi[INVESTIGATOR_11956]" is used when a subject: 
– Is admitted to a hospi[INVESTIGATOR_36222]-patient, irrespective of the duration of physical stay, or 
– Stays at the hospi[INVESTIGATOR_36223] 24 hoursCONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694766] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694767]'s ability to conduct normal life functions (e.g. following the 
event or clinical investigation the subject has significant, persistent or permanent change, 
impairment, damage or disruption in his/her body function or structure, physical activity and/or 
quality of life).
d. For example intensive treatment in an emergency room or at home of allergic bronchospasm, 
blood dyscrasiasis or convulsions that do not result in hospi[INVESTIGATOR_11956], or development of drug 
dependency or drug abuse.
Trial specific serious adverse event
The following laboratory abnormalities must be reported as an SAE:
!ALT or AST >3x UNL and total bilirubin >2x UNL
Additional assessments should be made for events meeting the above criterion (see Section 8.7.4 ).
Non-serious adverse event
A non-serious AE is any AE which does not fulfil the definition of an SAE.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694768] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694769] a special focus (e.g. required by [CONTACT_93420]). The AEs requiring additional data 
collection are:
!Acute coronary syndrome (myocardial infarction or hospi[INVESTIGATOR_36193])
!Cerebrovascular event (stroke or transient ischaemic attack (TIA))
!Heart failure requiring hospi[INVESTIGATOR_11956]
!Pancreatitis 
!Neoplasm (excluding thyroid neoplasm)
!Thyroid disease (including thyroid neoplasm)
!Renal event 
!Hypersensitivity reactions
!Acute gallstone disease
!Medication error (concerning trial products):
oAdministration of wrong drug. 
Note: Use of wrong DUN is not considered a medication error.
oWrong route of administration.
oAdministration of an overdose with the intention to cause harm (e.g. suicide 
attempt).
oAccidental administration of a higher dose than intended. A higher dose is a dose of 
at least one tablet more than the intended dose; however the administered dose must 
deviate from the intended dose to an extent where clinical consequences for the trial 
subject were likely to happen as judged by [CONTACT_093], although they did not 
necessarily occur.
!Lactic acidosis
!Creatine kinase (CK) > 10x UNL
!Hepatotoxicity events:
oALT or AST > 10x UNL and total bilirubin ≤ 2x UNL
oHepatotoxicity leading to trial product discontinuation 
Technical complaint
A technical complaint is any written, electronic, or oral communication that alleges product 
(medicine or device) defects. The technical complaint may be associated with an AE, but does not 
concern the AE itself.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694770] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 64 of 119
Examples of technical complaints:
!The physical or chemical appearance of trial products (e.g. discoloration, particles or 
contamination)
!The packaging material (e.g. cracks or errors in labelling text)
12.[ADDRESS_694771]-treatment follow-up period (V17) for subjects on trial product OR until the end of trial 
(V16 or V17A, whichever comes last) for the subjects who have discontinued trial product 
prematurely. The events must be recorded in the applicable eCRF forms in a timely manner, see 
timelines below and Figure 12–[ADDRESS_694772] be asked about AEs and technical 
complaints, for example by [CONTACT_7939]: "Have you experienced any problems since the last contact?"
All AEs, either observed by [CONTACT_36305], must be reported by [CONTACT_36306]. Novo Nordisk assessment of expectedness is performed according to the following reference documents: 
!IB for Oral administration of semaglutide (NN9924), edition 6
23and any updates hereof. 
!Summary of Product Characteristics (SmPC) for Januvia®(sitagliptin)50and any updates hereof.
All AEs must be recorded by [CONTACT_49738]. The investigator should report the 
diagnosis, if available. If no diagnosis is available, the investigator should record each sign and 
symptom as individual AEs using separate AE forms.
For SAEs, a SIF must be completed in addition to the AE form. A SIF is a form to collect 
supplementary clinical information. If several symptoms or diagnoses occur as part of the same 
clinical pi[INVESTIGATOR_1103], one SIF can be used to describe all the SAEs.
AEs requiring additional data collection must be reported using both the AE form and the specific 
event form. A specific event form is a form tailored to collect specific information related to the 
individual event (see Appendix B for details about the event specific forms and the additional 
information to report).
In case any of the above events fulfil the criteria for seriousness in Section 12.1, then the event 
should be reported as serious.
Some events will undergo event adjudication by [CONTACT_36355] (EAC), please 
refer to Section 12.7.2 . For AEs qualifying for event adjudication, the Event Adjudication Form will CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694773] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694774] of clinical data
to be provided from the site.
For an overview of AEs requiring additional data collection and AEs that will undergo event 
adjudication, please see Table 12–1 .
Table 12–[ADDRESS_694775] to event 
adjudication
EventAEs requiring additional 
data collectionEvent adjudication
Death No Yes
Acute coronary syndrome (myocardial infarction or 
hospi[INVESTIGATOR_36193])Yes Yes
Cerebrovascular event (stroke or transient ischaemic 
attack)Yes Yes
Heart failure requiring hospi[INVESTIGATOR_534938] (only if acute pancreatitis)
Neoplasm (excluding thyroid neoplasm) Yes Yes (only if malignant)
Thyroid disease (including thyroid neoplasm) YesYes (only if malignant thyroid 
neoplasm or C-cell hyperplasia)
Renal event Yes Yes (only if acute kidney injury)
Hypersensitivity reactions Yes No
Acute gallstone disease Yes No
Medication error Yes No
Lactic acidosis Yes Yes
Creatine kinase (CK) > 10x UNL Yes No
Hepatotoxicity events Yes No
Timelines for initial reporting of AEs:
The investigator must complete the following forms in the eCRF within the specified timelines:
!SAEs : The AE form within 24 hours and the SIF within 5 calendar days of the investigator's 
first knowledge of the SAE.
Both forms must be signed within 7 calendar days from the date the information was entered in 
the eCRF. 
!SAEs fulfilling criteria for additional data collection : In addition to above, the corresponding 
specific event form within 14 calendar days of investigators knowledge of the event.
!Events for adjudication: Specific Event Adjudication Form must be completed within 14 
calendar days . The investigator should preferably provide the medical documentation within 4 
weeks of event identification.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694776] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694777] details (fax, telephone, e-mail and address) are provided in the investigator trial master file.
An AE is observed 
and reported 
Fulfilling seriousness 
criteria?It is an SAE
complete:
!AE form ≤ 24 hours
!SIF ≤ 5 calendar days
It is a non-serious AE
complete:
!AE formRequiring 
additional data 
collection?Requiring 
additional data 
collection?Complete:
!Specific event form ≤ 14  calendar daysYes
Complete: 
!Specific event formYes
NoYes Complete:
!Adjudication form ≤ 14 calendar daysYes
AE: adverse event
SAE: serious adverse event
SIF: safety information form
All timelines are from the investigator’s
first knowledge of the event
Events for adjudication are described in chapter 12.7.2Is the event to 
be adjudicated?
Is the event to 
be adjudicated?Complete:!Adjudication form  ≤ 14 calendar daysYes
Figure 12–[ADDRESS_694778]-related S[LOCATION_003]Rs by [CONTACT_3454]:
Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious 
adverse reactions (S[LOCATION_003]Rs) in accordance with local requirements and GCP.1In addition, the 
investigator will be informed of any trial-related SAEs that may warrant a change in any trial procedure.
In accordance with regulatory requirements, Novo Nordisk will inform the regulatory authorities, 
including EMA, of trial product-related S[LOCATION_003]Rs. In addition, Novo Nordisk will inform the CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694779] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 67 of 119
IRBs/IECs of trial product-related S[LOCATION_003]Rs in accordance with local requirement and GCP1, unless 
locally this is an obligation of the investigator.
Novo Nordisk products used as concomitant medication:
If an SAE is considered to have a causal relationship with a Novo Nordisk marketed product used 
as concomitant medication in the trial, it is important that the suspected relationship is reported to 
Novo Nordisk, e.g. in the alternative aetiology section on the SIF. Novo Nordisk may need to report 
this AE to relevant regulatory authorities.
12.[ADDRESS_694780] be reported to Novo Nordisk according to the following:
!SAEs : All SAEs must be followed until the outcome of the event is “recovered/resolved”, 
“recovered/resolved with sequelae” or “fatal”, and until all queries have been resolved. Cases of 
chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE) 
may be closed with the outcome “recovering/resolving” or “not recovered/not resolved”. Cases 
can be closed with the outcome of “recovering/resolving” when the subject has completed the 
follow-up period and is expected by [CONTACT_36308].
The SAE follow-up information should only include new (e.g. corrections or additional) 
information and must be reported within 24 hours of the investigator's first knowledge of the 
information. This is also the case for previously non-serious AEs which subsequently become 
SAEs.
!Non-serious AEs: Non-serious AEs must be followed until the outcome of the event is 
“recovering/resolving”, “recovered/resolved” or “recovered/resolved with sequelae” or until the 
end of the follow-up period stated in the protocol, whichever comes first, and until all queries 
related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs ongoing at 
time of death (where death is due to another AE) may be closed with the outcome 
“recovering/resolving” or “not recovered/not resolved”. Cases can be closed with the outcome 
of “recovering/resolving” when the subject has completed the follow-up period and is expected 
by [CONTACT_36308].
The investigator must ensure that the worst case severity and seriousness of an event is kept 
throughout the trial. A worsening of an unresolved AE must be reported as follow up with re-
assessment of severity and/or seriousness of the event.
Queries or follow-up requests from Novo Nordisk must be responded to within [ADDRESS_694781].CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694782] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 68 of 119
12.4 Technical complaints and technical complaint samples
12.4.1 Reporting of technical complaints
All technical complaints on any of the following products: 
!Semaglutide 3 mg/7 mg/14 mg or placebo I tablets
!Sitagliptin [ADDRESS_694783] details (fax, e-mail and address) are provided in Attachment I to the protocol.
The investigator must assess whether the technical complaint is related to any AEs or SAEs.
Technical complaints must be reported on a separate technical complaint form. A technical 
complaint form for each code number or for each DUN must be completed.
The investigator must complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint:
!Technical complaint assessed as related to an SAE within 24 hours
!All other technical complaints within [ADDRESS_694784] coordinate the shipment to 
Customer Complaint Center, Novo Nordisk (the address is provided in Attachment I ) and ensure 
that the sample is sent as soon as possible. A print or copy of the technical complaint form must be 
sent with the sample.
The investigator must ensure that the technical complaint sample contains the code number and, if 
available, the DUN.
If the technical complaint sample is unobtainable, the investigator must specify on the technical 
complaint form why it is unobtainable.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694785] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694786]. The shipment of the technical complaint sample should be done in 
accordance with the same conditions as for storage (see Section 9).
12.[ADDRESS_694787](s).
The investigator must follow the pregnancy until the pregnancy outcome and the newborn infant is 
one month of age.
The investigator must report information about the pregnancy, pregnancy outcome and health of the 
newborn infant(s), as well as AEs in connection with the pregnancy and AEs in the foetus and 
newborn infant.
The following must be collected and reported by [CONTACT_36309] - electronically 
(e.g. in PDF format), or by [CONTACT_36310]:
1. Reporting of pregnancy information
Information about the pregnancy and pregnancy outcome/health of the newborn infant(s) has to 
be reported on Maternal Form 1A and 1B, respectively. 
When the pregnancy outcome is abnormal (i.e. congenital anomalies, foetal death including 
spontaneous abortion and/or any anomalies of the foetus observed at gross examination or 
during autopsy) and/or when a congenital anomaly is diagnosed within the first month, further 
information has to be reported for the female subject on Maternal Form 2. In addition, 
information from the male partner has to be reported on the Paternal Form, after an informed 
consent has been obtained from the male partner. 
Initial reporting and follow-up information must be reported within 14 calendar days of the 
investigator's first knowledge of initial or follow-up information. 
Reporting of AE information
The investigator has to report AEs in connection with the pregnancy as well as in the foetus and 
newborn infant(s). The SAEs that must be reported include abnormal outcome, such as foetal death (including spontaneous abortion), congenital anomalies (including those observed at gross 
examination or during autopsy of the foetus), as well as other pregnancy complications fulfilling 
the criteria of an SAE.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694788] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 70 of 119
Forms and timelines for reporting AEs:
Non-serious AEs: 
– Paper AE form* within 14 calendar days of the investigator's first knowledge of the initial 
or follow-up information to the non-serious AE.
SAEs: 
– Paper AE form* within 24 hours of the investigator's first knowledge of the SAE.
– Paper SIF within 5 calendar days of the investigator's first knowledge of the SAE.
–SAE follow-up information to the AE form and/or SIF within 24 hours of the 
investigator's first knowledge of the follow-up information.
* It must be clearly stated in the AE diagnosis field on the AE form if the event occurred in 
the subject, foetus or newborn infant.
Any queries or follow-up requests from Novo Nordisk to non-serious AEs, SAEs and pregnancy 
forms must be responded to by [CONTACT_19452] [ADDRESS_694789].
12.6 Precautions and/or overdose
There are no specific antidotes to semaglutide. Treatment of an overdose should be symptomatic.
There is a potential risk of hypoglycaemia during dosing with semaglutide. The typi[INVESTIGATOR_36226] a non-severe hypoglycaemia (mild/moderate) include: hunger, slight headache, 
nausea, light-headedness, palpi[INVESTIGATOR_36227]. Severe hypoglycaemia may produce loss of 
consciousness. Symptoms of non-severe hypoglycaemia should be treated by [CONTACT_237189].
Severe hypoglycaemia resulting in loss of consciousness should be treated at the investigator’s 
discretion according to best available medical practise.
One case of accidental overdose of oral semaglutide was reported in the NN9924-[ADDRESS_694790] felt CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694791] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694792] was 
withdrawn from the trial after  days of treatment due to an AE (diarrhoea).
For further details please see the current edition of the IB for Oral administration of semaglutide 
(NN9924), edition 623, and any updates hereof.
12.7 Committees related to safety
12.7.1 Novo Nordisk safety committee
Novo Nordisk will constitute an internal oral semaglutide safety committee to perform ongoing 
safety surveillance. The oral semaglutide safety committee may recommend unblinding of any data 
for further analysis and in this case an independent ad hoc group will be established in order to 
maintain the blinding of the trial personnel.
12.7.2 Event adjudication committee
An independent external event adjudication committee (EAC) is established to perform qualitative 
or quantitative validation of selected AEs according to pre-defined diagnostic criteria. The
validation is based on review of pre-defined clinical source data related to the specific AE. Pre-
defined clinical data consist of copi[INVESTIGATOR_534939].
The EAC is composed of permanent members covering required medical specialities. EAC 
members must disclose any potential conflicts of interest and must be independent of Novo 
Nordisk. 
The events are reviewed by [CONTACT_36312] a blinded manner. The EACs will have no authorisations to 
impact on trial conduct, trial protocol or amendments.
The EAC works in accordance with written guidelines included in the EAC Charter describing in 
details the composition, tasks, responsibilities and work processes of the committee.
The events outlined in Table 12–[ADDRESS_694793] been selected for adjudication in order to obtain an external 
independent validation of the diagnosis. In addition, cardiovascular events are being adjudicated 
according to FDA requirements51.
The EAC will review copi[INVESTIGATOR_36229] (translated if necessary) of medical documentation received in the adjudication packages (e.g. x-ray, ECGs, ultrasound images, discharge summaries, pathology CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694794] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 72 of 119
reports and death certificates). The investigator must provide medical documentation as soon as 
possible, when they receive the request from Novo Nordisk or the event adjudication vendor.
The assessments made by [CONTACT_135552]. However, the adjudication made by [CONTACT_36320], given its independence and 
in-depth analysis of each event, will be attributed with greater importance of the two. The outcome 
of adjudication will be kept in the clinical trial database.
The following AEs will be adjudicated in this trial:
Table 12–2 Adverse events for adjudication
Events Description Adjudication outcome
Death !All-cause death !Cardiovascular death 
(including undetermined 
cause of death)
!Non-Cardiovascular death
Acute Coronary 
SyndromeAcute Coronary Syndrome conditions include:
!ST-elevation acute myocardial infarction (STEMI)
!Non-ST elevation acute myocardial infarction 
(NSTEMI)
!Silent MI 
!Unstable angina pectoris (UAP)!Acute myocardial 
infarction (STEMI or NSTEMI), silent MI
!Unstable angina pectoris
requiring hospi[INVESTIGATOR_237158]!Epi[INVESTIGATOR_36231], spi[INVESTIGATOR_1831], or retinal vascular injury as a result of haemorrhage or infarction
!Transient Ischaemic Attack (TIA) is defined as a 
transient epi[INVESTIGATOR_1865] (< 24 hours) of focal 
neurological dysfunction caused by [CONTACT_36313], spi[INVESTIGATOR_1831], or retinal ischaemia, without acute infarction!Ischaemic stroke
!Haemorrhagic stroke
!Undetermined stroke
!TIA
Heart failure 
requiring 
hospi[INVESTIGATOR_11956]!Hospi[INVESTIGATOR_36233] a primary diagnosis of heart 
failure (new epi[INVESTIGATOR_534940])!Heart failure requiring 
hospi[INVESTIGATOR_534941]:
!Abdominal pain consistent with acute pancreatitis 
(acute onset of a persistent, severe, epi[INVESTIGATOR_244173])
!Serum lipase activity (and/or amylase activity) at 
least three times greater than the upper limit of 
normal
!Characteristic findings of acute pancreatitis on 
imagingAcute pancreatitis
!Mild
!Moderate 
!Severe
Malignant 
neoplasmMalignant neoplasms are defined as
!neoplasms in which abnormal cells divide without 
control and can invade nearby [CONTACT_36315]/or !Malignant neoplasmCONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694795] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 73 of 119
spread to other parts of the body through the blood 
and lymph systems
Thyroid neoplasms are excluded in this event category
Thyroid disease, if 
malignant thyroid
neoplasm or C-cell 
hyperplasiaMalignant thyroid neoplasms are defined as 
!thyroid neoplasms in which abnormal cells divide 
without control and can invade nearby [CONTACT_36314]/or spread to other parts of the body through 
the blood and lymph systems
!C-cell hyperplasia, defined as hyperplasia of the 
parafollicular C-cells of the thyroid gland!Malignant thyroid 
neoplasm
!C-cell hyperplasia
Acute kidney 
injuryAcute kidney injury52is defined as any of the following 
(not graded):
!Increase in serum creatinine by ≥0.3 mg/dL
(≥26.5μmol/L) within 48 hours, or
!Increase in serum creatinine to ≥1.[ADDRESS_694796] occurred within the prior 7 days, or
!Urine volume < 0.5 mL/kg/h for 6 hours!Acute kidney injury
Lactic acidosis !Lactic acidosis is characterized by [CONTACT_534959]!Lactic acidosis
All AEs will be screened for potential missed events for adjudication and if needed, the investigator 
will be asked to provide additional information such as an alternative aetiology, underlying cause(s) 
and/or clinical details.
The event adjudication vendor or EAC can decide to have an AE adjudicated even if not initially 
reported as an event for adjudication by [CONTACT_093].
Event adjudication will be performed for AEs in randomised subjects including AEs with an onset 
date during the screening period. Event adjudication will not be performed for AEs in screening 
failures.
AEs for adjudication must be reported according to Section 12.2. In addition the specific event 
adjudication form should be completed within 14 calendar days of the investigator's first knowledge 
of the AE and all relevant predefined documents provided according to instructions in the event 
adjudication site manual.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694797] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694798] or an 
assessment has not been done and will not be available, or if the question is irrelevant (e.g. is not 
applicable), indicate this according to the data entry instructions.
The following will be provided as paper case report forms (CRF):
!Pregnancy forms
In addition paper AE forms and paper SIFs will be provided. These must be used when access to the 
eCRF is revoked or if the eCRF is unavailable. The paper technical complaint form must also be 
used for complaints that are not subject specific.
On the paper CRF forms print legibly, using a ballpoint pen. Ensure that all questions are answered
and that no empty data blocks exist. Ensure that no information is recorded outside the data blocks. If a test/assessment has not been done and will not be available, indicate this by [CONTACT_565] "ND" (not 
done) in the appropriate answer field in the CRF. If the question is irrelevant (e.g. is not applicable) 
indicate this by [CONTACT_565] "NA" (not applicable) in the appropriate answer field. Further guidance can 
be obtained from the instructions in the CRF.
The investigator must ensure that all information is consistent with the source documentation. By 
[CONTACT_36321], the investigator confirms that the information in 
the eCRF and related forms is complete and correct.
13.1 Corrections to case report forms 
Corrections to the CRF data may be made by [CONTACT_36322]'s delegated staff.
An audit trail will be maintained in the CRF application containing as a minimum: the old and the 
new data, identification of the person entering the data, date and time of the entry and reason for the 
correction.
If corrections are made by [CONTACT_093]'s delegated staff after the date the investigator has signed 
the case book, the case book must be signed and dated again by [CONTACT_093].
13.[ADDRESS_694799] ensure that data is recorded in the eCRF as soon as possible, preferably 
within 5 days after the visit. Once data has been entered, it will be available to Novo Nordisk for 
data verification and validation purposes.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694800] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694801] been entered into the 
eCRF no later than 3 days after LSLV at the site in order to ensure the planned lock of the database.
Site specific eCRF data (in an electronic readable format) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site. When the final CTR is 
available, the data will be archived by [CONTACT_3454].CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694802] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694803] monitoring visit will be performed as soon as possible after FSFV at 
the trial site and no later than 4 weeks after. The monitoring visit intervals will depend on the 
outcome of the remote monitoring of the CRFs, the trial site's recruitment rate and the compliance 
of the trial site to the protocol and GCP, but will not exceed 12 weeks for trial sites with active 
subjects (defined as subjects in screening, treatment or follow-up).
The monitor must be given direct access to source documents (original documents, data and 
records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are important to the evaluation of the trial. If the electronic medical record does 
not have a visible audit trail, the investigator must provide the monitor with signed and dated 
printouts. In addition the relevant trial site staff should be available for discussions at monitoring 
visits and between monitoring visits (e.g. by [CONTACT_756]).
All data must be verifiable in source documentation other than the CRF (BMI and age are not 
source data verified as they are calculated in EDC).
For all data recorded the source document must be defined in a source document agreement at each 
trial site. There must only be one source defined at any time for any data element.
Source data generated by [CONTACT_36323]; any correction must be explained, signed and dated 
by [CONTACT_36324].
The original diaries and/or PROs must not be removed from the trial site, unless they form part of 
the CRF and a copy is kept at the site.
The monitor will ensure that the CRFs are completed and that paper CRFs are collected.
The following data will be source data verified for screening failures:
!Date for obtaining informed consent.
!Reason for screening failure
Monitors must review the subject's medical records and other source data (e.g. the diaries and 
PROs) to ensure consistency and/or identify omissions compared to the CRF. If discrepancies are 
found, the investigator must be questioned about these.
A follow-up letter (paper or electronic) will be sent to the investigator following each monitoring 
visit. This should address any action to be taken.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694804] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694805] the identity of subjects in all presentations and publications as required by 
[CONTACT_5737], regional and national requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694806] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694807] Operating Procedures and IT architecture documentation. The use and 
control of these systems are documented.
Investigators working on the trial may use their own electronic systems to capture source data.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694808] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 79 of 119
17 Statistical considerations
General considerations
The blinding of the randomised treatments will be maintained until the database has been released 
for statistical analysis. No interim analyses or other analyses of unblinded data will be performed 
before the database is locked.
If necessary, a statistical analysis plan (SAP) may be written in addition to the protocol, including a 
more technical and detailed elaboration of the statistical analyses. The SAP will be finalised before 
database lock.
Data from all sites will be analysed and reported together. 
In statistical analyses where stratification is included, the two combinations (metformin; 
metformin+SU) will be included based on the actual information collected through the eCRF. In 
case of missing eCRF information the information collected from IWRS system will be used.
The latest available measurement, at or prior to the randomisation visit, will be used as the baseline 
measurement. If no measurement(s) have been obtained, at or prior to randomisation, the baseline 
value will be left missing.
Laboratory values below the lower limit of quantification (LLoQ) will be set to ½LLoQ. Number of 
values below LLoQ by [CONTACT_36326].
The primary and confirmatory efficacy endpoints will be confirmed at week 26. This approach will 
result in a lower proportion of missing data compared to the expected proportion of missing data at 
week 52 and week 78 and therefore a more reliable estimate of efficacy. 
Results from a statistical analysis will as a minimum be presented by [CONTACT_534960] 26, week 52 and week 78 with associated two-
sided 95% confidence intervals and p-values corresponding to two-sided tests of no difference:
!oral semaglutide 14 mg vs. sitagliptin 100 mg
!oral semaglutide 7 mg vs. sitagliptin 100 mg
!oral semaglutide 3 mg vs. sitagliptin 100 mg
If no statistical analysis is specified, data will be presented using relevant summary statistics.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694809] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694810] of the trial objective will be defined; a primary de-facto 
(effectiveness) estimand and a secondary de-jure (efficacy) estimand: 
!Primary estimand
ode-facto treatment difference at week 26 for all randomised subjects
!Secondary estimand 
ode-jure treatment difference at week [ADDRESS_694811] in a future population that results from 
initiating treatment with oral semaglutide including potential rescue medication(s) as compared to 
initiating treatment with sitagliptin 100 mg including potential rescue medication(s). Generalisation 
of this estimand depends among other things on the extent to which the use of rescue medication 
and treatment adherence in this trial reflects clinical practice. All post-baseline scheduled visit data 
will be included in the analysis, including data collected after discontinuation of trial product or 
initiation of rescue medication(s).
The secondary de-jure estimand assesses the glycaemic benefit a future subject is expected to 
achieve if initiating and continuing treatment with oral semaglutide as compared to sitagliptin [ADDRESS_694812] even though subjects are intended to stay in 
the trial regardless of treatment status and initiation of rescue medication(s), when estimating the 
primary estimand , is expected to be maximum 10% based on the oral semaglutide phase 2 trial 
(NN9924-3790). Thus, missing data will be due to withdrawal from trial or lost to follow-up.
The proportion of missing data when estimating the secondary estimand is expected to be higher 
(20%) since data collected after discontinuation of trial product or initiation of rescue medication(s) 
will be set to missing. The 20% of missing data is based on the sitagliptin phase 3 trials50the oral 
semaglutide phase 2 trial (NN9924-3790) and the indication that a low starting dose with gradual dose escalation diminishes GI AEs compared with more aggressive dosing regimens. Across 
treatment arms the main reasons for missing data are expected to be early treatment discontinuation 
due to GI AEs and eventually initiation of rescue medication. Initiation of rescue medication is 
expected to be more frequent in the sitagliptin 100 mg arm and in the oral semaglutide 3 mg armCONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694813] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694814] dose levels of oral semaglutide. A higher proportion of subjects are 
expected to discontinue treatment due to AEs in the oral semaglutide 14 mg arm, compared to the 
other treatment arms. So overall the frequency of missing data is expected to be similar across 
treatment arms.
Descriptive summaries and graphical representation of extent, reason(s) for and pattern of missing 
data will be presented by [CONTACT_2939].
17.1 Sample size calculation
The primary endpoint is change from baseline to week 26 in HbA 1c. For HbA 1cboth non-inferiority 
and superiority versus sitagliptin 100 mg are planned to be tested at each dose level. The 
confirmatory secondary endpoint is change from baseline to week 26 in body weight (kg). For body 
weight, superiority versus sitagliptin 100 mg is planned to be tested at each dose level. The sample 
size calculation is based on jointly meeting the below three out of the nine pre-specified 
confirmatory hypotheses shown in Figure 17–1 . The closed testing procedure described in Bretz et 
al 201153is used to control the overall type-1 error at a nominal two-sided 5% level. The three 
hypotheses are
!HbA 1csuperiority of oral semaglutide 14 mg vs. sitagliptin 100 mg
!HbA 1csuperiority of oral semaglutide 7 mg vs. sitagliptin 100 mg
!HbA 1cnon-inferiority of oral semaglutide 3 mg vs. sitagliptin 100 mg (margin 0.3%) 
The statistical testing strategy is based on the following two principles:
!Within a dose level, glycaemic efficacy must be established by [CONTACT_13505] 1cnon-inferiority before 
testing for added benefits in terms of superiority for HbA 1cand/or superiority of body weight. 
!Glycaemic efficacy by [CONTACT_13505] 1cnon-inferiority must be established on all higher dose levels 
before continuing testing hypotheses on lower dose levels.
The sample size is calculated using the calcPower function in the R package, gMCP54using [ZIP_CODE] 
simulations. All of the nine pre-specified confirmatory tests are assumed to be independent. Since 
positive correlations among the tests are expected, the assumption of independence is viewed as 
conservative.
The sample size assumptions for treatment effects (TE), adjusted treatment effects and the common 
standard deviation (SD) used across dose levels are given in Table 17–1 . These are based on the 
oral semaglutide phase 2 results (NN9924-3790), sitagliptin phase 3a trial results50and supported 
by [CONTACT_135554] s.c. semaglutide phase 2 trial (NN9535-1821).
Since the equalising effect of rescue medication will be included in the primary analysis as well as a 
conservative approach for handling of missing data will be performed, an adjustment in treatment 
effect will be implemented for the 10% of subjects who discontinue trial product or initiate rescue 
medication and for the 10% of subjects with missing data. The treatment effects used in the sample CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694815] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 82 of 119
size calculation will be adjusted according to a 75% smaller effect in these subjects. In addition, the 
non-inferiority margin of 0.3 % for HbA 1cis used, when testing for non-inferiority. The adjusted 
treatment effects for testing non-inferiority (HbA 1c only) and superiority are as described below:
!Non-inferiority 
o0.8*TE + 0.2*TE*0.25 + non-inferiority margin*0.1
!Superiority
o0.8*TE + 0.2*TE*0.25 
Table 17–[ADDRESS_694816] (TE) -0.5% -0.3% -0.1% -3.0 kg -2.0 kg -1.0 kg
Adjusted TE, non-inferiority - 0.395% -0.225% -0.055% -2.52 kg -1.67 kg -0.82 kg
Adjusted TE, superiority -0.425% -0.255% -0.085% -2.55 kg -1.70 % -0.85%
Standard deviation 1.1% 1.1% 1.1% 4.0 kg 4.0 kg 4.0 kg
With the above assumptions, allocating 465 subjects to each of the semaglutide treatment arms and 
sitagliptin 100 mg provides 90 % power to jointly confirm HbA 1csuperiority of semaglutide 14 mg 
vs. sitagliptin 100 mg, HbA 1csuperiority of semaglutide 7 mg vs. sitagliptin 100 mg and HbA 1c
non-inferiority of semaglutide 3 mg vs. sitagliptin 100 mg. Calculated powers for selected individual hypotheses are presented in Table 17–2 . In total 4×465 = 1860 subjects are planned to be 
randomised.
Table 17–[ADDRESS_694817] HbA 1csuperiority Body weight superiorityHbA 1cnon-inferiority 
(margin = 0.3 %)
Treatment dose 14 mg 7 mg 3 mg 14 mg 7 mg 3 mg 3 mg
Power (%) > 99 90 19 > 99 > 99 89 > 99CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694818] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 83 of 119
Figure 17–1 Graphical illustration of the closed testing procedure
The overall significance level of α= 0.05 (two-sided) is initially allocated to the HbA 1cnon-
inferiority test of semaglutide 14 mg vs. sitagliptin 100 mg. The local significance level ( α-local) 
will be reallocated if a hypothesis is confirmed according to the weight given by [CONTACT_534961] (hypotheses).       =0 . 0 5HbA 1c(%)
Non-inferiority
       =0HbA 1c(%)
Superiority
       =0HbA 1c(%)
Non-inferiority       =0Body weight (kg)
Superiority13⁄
12⁄13⁄13⁄
12⁄
12⁄12⁄
       =0HbA 1c(%)
Superiority
       =0HbA 1c(%)
Non-inferiority       =0Body weight (kg)
Superiority13⁄
12⁄13⁄13⁄
12⁄
12⁄12⁄
       =0Body weight (kg)
Superiority
       =0HbA 1c(%)
Superiority 11semaglutide 7 mg
vs. sitagliptin 100 mg
semaglutide 3 mg
vs. sita gliptin 100 m gsemaglutide 14 mg
vs. sitagliptin 100 mgCONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694819] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 84 of 119
17.2 Definition of analysis sets
The following analysis sets will be defined:
Full analysis set (FAS): includes all randomised subjects. Subjects in the FAS will contribute to 
evaluation “as randomised”.
Safety analysis set (SAS): includes all subjects exposed to at least one dose of trial product. 
Subjects in the SAS will contribute to the evaluation based on the trial product received for the 
majority of the period where they were on treatment. This will be referred to as contributing to the 
evaluation “as treated”.
Per protocol (PP) analysis set: includes all subjects in the full analysis set who fulfils the 
following criteria
!have not violated any inclusion criteria
!have not fulfilled any exclusion criteria
!have a baseline HbA 1cmeasurement
!is exposed to trial product and have at least one HbA 1cmeasurement at or after week 14
Subjects in the PP analysis set will contribute to the analysis “as treated”.
Before data are locked for statistical analysis and the randomisation code is broken, a review of all 
data will take place. Any decision to exclude either a subject or single observations from the 
statistical analysis is the joint responsibility of the members of the Novo Nordisk study group. 
Exclusion of data from analyses will be used restrictively and normally no subjects will be excluded 
from the FAS. If any subjects or observations are to be excluded from the analysis sets or the 
observation periods defined below, this, together with the reasons for their exclusion, will be 
documented and signed by [CONTACT_36331]. A description of these exclusions 
will be included in the clinical trial report.
Data selections and observation periods
Unless subjects withdraw their informed consent, data collection will continue for the full duration 
of the trial.  The full duration of the trial is defined as
!up to and including the follow-up visit (V17) for subjects on trial product
!the End-of-treatment visit (V16) or the follow-up premature discontinuation visit (V17A), 
whichever comes last, for subjects who have discontinued trial product prematurely.
Subjects and data to be used in an analysis will be selected in a two-step manner.
!First, subjects will be selected based on the specified analysis set
!Next, data points on the selected subjects from first step will be selected based on the specified 
observation periodCONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694820] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 85 of 119
In this trial, three observation periods will be defined, as described below. Data points collected 
outside an observation period will be treated as missing in the analysis. Baseline data will always be 
included in an observation period. For adjudicated events, onset date will be the EAC adjudicated 
onset date.
Definition of the observation periods:
!In-trial: This observation period will include information assessed at or after date of 
randomisation (as registered in the IWRS system) and up to and including the last direct 
subject-site contact, which is scheduled to take place 5 weeks (+3 days visit window) after the  
planned last dose on trial product at a follow-up visit. For subjects who withdraw their informed 
consent, the in-trial observation period ends at their date of withdrawal. If a subject is lost to 
follow-up, the end of the in-trial period is defined as the date of the last subject-investigator 
contact (site or phone visit). In the case a subject dies during the trial the date of death will be 
the end-date of the in-trial observation period regardless of the above defined end-dates. This 
observation period will be the primary observation period for estimating the primary estimand 
used for evaluating safety.
!On-treatment: This observation period is a subset of the in-trial observation period and 
represents the time period in which a subject is considered exposed to trial product. For 
adjudicated events, ECGs, anti-semaglutide antibodies and AEs including hypoglycaemic 
epi[INVESTIGATOR_534942] (i) the follow-up visit V17, (ii) the follow-up prematurely discontinuation visit 
V17A, (iii) the last date on trial product +38 days or (iv) the end-date for the in-trial observation 
period will be used. The follow-up visit is scheduled to take place [ADDRESS_694821] corresponding to approximately five half-lives of oral semaglutide. In addition, the 
ascertainment window includes the follow-up visit window of +[ADDRESS_694822]. For efficacy and other safety assessments (laboratory assessments, physical 
examination and vital signs) information collected on or after the first date of trial product up to 
and including the last date on trial product +3 days will be used in order to ensure specificity to 
reversible effects of treatment. The end-date for all assessments in the on-treatment observation 
period will be before or the same date as the end-date for the in-trial observation period. This 
observation period will be considered supportive for evaluating efficacy and used for evaluating 
safety. 
!On-treatment without rescue medication: This observation period is a subset of the on-
treatment observation period. To avoid potential confounding from rescue medications, 
information that is collected after initiation of rescue medication will be excluded from this 
observation period. Specifically, it includes information collected at or after date of first dose on 
trial product up to and including the first date of; (i) last date on trial product +3 days or 
(ii) initiation of rescue medication. Thus, an ascertainment window of 3 days for subjects not 
initiating rescue medication. This observation period will be the primary observation period for 
estimating the secondary estimand.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694823] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 86 of 119
17.3 Primary endpoint 
The primary endpoint is change from baseline to week 26 in HbA 1c.
17.3.1 Primary analysis for the primary estimand 
The primary estimand will be estimated based on the FAS using week 26 measurements from the 
in-trial observation period. The primary statistical analysis will be a pattern mixture model using 
multiple imputation to handle missing data assuming that the missing data mechanism is missing at 
random (MAR). Imputation of missing data at week 26 will be done within 16 groups of subjects 
defined by [CONTACT_36333], stratification factor and whether subjects at week 26; (i) have 
discontinued treatment or initiated rescue medication or (ii) still on treatment and have not initiated  
rescue medication. It is hereby [CONTACT_534962] 26 are similar in 
terms of randomised treatment arm and treatment adherence/rescue status.
Missing values for each group will be imputed as follows:
!An analysis of covariance (ANCOVA) with region as a categorical fixed effect and baseline 
HbA 1cmeasurement as a covariate will be fitted to observed values of the change from baseline 
in HbA 1cat week 26.
!The estimated parameters for location and dispersion will be used to impute [ADDRESS_694824] with missing week 26 data based on region and baseline HbA 1c. Thus, 100 complete 
data sets will be generated including observed and imputed values.
Analysis used for confirming superiority versus sitagliptin at week 26:
For each of the 100 (now complete) imputed data sets the change from baseline to week 26 will be 
analysed using an ANCOVA with treatment, stratification factor and region as categorical fixed 
effects and baseline HbA 1cas covariate. The results obtained from analysing the datasets will be 
combined using Rubin’s rule55to draw inference.
From this analysis the estimated treatment differences between each of the oral semaglutide dose 
levels and sitagliptin 100 mg together with associated two-sided 95 % CIs and unadjusted two-sided 
p-values for testing no difference from zero will be presented.
Analysis used for confirming non-inferiority versus sitagliptin at week 26:
Prior to analysing the data using the same model and approach as used for confirming superiority 
(see above) a value of 0.3 % (the non-inferiority margin) will be added to imputed values at week 
26 for the oral semaglutide treatment arms only (Koch 2008)56. For evaluating non-inferiority 
versus sitagliptin 100 mg unadjusted two sided p-values for testing no difference from the non-inferiority margin will be presented.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694825] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694826]-baseline measurements up 
to and including week 26 from the on-treatment without rescue observation period. The primary 
analysis for the secondary estimand will be a Mixed Model for Repeated Measurements (MMRM). 
A restricted maximum likelihood (REML) will be used. The model will include all post baseline 
HbA 1cmeasurements collected at scheduled visits up to and including week [ADDRESS_694827] 
scheduled visit to ensure that all randomised subjects will contribute to the statistical analysis.
The MMRM is a well-established method that accounts for the uncertainty pertaining to missing 
data. This analysis assumes that the missing data mechanism is MAR. Under this assumption the 
statistical behaviour of the missing data (given the observed responses and model fixed effects and 
covariates) is assumed to be same as the observed data. Even if the assumption of MAR is not 
satisfied, this analysis is not expected to bias the estimated HbA 1ctreatment effect for the secondary 
estimand in favour of oral semaglutide to any important degree. This is supported by [CONTACT_534963] 2 results (NN9924-3790) that showed that subjects who discontinue oral 
semaglutide do not have better outcome on average than those who remain on treatment.
Primary hypotheses 
For the primary HbA 1cendpoint the following two confirmatory one-sided hypotheses are planned 
to be tested at each dose level of oral semaglutide versus sitagliptin 100 mg. Let the mean treatment 
difference be defined as μ= (oral semaglutide minus sitagliptin 100 mg):
!Non-inferiority, using a non-inferiority margin of 0.3 %
oH0: μ≥0.3 % against Ha: μ< 0.3 %
!Superiority
oH0: μ≥0.0 % against Ha: μ< 0.0 %
Operationally the hypotheses will be evaluated by [CONTACT_1192]-sided tests.
Multiplicity and criteria for confirming hypotheses
The Type-I error for testing the nine confirmatory hypotheses related to the HbA 1cand body weight 
endpoints (see Section 17.1) will be preserved in the strong sense at 5 % (two-sided) using the 
weighted Bonferroni-based closed testing procedure described in Bretz et al 201153and outlined in 
Figure 17–[ADDRESS_694828] dose level. It 
will be tested at the overall significance level (5 %) while allocating 0 % local significance level to 
the remaining of the hypotheses. For this hypothesis, and in general, if a hypothesis is confirmed the CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694829] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 88 of 119
significance level will be reallocated according to the weight and the direction of the edges going 
from the confirmed hypothesis to the next hypotheses as specified in Figure 17–1 . Each of the 
following hypotheses will be tested at their local significance level ( α-local). This process will be 
repeated until no further hypotheses can be confirmed.
Non-inferiority and/or superiority will be considered confirmed if the mean treatment difference is 
supporting the corresponding alternative hypothesis and the two-sided p-value from the primary 
analysis of the primary estimand is strictly below its local two-sided significance level as defined by 
[CONTACT_36332] 17–1 . This is equivalent to using a one-sided p-value 
(nominal alpha = 0.025) and a one-sided 2.5 % overall significance level in the closed testing 
procedure.
17.3.[ADDRESS_694830] of missing data. Since conservatism, i.e. avoiding bias in 
favour of semaglutide, depends on the context, separate sensitivity analyses will be made for non-
inferiority and superiority testing.
The evaluation of the robustness of the primary analysis results will primarily be based on a pattern 
mixture model approach using multiple imputation. An overview of the sensitivity analyses for each 
of the estimands are specified below followed by a more detailed description of the three different 
pattern mixture models used. Finally, three additional sensitivity analyses for the primary analysis 
will be described that are not based on the pattern mixture model approach.
Sensitivity analyses for the primary estimand
The estimation of the primary estimand will be repeated using the following sensitivity analyses: 
!A comparator multiple imputation analysis based on FAS using the in-trial observation period
(superiority).
!A comparator multiple imputation analysis based on FAS using the on-treatment observation 
period (superiority). This sensitivity analysis aims to compare oral semaglutide versus 
sitagliptin 100 mg for subjects who adhere to treatment regardless of whether or not rescue 
medication has been initiated.
!A comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely based on FAS using the in-trial observation period (superiority).
!A tippi[INVESTIGATOR_007]-point multiple imputation analysis based on FAS using the in-trial observation period
(non-inferiority and superiority).
!A MMRM analysis (the primary for the secondary estimand) based on FAS using the in-trial 
observation period (non-inferiority and superiority).CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694831] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 89 of 119
Sensitivity analyses for the secondary estimand
The estimation of the secondary estimand will be repeated using the following sensitivity analyses: 
!A comparator multiple imputation analysis based on FAS using the on-treatment without rescue 
medication observation period (superiority).
!A comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely based on FAS using the on-treatment without rescue medication 
observation period (superiority).
!A tippi[INVESTIGATOR_007]-point multiple imputation analysis based on FAS using the on-treatment without 
rescue medication observation period (non-inferiority and superiority).
[IP_ADDRESS] Pattern mixture models
Common for the three pattern mixture model sensitivity analyses is that they all aim to stress-test 
the primary HbA 1cresults by [CONTACT_135559], while maintaining the missing data assumption for the sitagliptin 100 
mg arm. The analyses will all be implemented using multiple imputation as described for the 
primary analysis of the primary estimand:
!Comparator multiple imputation analysis: In this sensitivity analysis missing data at week [ADDRESS_694832] this imputation approach removes the treatment 
difference between oral semaglutide and sitagliptin 100 mg for all subjects randomised to oral 
semaglutide, given that oral semaglutide is better than sitagliptin 100 mg. Due to the potential 
lack of sensitivity for testing non-inferiority this sensitivity analysis will only be used to 
evaluate the robustness of HbA 1csuperiority conclusions.
!Comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely: In this sensitivity analysis missing data at week 26 for subjects who 
discontinue oral semaglutide treatment due to treatment related AE(s) will be imputed to 
resemble in distribution the week [ADDRESS_694833] sensitivity analysis. Due to the potential lack of sensitivity for testing non-inferiority this 
sensitivity analysis will only be used to evaluate the robustness of HbA 1csuperiority 
conclusions.
!Tippi[INVESTIGATOR_007]-point multiple imputation analysis: In this sensitivity analysis, missing data will first be 
imputed according to the primary analysis. Second, for all oral semaglutide treatment arms a 
penalty will be added to the imputed values at week 26. The approach is to gradually increase 
this penalty until all confirmed HbA 1cconclusions from the primary analysis are reversed. For 
each hypothesis tested the specific value of the penalty that reverses the conclusion will be used CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694834] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 90 of 119
to evaluate the robustness of the primary analysis results. This sensitivity analysis will be used 
for evaluating the robustness of the HbA 1cnon-inferiority and superiority conclusions.
[IP_ADDRESS] Other sensitivity analysis
The following additional sensitivity analysis will be specified
!Per-protocol analysis : This sensitivity will be based on the per-protocol analysis set. Data from 
the in-trial observation period will be analysed using the primary analysis approach for the 
primary estimand. This sensitivity analysis will be used to evaluate the robustness of the HbA 1c 
non-inferiority conclusions.
!Complete case analysis: This sensitivity analysis will be based on the on-treatment without 
rescue medication observation period and include subjects in the FAS who have a valid HbA 1c 
measurement at week 26. The change from baseline to week 26 in HbA 1cwill be analysed by a 
linear normal model (ANCOVA) with treatment, stratification factor and region as categorical 
fixed effects and baseline HbA 1cas a covariate. This sensitivity analysis will be used to evaluate 
the robustness of the HbA 1c non-inferiority conclusions. 
!Last observation carried forward (LOCF) analysis: This sensitivity analysis will be based on 
the FAS using the on-treatment without rescue medication observation period. The change from baseline to week 26 in HbA
1cwill be analysed by a linear normal model (ANCOVA) with 
treatment, stratification factor and region as categorical fixed effects and baseline HbA 1cas a 
covariate. This sensitivity analysis will be used for evaluating the robustness of the HbA 1c non-
inferiority and superiority conclusions.
[IP_ADDRESS] Assessment of sensitivity analyses
The results from the sensitivity analyses will be collectively used to interpret the robustness of the 
trial results for HbA 1cand body weight. Due to the large number of sensitivity analyses and their 
inherent conservative nature, it will not be a requirement that all confirmatory hypotheses are 
consistently confirmed across the sensitivity analyses. Thus, no absolute success criteria will be pre-
defined for each sensitivity analysis. The sensitivity results in totality will be used to substantiate 
the credibility of the trial results. 
17.4 Secondary endpoints
17.4.1 Confirmatory secondary endpoints
Change from baseline to week 26 in body weight (kg) will be a confirmatory secondary endpoint. 
The primary and secondary estimands will be estimated using the same approaches as described for 
the primary HbA 1cendpoint. Body weight will only be tested for superiority. Baseline body weight 
will be used as a covariate instead of baseline HbA 1cin both the imputation and analysis model.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694835] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 91 of 119
From the analyses the three estimated treatment differences between each of the oral semaglutide 
dose levels and sitagliptin 100 mg will be presented together with associated two-sided 95 % CIs 
and unadjusted two-sided p-values for testing no difference from zero.
Superiority will be considered confirmed if the mean treatment difference is supporting the 
corresponding hypothesis and the two-sided p-value from the analysis of the primary estimand is 
strictly below its local two-sided significance level resulting from the closed testing procedure in 
Figure 17–1 .
Sensitivity analyses similar to the ones pre-specified for testing superiority for the primary HbA 1c
endpoint will be made to evaluate the robustness of the body weight results.
17.4.2 Supportive secondary endpoints
[IP_ADDRESS] Efficacy endpoints
The below supportive secondary efficacy endpoints will be evaluated for
!the primary estimand based on FAS using the  in-trial observation period
!the secondary estimand based on FAS using the on-treatment without rescue medication 
observation period
Continuous efficacy endpoints
Change from baseline to week 52 and 78 in:
!HbA 1c
!Body weight (kg)
Change from baseline to week 26, 52 and 78 in:
!Body weight (%)
!FPG
!BMI
!Waist circumference
!Fasting lipid profiles (total cholesterol, LDL cholesterol, VLDL cholesterol, HDL cholesterol, 
triglycerides, free fatty acids)
Change from baseline to week 26, 52 and 78 in the below derived endpoints from the 7-point 
profile:
!Mean of the 7-point profile, defined as the area under the profile, calculated using the 
trapezoidal method, divided by [CONTACT_36336]
!Mean increment over all meals
The above continuous endpoints will be analysed separately using similar model approaches as for 
the primary endpoint with the associated baseline response as a covariate. Fasting lipid profile CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694836] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694837]-baseline measurement up to and including week 78. From this model the estimated 
treatment differences (ratios) will be presented at week 26 (except for HbA 1cand body weight), 52 
and 78 with 95 % confidence intervals and two-sided p-values for test of no difference.
Binary efficacy endpoints
Subjects who after 26 weeks of treatment achieve (yes/no):
!HbA 1c< 7.0 % (53 mmol/mol) (ADA) target*
!HbA 1c≤6.5 % (48 mmol/mol) (AACE) target
!HbA 1c reduction ≥1%
!Weight loss ≥3%
!Weight loss ≥5%
!Weight loss ≥10 %
!HbA 1c< 7.0 % (53 mmol/mol) without confirmed hypoglycaemia (treatment emergent severe or 
BG confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_1841]) and no weight gain
!HbA 1creduction ≥1 % and weight loss ≥3%
The above eight endpoints will be evaluated after week 52 and after week 78 as well.
Handling of missing data for the response status of the above categorical endpoints will be 
determined from the imputed continuous responses. A total of 100 imputed data sets will be created 
based on the same models as used to analyse HbA 1cand body weight. For the secondary estimand 
the MMRM based analysis will be implemented in a MI setting. The imputed complete data sets 
will be analysed using a logistic regression model with treatment, stratification factor and region as 
categorical fixed effects and baseline response as covariate (i.e. baseline HbA 1c for binary HbA 1c 
endpoints, baseline weight for binary weight endpoints and both baseline HbA 1c and body weight 
for the binary endpoint that combines both parameters). Inference comparing treatments will be
drawn using Rubin’s rule55.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694838] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 93 of 119
Time to event endpoint
!Time to rescue medication
Subjects completing the study without need for rescue medication will be censored at the time point 
of actual date of last trial product. Start time is date of first trial product. Time to rescue medication 
will be described and compared for each of the oral semaglutide dose level versus sitagliptin [ADDRESS_694839] ratios between each dose levels and sitagliptin will be presented together with 
95 % confidence intervals and two-sided p-values for test of no difference. This endpoint will be 
evaluated after week 26, after week 52 and after week 78.
[IP_ADDRESS] Safety endpoints
The safety endpoints will be evaluated based on SAS using the on-treatment observation period and 
based on FAS using the in-trial observation period unless otherwise stated. The following endpoints 
are used to support the safety objectives:
Adverse events 
!Number of TEAEs during exposure to trial product, assessed up to approximately [ADDRESS_694840] recent version of the Medical Dictionary for Regulatory 
Activities (MedDRA) coding. 
A treatment emergent AE is defined as an AE with onset in the on-treatment observation period (see 
definition of observation periods in Section 17.2).
TEAEs will be summarised in terms of the number of subjects with at least one event (N), the 
percentage of subjects with at least one event (%), the number of events (E) and the event rate per 
100 patient years of observation time (R) for the on-treatment observation period. Supportive 
summaries of AEs will be made for the in-trial observation period. 
Other safety endpoints
Change from baseline to week 78 in:
!Amylase
!Lipase
!Pulse
!Systolic blood pressure
!Diastolic blood pressure
The above safety endpoints will be evaluated using the primary analysis for the primary estimand 
based on SAS using the in-trial observation period and using the primary analysis for the secondary 
estimand based on SAS using the on-treatment observation period. Endpoints will be analysed CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694841] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 94 of 119
separately as described above for continuous efficacy endpoints. Results will be presented at week 
26, 52 and 78. Amylase and lipase endpoints will be log-transformed prior to analysis with the 
associated log-transformed baseline value as a covariate.
Change from baseline to week 78 in:
!Haematology 
!Biochemistry (except for amylase and lipase)
!Calcitonin
!Electrocardiogram (ECG) evaluation
!Physical examination
Occurrence of anti-semaglutide antibodies (positive/negative):
!Anti-semaglutide binding antibodies
!Anti-semaglutide neutralising antibodies 
!Anti-semaglutide binding antibodies cross reacting with native GLP-1
!Anti-semaglutide neutralising antibodies cross reacting with native GLP-1
Anti-semaglutide binding antibody levels
The above safety assessments will be summarised descriptively by [CONTACT_31703]. 
Categorical safety endpoints will be summarised as counts and relative frequencies. Calcitonin will 
also be presented by [CONTACT_547]. 
Pharmacokinetics 
Please refer to Section 17.5.
Hypoglycaemia
!Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_534932], assessed up to approximately 83 weeks
!Treatment emergent severe or BG confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_36237], assessed up to approximately 83 weeks (yes/no) 
Classification of Hypoglycaemia:
Hypoglycaemic epi[INVESTIGATOR_36238]-treatment observation period 
only.
Treatment emergent: hypoglycaemic epi[INVESTIGATOR_534943]-treatment observation period (see definition of observation periods 
in Section 17.2).CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694842] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 95 of 119
A treatment emergent hypogl ycaemic epi[INVESTIGATOR_67662] a hypoglycaemic epi[INVESTIGATOR_534944]-treatment observation period (see definition of observation periods in Section 17.2).
Nocturnal hypoglycaemic epi[INVESTIGATOR_1841]: are epi[INVESTIGATOR_1841] o ccurring between 00:01 and 05.59 both inclusive.
Hypoglycaemic epi[INVESTIGATOR_36242] (see Figure 17–2 ).
Novo Nordisk classification of hypoglycaemia
In normal physiology, symptoms of hypoglycaemia occur below a PG level of 3.1 mmol/L 
(56 mg/dL)59. Therefore, Novo Nordisk has included hypoglycaemia with PG levels below this cut-
off point in the definition of BG confirmed hypoglycaemia.
Novo Nordisk uses the following classification in addition to the ADA classification:
!Severe or BG confirmed symptomatic hypoglycaemia: An epi[INVESTIGATOR_534945]33or BG confirmed by a PG value < 3.1 mmol/L (56 mg/dL) with
symptoms consistent with hypoglycaemia. 
ADA classification33of hypoglycaemia 
!Severe hypoglycaemia: An epi[INVESTIGATOR_36244], glucagon, or take other corrective actions. PG concentrations may not be 
available during an event, but neurological recovery following the return of PG to normal is 
considered sufficient evidence that the event was induced by a low PG concentration.
!Asymptomatic hypoglycaemia: An epi[INVESTIGATOR_36245], but with a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL).
!Documented symptomatic hypoglycaemia: An epi[INVESTIGATOR_36246] a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL).
!Pseudo-hypoglycaemia: An epi[INVESTIGATOR_36247] a measured PG concentration > 3.9 mmol/L (70 
mg/dL) but approaching that level.
!Probable symptomatic hypoglycaemia: An epi[INVESTIGATOR_36248] a PG determination but that was presumably caused by a PG
concentration ≤ 3.9 mmol/L (70 mg/dL).CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694843] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 96 of 119
Hypoglycaemic 
epi[INVESTIGATOR_36249] ≤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurementAsymptomatic 
hypoglycaemia
Documented 
symptomatic 
hypoglycaemia
Pseudo-
hypoglycaemia
Probable 
symptomatic 
hypoglycaemiaNo
Yes
No measurement 
with symptomsPG > 3.9 mmol/L 
(70 mg/dL)
with symptomsPG ≤3.9 mmol/L 
(70 mg/dL)
with symptomsPG ≤3.9 mmol/L 
(70 mg/dL)
without symptoms
NoYes
Note: Glucose measurements are performed with capi[INVESTIGATOR_36250]/
herselfSevere 
hypoglycaemia
(ADA 2013)
Figure 17–[ADDRESS_694844] one epi[INVESTIGATOR_1865] (%), the total 
number of epi[INVESTIGATOR_36252] [ADDRESS_694845]’s on-treatment observation period as offset. The model will 
include factors for treatment, stratification factor and region as fixed factors and baseline HbA 1cas 
covariate.
The binary endpoint showing whether a subject has at least one treatment emergent severe or BG 
confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_36253] a logistic regression model 
with treatment, stratification factor and region as fixed factors and baseline HbA 1cas covariate.
17.5 Pharmacokinetic modelling
Exploratory population PK modelling will be used to evaluate semaglutide exposure and the effects 
of pre-specified covariates on the exposure. As a minimum, the covariates sex, body weight at CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694846] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 97 of 119
baseline and age at baseline will be explored. The modelling will include data from approximately 
50 % of randomised subjects that were exposed to semaglutide in this trial and will be performed as 
a meta-analysis across phase 3a trials. Actual time points for dose administration and PK sampling 
will be used. Results will be presented using criteria which will be pre-specified in a modelling 
analysis plan that is to be finalised before DBL. The modelling will be performed by [CONTACT_135561] A/S and will be reported separately from the CTR.
Covariate analysis 
Covariates will be tested on CL/F. Covariates for inclusion:
!Body weight
!Age group (< 65, 65-75 and ≥75 years)
!Sex (Male/Female)
!Race (White/ Black or African American/ Asian/ Hawaiian or Pacific Islander/ Other)
!Ethnicity (Hispanic or Latino/ not Hispanic or Latino)
!Upper GI comorbidity (Yes/No)
17.6 Health economics and/or patient reported outcomes
PROs
Change from baseline to week 26, 52 and 78 in:
!SF-36v2™ (acute version) health survey: Total score and scores from the 8 domains
!IWQoL-Lite Clinical Trial Version: Total score of the 23 items
!CoEQ: Scores from the 4 domains and scores from 19 individual items
The PRO questionnaires, SF-36v2™, IWQOL and Control of Eating questionnaire will be used to 
evaluate the objective regarding Quality of Life. The PRO endpoints will be analysed separately as 
the other continuous efficacy endpoints using a similar model approaches as for the primary 
endpoint with the associated baseline response as a covariate.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694847] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 98 of 119
18 Ethics
18.1 Benefit-risk assessment of the trial
18.1.1 Risks and precautions
[IP_ADDRESS] Oral Semaglutide
The non-clinical safety programme of oral semaglutide has not revealed any safety issues 
precluding use in humans (see Section 3.1.4 ).
The sections below describe identified and potential risks associated with oral semaglutide 
treatment. The identified/potential risks are based on findings in non-clinical and clinical trials with 
oral semaglutide as well as other GLP-[ADDRESS_694848] that rodents are more sensitive to the mode of action of GLP-1 RAs 
for induction of C-cell tumours. However, as a precaution, subjects with a family or personal 
history of MEN 2, or MTC will not be enrolled in the trial. During the trial, calcitonin will be 
measured on a regular basis and guidance for investigators of further evaluation and action on 
elevated calcitonin concentrations is included in Appendix A . This will ensure appropriate and 
consistent handling of elevated calcitonin levels.
Teratogenicity (embryo-foetal development toxicity)
Semaglutide caused embryo-foetal malformations in the rat through a GLP-[ADDRESS_694849] been GI disorders (nausea, vomiting, diarrhoea, dyspepsia and 
constipation). Clinical trials have indicated that a low starting dose with gradual dose escalation 
diminishes GI AEs compared with more aggressive dosing regimens. Consequently, a low starting 
dose and gradual dose escalation with [ADDRESS_694850] been 
implemented in the trial in order to mitigate GI side effects.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694851] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694852](s) or related products 
will not be enrolled in the trial. In addition, subjects will be instructed to contact [CONTACT_36339][INVESTIGATOR_1884] a hypersensitivity reaction occurs.
Hypoglycaemia
Based on current knowledge about the GLP-[ADDRESS_694853] mainly been observed when a GLP-1 RA is combined with 
SU or insulin. The risk for development of hypoglycaemia with oral semaglutide in combination 
with SU and insulin is unknown due to limited data. In this trial subjects can be on anti-diabetic 
background medication with SU, but not insulin (however, if rescue medication is needed insulin 
can be prescribed as add-on to randomised treatment). If a subject on SU develops unacceptable 
hypoglycaemia the dose of SU can be reduced.
Acute renal impairment
In subjects treated with GLP-[ADDRESS_694854] to ensure acceptable glycaemic control during the trial. If rescue 
medication is required it should be in accordance with ADA/European Association for the Study of CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694855] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 100 of 119
Diabetes25,26(excluding GLP-RAs, DPP-4 inhibitors and amylin analogues). It is the responsibility 
of the investigator to ensure the best possible care according to the principles outlined in Diabetes 
Care 2014 Standards of Medical Care in Diabetes60.
[IP_ADDRESS] Sitagliptin
The most commonly reported side effects are upper respi[INVESTIGATOR_1092], nasopharyngitis and 
headache. Also acute pancreatitis, acute renal failure, hypersensitivity reactions and hypoglycaemia 
have been reported50. 
18.1.[ADDRESS_694856] with the study site, with close follow-up of their T2DM and a careful medical examination; all of which 
will most likely result in an intensified management of their T2DM.
All subjects in this trial will receive trial products and auxiliary supplies free of charge. 
18.1.3 Risk and benefit conclusion 
The safety profile of oral semaglutide generated from the non-clinical and clinical development 
programme has not revealed any safety issues that would prohibit administration of doses in 
accordance with the planned clinical trial. The phase 2 results indicate that oral semaglutide will 
provide clinically significant improvements in glycaemic control and body weight. Sitagliptin is 
already a marketed drug approved for the use in subjects with T2DM. In conclusion, the potential 
risk to the subjects in this trial is considered low and acceptable in view of the anticipated benefits 
oral semaglutide/sitagliptin will provide to subjects with T2DM.
18.[ADDRESS_694857] comply with applicable 
regulatory requirement(s) and adhere to ICH GCP
1and the requirements in the Declaration of 
Helsinki2.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694858] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694859]’s willingness to continue 
participating in the trial, the investigator must inform the subject in a timely manner and a revised 
written subject information must be provided and a new informed consent must be obtained.
In order to avoid missing data, the subjects will be informed about the importance of completing the 
trial also if the subjects discontinue from trial product.
18.[ADDRESS_694860]’s data will be handled 
as follows:
!Data already collected and data collected at the end-of-trial visit will be retained by [CONTACT_49753], entered into the database and used for the trial report. 
!Safety events will be reported to Novo Nordisk and regulatory authorities according to 
local/national requirements.
If data is used, it will always be in accordance with local regulations and IRBs/IECs.
18.[ADDRESS_694861] be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_17950].CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694862] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 102 of 119
18.5 Premature termination of the trial and/or trial site
Novo Nordisk, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial 
or a trial site at any time, but agreement on procedures to be followed must be obtained.
If a trial is suspended or prematurely terminated, the investigator must inform the subjects promptly 
and ensure appropriate therapy and follow-up. The investigator and/or Novo Nordisk must also 
promptly inform the regulatory authorities and IRBs/IECs and provide a detailed written 
explanation. 
If, after the termination of the trial, the benefit-risk analysis changes, the new evaluation must be 
provided to the IRBs/IECs in case it has an impact on the planned follow-up of subjects who have 
participated in the trial. If it has an impact, the actions needed to inform and protect the subjects 
should be described.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694863] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694864] be documented and explained in a protocol deviation by [CONTACT_18030], date
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the clinical database .
Documentation on protocol deviations must be kept in the investigator's trial master file and 
sponsor trial master file.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694865] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694866] to audits conducted by [CONTACT_36341]/IECs. Audits and inspections may 
take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff 
have an obligation to cooperate and assist in audits and inspections. This includes giving auditors 
and inspectors direct access to all source documents and other documents at the trial site relevant to 
the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are relevant to the evaluation of the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694867] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694868] be available 
to Novo Nordisk:
!Regulatory approval and/or acknowledgement of notification as required 
!Approval/favourable opi[INVESTIGATOR_36254]/IECs clearly identifying the documents reviewed as 
follows: protocol, any protocol amendments, subject information/informed consent form, any 
other written information to be provided to the subject and subject recruitment materials
!List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
!Curricula vitae of investigator and sub-investigator(s) (current, dated and signed - must include 
documented GCP training or a certificate)
!Signed receipt of IB and SmPC or local label of comparator
!Signed and dated Agreement on Protocol
!Signed and dated agreement on protocol amendment, if applicable
!Contract, signed by [CONTACT_1755]/or appropriate parties on behalf of the investigator’s site 
and Novo Nordisk
!Source document agreement
!Central laboratory certification and normal ranges
!Insurance statement, if applicable
!Financial disclosure form from investigator and sub-investigator(s)
Only applicable for US trial sites: 
!For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest
!For US trial sites: FDA form [ADDRESS_694869] be completed and signed by [CONTACT_534964]: A seal is accepted as signature.
FDA form 1572:
For US sites:
!Intended for US sites
!Conducted under the IND
!All US investigators, as described above, will sign FDA Form 1572CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694870] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 106 of 119
For sites outside the US:
!Intended for participating sites outside of the US
!Not conducted under the IND
!All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will analyse and report data from all sites together if more than one site is involved in 
the trial.
By [CONTACT_12142], each investigator agrees to comply fully with ICH GCP1, applicable 
regulatory requirements and the Declaration of Helsinki2.
By [CONTACT_12142], each investigator also agrees to allow Novo Nordisk to make investigator's 
name [CONTACT_136821] 
[CONTACT_36344].CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694871] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694872] of the trial at his/her site. If any tasks are delegated, 
the investigator must maintain a log of appropriately qualified persons to whom he/she has 
delegated specified trial-related duties. The investigator must ensure that there is adequate training 
for all staff participating in the conduct of the trial. It is the investigator's responsibility to supervise 
the conduct of the trial and to protect the rights, safety and well-being of the subjects.
A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible 
for all trial-related medical decisions.
The investigator must ensure adequate supervision of the conduct of the trial at the trial site. 
The investigator will follow instructions from Novo Nordisk when processing data.
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data
produced) in the investigator trial master file. The documents including the subject identification 
code list should be kept in a secure locked facility, so no unauthorized persons can get access to the 
data. 
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.
During any period of unavailability, the investigator must delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk. 
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694873] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694874], if deemed necessary by [CONTACT_3454]. Provided that certain 
conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial to 
researchers who require access for research projects studying the same disease and/or trial product 
studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted clinical trial report for this trial.
One or two investigators will be appointed by [CONTACT_36345] (signatory investigator) on behalf of all participating investigators. The signatory 
investigator(s) will be appointed based upon the criteria defined by [CONTACT_156082]61.
23.[ADDRESS_694875] for 
Clinical Trial Disclosure4.
Novo Nordisk reserves the right to defer the release of data until specified milestones are reached, for example when the clinical trial report is available. This includes the right not to release the 
results of interim analyses, because the release of such information may influence the results of the 
entire trial.
At the end of the trial, one or more scientific publications may be prepared collaboratively by [CONTACT_1275](s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to [ADDRESS_694876] intellectual property.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694877] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 109 of 119
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. All authors will be given the relevant 
statistical tables, figures and reports needed to evaluate the planned publication. In the event of any 
disagreement on the content of any publication, both the investigators' and Novo Nordisk opi[INVESTIGATOR_36255].
Where required by [CONTACT_18038], the investigator from each trial site will be named in an 
acknowledgement or in the supplementary material, as specified by [CONTACT_18038].
Novo Nordisk maintains the right to be informed of plans by [CONTACT_36347], presentation, communication or other information concerning the 
investigation described in this protocol. Any such communication must be submitted in writing to 
Novo Nordisk before submission for comments. Comments will be given within four weeks from 
receipt of the planned communication.
23.1.1 Authorship
Authorship of publications should be in accordance with the Uniform Requirements of the 
International Committee of Medical Journal Editors61(sometimes referred to as the Vancouver 
Criteria). Novo Nordisk will appoint investigator(s) to prepare publications in collaboration with Novo Nordisk.
23.1.2 Site-specific publication(s) by [CONTACT_1697](s)
For a multi-centre clinical trial, analyses based on single-site data usually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
subjects and therefore may not be supported by [CONTACT_3454]. It is a Novo Nordisk policy that such 
individual reports do not precede the primary manuscript and should always reference the primary 
manuscript of the trial.
Novo Nordisk reserves the right to prior review of such publications. Further to allow for the 
primary manuscript to be published as the first, Novo Nordisk asks for deferment of publication of 
individual site results until the primary manuscript is accepted for publication. As Novo Nordisk 
wants to live up to the industry publication policy, submission of a primary publication will take 
place no later than [ADDRESS_694878] their own research subjects' data and will be provided with the 
randomisation code after results are available.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694879] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694880]'s medical records must be kept for the maximum period permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper-
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if 
not otherwise notified. The investigator should not destroy any documents without prior permission 
from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk 
can refer the investigator to an independent archive provider that has a system in place to allow only 
the investigator to access the files.
The investigator must be able to access his/her trial documents without involving Novo Nordisk in 
any way. Site-specific CRFs and other subject data (in an electronic readable format or as paper 
copi[INVESTIGATOR_17951]) will be provided to the investigator before access is revoked to the systems and/or 
electronic devices supplied by [CONTACT_3454]. These data must be retained by [CONTACT_21655]. If the 
provided data (e.g. the CD-ROM) is not readable during the entire storage period, the investigator 
can request a new copy. A copy of all data will be stored by [CONTACT_3454].
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for as long as the 
product is on the market plus 20 years. 
The files from the trial site/institution must be retained for 15 years after the completion of the trial, 
or longer if required by [CONTACT_36348]. In any case trial files cannot be 
destroyed until the trial site/institution is notified by [CONTACT_3454]. The deletion process must 
ensure confidentiality of data and must be done in accordance with local regulatory requirements.
24.2 Retention of human biospecimens
Antibody samples may be stored at the special laboratory until market authorisation in case Health 
Authorities requests further characterisation of the antibody response (maximum up to 15 years 
from end of trial).
Semaglutide PK samples will be stored at the specialised laboratory until final CTR in case Novo 
Nordisk request further analysis of the PK samples.
None of the data will be identified by [CONTACT_2300]. Antibody samples and semaglutide PK samples will be 
identified only by a subject number, a visit number and a trial identification number. The trial staff 
is responsible for maintaining a code list which links to the subject number. The code list must be 
kept for at least [ADDRESS_694881] may be reviewed by [CONTACT_534965]: [ADDRESS_694882] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694883] the investigator if they wish to be informed about 
results derived from stored antibody samples obtained from their own body.
For Brazil only: Biological samples from Brazil will be destroyed at the end of the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694884] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 112 of 119
25 Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval or favourable opi[INVESTIGATOR_36256]/IEC prior to commencement of 
the trial.
During the trial, the investigator or Novo Nordisk, as applicable, must promptly report the 
following to the IRB/IEC, in accordance with local requirements: updates to IB, unexpected SAEs 
where a causal relationship cannot be ruled out, protocol amendments according to local 
requirements, deviations to the protocol implemented to eliminate immediate hazards to the 
subjects, new information that may affect adversely the safety of the subjects or the conduct of the 
trial (including new benefit-risk analysis in case it will have an impact on the planned follow-up of 
the subjects), annually written summaries of the trial status and other documents as required by [CONTACT_36349]/IEC.
The investigator must ensure submission of the clinical trial report synopsis to the IRB/IEC.
Protocol amendments must not be implemented before approval or favourable opi[INVESTIGATOR_36257], unless necessary to eliminate immediate hazards to the subjects.
The investigator must maintain an accurate and complete record of all submissions made to the 
IRB/IEC. The records must be filed in the investigator trial master file and copi[INVESTIGATOR_36258].
Regulatory Authorities:
Regulatory authorities will receive the clinical trial application, protocol amendments, reports on 
SAEs and the clinical trial report according to national requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694885] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: [ADDRESS_694886] liability for its products and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.
Novo Nordisk assumes no liability in the event of negligence, or any other liability of the sites or 
investigators conducting the trial, or by [CONTACT_18033].
Novo Nordisk accepts liability in accordance with:
For Russia only: Federal law of 12 April 2010 No. 61-FZ ‘On Medicinal Drugs’ Circulation.
For [LOCATION_013] only: German Drug Law dated August 24, 1976, last amended by [CONTACT_36350] 3 of the law 
dated December 17, 2014 (Federal Law Gazette I p. 2222)
For [LOCATION_009] only: The French Public Health Code article L 1121-10 (law n° 2004-[ADDRESS_694887] 2004. "The sponsor is responsible for identification 
of the harmful consequences of the biomedical research for the person lending himself thereto and 
for indemnification of his beneficiaries, except in case of proof, incumbent on it, that the prejudice 
is not attributable to his fault of or the fault of any intervening party, without the sponsor's being 
entitled to call on acts by a third party or the voluntary withdrawal of the person who had initially 
consented to cooperating in the research.
For Mexico only: 
a) Novo Nordisk carries product liability for its products assumed under the special laws, 
acts/and/or guidelines for conducting trials in any country, including those applicable 
provisions on the Mexican [LOCATION_002].   If the subject feels that something goes wrong during 
the course of this trial, the subject should contact [CONTACT_215592].
b) If during their participation in the trial the subject experiences a disease or injury that, 
according to the trial doctor and the sponsor, is directly caused by [CONTACT_237207]/or 
a study procedure that otherwise would not have been part of his/her regular medical care, the 
subject will receive from the Institution or Medical Care Establishment and free of charge, the 
appropriate medical treatment as required. In this case, the costs resulting from such treatment  
as well as the costs of any indemnification established by [CONTACT_534966]; even if the  subject 
discontinues his/her participation in the study by [CONTACT_237209] a decision from the 
investigator.
c) By [CONTACT_79844], the  subject will not renounce to any compensation or 
indemnification he/she may be entitled to by [CONTACT_2371], nor will he/she will incur  any additional CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694888] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 114 of 119
expense as a result of his/her participation in the trial; any additional expense resulting from 
the subject’s participation in the trial  will be covered by [CONTACT_135568].CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694889] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 115 of 119
27 References
1 International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Guideline    
for Good Clinical Practice E6 (R1), Step 4.  [ADDRESS_694890] 2013.
3 DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004; 88(4):787-
835, ix.
4 [LOCATION_006] Prospective Diabetes Study ([LOCATION_006]PDS) Group. Intensive blood-glucose control with 
sulphonylureas or insulin compared with conventional treatment and risk of complications in 
patients with type 2 diabetes ([LOCATION_006]PDS 33). Lancet 1998; 352(9131):837-853.
[ADDRESS_694891], Huang BY, Tai TY, Diabcare A. The status of diabetes control in Asia--a 
cross-sectional survey of 24 317 patients with diabetes mellitus in 1998. Diabet Med 2002; 
19(12):978-985.
[ADDRESS_694892] ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among U.S. adults with 
diagnosed diabetes from 1999 to 2004. Diabetes Care 2008; 31(1):102-104.
[ADDRESS_694893] JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. 
Mol Cell Endocrinol 2009; 297:127-136.
8 Kieffer TJ, Habener JL. The glucagon-like peptides. Endocr Rev 1999; 20(6):876-913.
[ADDRESS_694894] in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96(3):737-745.
[ADDRESS_694895] in type 2 (non-insulin-
dependent) diabetes. Diabetologia 1986; 29(1):46-52.
[ADDRESS_694896] JJ, Meier JJ. Secretion of glucagon-like peptide-1 
(GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011; 54:10-18.
12 Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in 
normal and diabetic subjects. J Clin Invest 1967; 46(12):1954-1962.
13 Højberg PV, Vilsbøll T, Rabøl R, Knop FK, Bache M, Krarup T et al. Four weeks of near-
normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694897] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 116 of 119
glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009; 
52:199-207.
14 Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat 
Rev Endocrinol 2012; 8(12):728-742.
[ADDRESS_694898] 1998; 101(3):515-520.
[ADDRESS_694899] JJ, Orskov C, Ritzel R et al. Glucagon-like 
peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am 
J Physiol 1997; 273(5:PART 1):E981-E988.
[ADDRESS_694900] JJ, Willms B, Creutzfeldt W. Normalization of fasting 
hyperglycaemia by [CONTACT_36353]-like pe ptide 1 (7-36 amide) in type 2 (non-insulin-
dependent) diabetic patients. Diabetologia 1993; 36(8):741-744.
18 Nauck MA. Incretin based therapi[INVESTIGATOR_36259] 2 diabetes mellitus: properties, functions, and 
clinical implications. Am J Med 2011; 124 ([ADDRESS_694901]):S3-S18.
19 Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK et al. 
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin 
Endocrinol Metab 2001; 86(8):3717-3723.
[ADDRESS_694902] . 2012. 
21 Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC. Glucagon-like-peptide-1 receptor 
expression in normal and diseased human thyroid and pancreas. Mod Pathol 2014;1-12.
22 Investigators Brochure for s.c. Semaglutide (NN9535), Edition 10 or any updates hereof.  2015. 
23 Investigators Brochure for oral Semaglutide (NN9924), Edition 6 or any updates hereof. 2015.
24 Guidance for Industry Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic 
Therapi[INVESTIGATOR_237166] 2 Diabetes. Food and Drug Administration, December 2008.  
25 Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management 
of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes 
(EASD). Diabetes Care 2012; 35(6):1364-1379.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694903] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 117 of 119
26 Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management 
of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position 
statement of the American Diabetes Association and the European Association for the Study of 
Diabetes. Diabetologia 2015; 58(3):429-442.
27 Novo Nordisk. http://www.novonordisk-trials.com/website/content/how-we-disclose-trial-
information.aspx.  2015. 
28 De Angelius C., Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R et al. Clinical Trial 
Registration: A statement from the International Committee of Medical Journal Editors. N Engl J 
Med 2004; 351:1250-1251.
[ADDRESS_694904] 2007.
30 The European Parliament and the Council of the European Council. Directive 2001/20/EC of 
the European Parliament and of the Council of [ADDRESS_694905] of clinical trials on medicinal products for human use, article 
11. Official Journal of the European Communities May 2001.
31 The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down 
Community procedures for the authorisation and supervision of medicinal products for human and 
veterinary use and establishing a European Medicines Agency, article 57. Official Journal of the 
European Communities April 2001.
32 KDOQI Clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis -
2012; 60(5):850-886.
[ADDRESS_694906] ER, Anderson J, Childs B, Cryer P,  Dagogo-Jack S, Fish L et al. Hy poglycemia and 
Diabetes: A report of a workgroup of the American Diabetes Association and The Endocrine 
Society. Diabetes Care 2013; 36(May):1384-1395.
34 McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. Diabet 
Med 2001; 18(9):690-705.
35 Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for 
Industry - Patient-Reported Outcome Measures: Use in Medical Product Development to Support 
Labeling Claims. Dec 2009.
36 Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-reported 
outcomes: challenges and potential solutions. Curr Med Res Opin 2009; 25(4):929-942.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694907] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 118 of 119
37 Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. 
Conceptual framework and item selection. Med Care 1992; 30(6):473-483.
[ADDRESS_694908] RI: QualityMetric, Incorporated, 2000.
39 Turner-Bowker DM BPWJJ. SF-36® Health Survey & "SF" Bibliography.  2002.  Lincoln, RI: 
QualityMetric Incorporated. 
[ADDRESS_694909], Kosloski KD, Williams GR. Development of a brief measure to 
assess quality of life in obesity. Obes Res 2001; 9(2):102-111.
[ADDRESS_694910] of Weight on Quality of Life-Lite for Use in Clinical Trials - Draft 
Instrument Adaptation Report. RTI Health Solutions. 22 May 2015.
42 Hill AJ. The psychology of food craving. Proc Nutr Soc 2007; 66(2):277-285.
43 Hill AJ, Heaton-Brown L. The experience of food craving: a prospective investigation in 
healthy women. J Psychosom Res 1994; 38(8):801-814.
44 Hill AJ, Weaver CF, Blundell JE. Food craving, dietary restraint and mood. Appetite 1991; 
17(3):187-197.
45 Hill AJ, Rogers PJ, Blundell JE. Techniques for the experimental measurement of human eating 
behaviour and food intake: a practical guide. Int J Obes Relat Metab Disord 1995; 19(6):361-375.
46 Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol 2006; 
101(10):2379-2400.
47 Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG et al. Classification of 
acute pancreatitis--2012: revision of the Atlanta classification and definitions by [CONTACT_534967]. Gut 2013; 62(1):102-111.
48 Food and Drug Administration. Guidance for Industry: Immunogenicity Assessment for 
Therapeutic Protein Products  . Aug 2015.
49 The rules governing medicinal products in the European Union, volume 4, Annex 13, 
Manufacture of Investigational Medicinal Products - Brussel. European Commission. Feb 2010.
50 [COMPANY_006] Sharp & Dohme Limited. JANUVIA - European Summary of Product Characteristics 
Annex 1. 26 May 2015.CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_694911] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT no.: 2015-001351-71 Page: 119 of 119
51 Hicks KA, Hung HMJ, Mahaffey KW, Mehran R, Nissen SE, Strockbridge NL et al. 
Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials 
(DRAFT).  20 Aug 2014. 
52 KDIGO. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney international 
supplements 2012; 2(1):1-138.
53 Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical approaches 
for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biom J 
2011; 53(6):894-913.
54 Rohmeyer, K. and Klinglmueller, F. gMCP: Graph Based Multiple Test Procedures. R package 
version 0.8-8. [ADDRESS_694912] 2014.
55 Little RJA, Rubin DB. Statistical analysis with missing data. [LOCATION_001]: John Wiley & Sons, 
1987.
56 Koch GG. Comments on 'Current issues in non-inferiority trials' by [CONTACT_19617] R. Fleming, 
Statistics in Medicine, DOI: 10.1002/sim.2855. Stat Med 2008; 27(3):333-342.
57 European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). 
Guideline on Missing Data in Confirmatory Clinical Trials (EMA/CPMP/EWP/1776/99 Rev. 1). 
EMA . 2 Jul 2010. 
58 National Academy of Sciences (NAS). The Prevention and Treatment of Missing Data in 
Clinical Trials. Washington D.C.: The National Academies Press, 2010.
59 Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose 
counterregulatory systems are higher than the threshold for symptoms. Journal of clinical 
investigation 1987; 79(3):777-781.
60 Standards of medical care in diabetes--2015. Diabetes Care 2015; [ADDRESS_694913] 1:S4-85.:S4-S85.
[ADDRESS_694914], 
Reporting, Editing and Publication of Scholarly Work in Medical Journals. Dec 2014.CONFIDENTIAL
Global and country key Novo Nordisk staff
Attachments I and II (if applicable) to the protocol are located in the Trial Master File.
Content: Global key staff and Country key staffCONFIDENTIALDate: Novo Nordisk
Version:
Status:Oral semaglutide
Trial ID: NN9924-4222Clinical Trial Report
Appendix 16.1.121 November 2018
1.0
FinalCONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: [ADDRESS_694915] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: [ADDRESS_694916] be restricted to relevant 
parties.
Protocol - Appendix A
CONFIDENTIALDate: [ADDRESS_694917] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 2 of 6
1 Background
Treatment with GLP-1 receptor agonists has shown to be associated with thyroid C-cell changes in 
rodents but not in non-human primates. The human relevance of this finding is unknown. However, 
based on the findings in rodents, monitoring of serum calcitonin (a sensitive biomarker for C-cell 
activation) is currently being performed in clinical trials with semaglutide.
While there is general agreement on the clinical interpretation of substantially elevated calcitonin 
levels (greater than 100 ng/L) as likely indicative of C-cell neoplasia, the interpretation of values 
between upper normal range (5.0 and 8.4 ng/L for women and men, respectively) and 100 ng/L is 
less clear with regards to indication of disease.
There are several known confounding factors affecting calcitonin levels, e.g.:
!renal dysfunction
!smoking
!autoimmune thyroiditis
!several drug classes (e.g. proton pump inhibitors, beta-blockers, H 2-blockers and 
glucocorticoids)
Physiology of C-cell activation in various clinical conditions and in different patient populations 
(i.e. with various co-morbidities) is poorly understood. There may be various clinical conditions not 
identified so far which mildly or moderately affect calcitonin secretion by C-cells.CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: [ADDRESS_694918] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: [ADDRESS_694919] has a calcitonin value ≥ 10 ng/L the algorithm outlined in Figure 1 and described 
below should be followed. The algorithm applies for all calcitonin values in the trial.
Calcitonin < 10ng/L
Calcitonin  ≥ 10 ng/L and 
< 50 ng/L
Calcitonin  ≥ 50 ng/L and 
< 100 ng/L
Calcitonin  ≥ 100 ng/LEvaluation of 
calcitonin results
Calcitonin  ≥ 10 ng/L and 
last measurement in the 
trialNo action
●Investigate potential confounding 
factors
●Continue sampling of calcitonin 
according to protocol
●Refer to thyroid specialist
●Discontinue trial product
●Refer to thyroid specialist
●Refer to thyroid specialist
Figure 1 Flow of calcitonin monitoring
2.1 Calcitonin ≥ 100 ng/L  
Action: The subject must immediately be referred to a thyroid specialist for further evaluation and 
the trial product must be discontinued (see protocol Section 6.5premature discontinuation of trial CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: [ADDRESS_694920] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: [ADDRESS_694921]). The subject should remain in the trial, however, all medications suspected to relate to this 
condition must be discontinued until diagnosis has been established.
Background: These values were found in 9 (0.15%) of a population of 5817 patients with thyroid 
nodular disease.1All of these patients were diagnosed with MTC resulting in a positive predictive 
value of 100 %.
Diagnostic evaluation should include:
!thyroid ultrasound examination
!fine needle aspi[INVESTIGATOR_36260] > 1 cm 
!potentially surgery with neck dissection
In case a subject is diagnosed with MTC, it is common clinical practice to explore the family 
history of MTC or MEN2 and perform a genetic test for RET proto-oncogene mutation.
2.2 Calcitonin ≥ 50 and < 100 ng/L
Action: The subject should be referred to a thyroid specialist for further evaluation. The subject 
should remain in the trial and continuation on trial product should be based on the evaluation done 
by [CONTACT_36354]. 
Background: These values were found in 8 (0.14%) of the population of 5817 patients with thyroid 
nodular disease1. Two of these subjects were diagnosed with MTC and two were diagnosed with 
C-cell hyperplasia, resulting in a positive predictive value of a C-cell anomaly of 50%.
Diagnostic evaluation should include: 
!thyroid ultrasound examination 
!if available and there are no contraindication, a pentagastrin stimulation test should be done. For 
subjects with positive pentagastrin stimulation test, surgery should be considered.
!if pentagastrin stimulation test is not available, thyroid ultrasound and fine needle aspi[INVESTIGATOR_36261].
2.3 Calcitonin ≥ 10 and < 50 ng/L
Action: The subject can continue in the trial on trial product. Continue sampling of calcitonin 
according to the protocol.
If the value is from the last sample taken in the trial, the subject should be referred to a thyroid 
specialist for further evaluation.CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: [ADDRESS_694922] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 5 of 6
Background: Calcitonin values from 20-50 ng/L were found in up to 1% of subjects of the 
population of 5817 patients with thyroid nodular disease1. The predictive value of a C-cell anomaly 
for this calcitonin level was 8.3%. However, the likelihood of having a medullary carcinoma >1 cm with calcitonin in this range is extremely low.
For calcitonin values between 10-20 ng/L Costante et al
1identified 216 (3.7%) patients. One patient 
out of the 216 had a subsequent basal (unstimulated) calcitonin of 33 ng/L, and had C-cell 
hyperplasia at surgery. Two other studies used a cut-off of CT > 10 ng/L to screen for C-cell 
disease, but they do not provide sufficient information on patients with basal CT > 10 and < 20 ng/L 
to allow conclusions.2,3CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: [ADDRESS_694923] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 6 of 6
3 References
1 Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S et al. Predictive value of serum calcitonin 
levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007; 92(2):450-455.
2 Scheuba C, Kaserer K, moritz A, drosten R. Sporadic hypercalcitoninemia: clinica and therapeutic consequences. 
Endocrine Related Cancer 2009; 16(1):243-253.
3 Verga U, Ferrero S, Vicentini L, Brambilla T, Cirello V, Muzza M et al. Histopathological and molecular studies in 
patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia? Endocr Relat Cancer 2007; 
14(2):393-403.CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: [ADDRESS_694924] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: [ADDRESS_694925] be restricted to relevant 
parties.
Protocol - Appendix B
CONFIDENTIALDate: [ADDRESS_694926] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: [ADDRESS_694927] be 
completed in the eCRF in addition to the AE form:
!Acute coronary syndrome (myocardial infarction or hospi[INVESTIGATOR_36193])
!Cerebrovascular event (stroke or TIA)
!Heart failure requiring hospi[INVESTIGATOR_11956]
!Pancreatitis
!Neoplasm (excluding thyroid neoplasm)
!Thyroid disease (including thyroid neoplasm)
!Renal event
!Hypersensitivity reactions
!Acute gallstone disease
!Medication error (concerning trial products):
oAdministration of wrong drug. 
Note: Use of wrong DUN is not considered a medication error.
oWrong route of administration.
oAdministration of an overdose with the intention to cause harm (e.g. suicide 
attempt).
oAccidental administration of a higher dose than intended. A higher dose is a dose of 
at least one tablet more than the intended dose; however the administered dose must 
deviate from the intended dose to an extent where clinical consequences for the trial 
subject were likely to happen as judged by [CONTACT_093], although they did not necessarily occur.
!Lactic acidosis
!Creatine kinase (CK) > 10x UNL
!Hepatotoxicity  events:
oALT or AST > 10x UNL and total bilirubin ≤ 2x UNL
oHepatotoxicity leading to trial product discontinuation
In case any of these events fulfil the criteria for an SAE, please report accordingly, see Section 12.2.
Some of these events will undergo event adjudication by [CONTACT_36355] (EAC), 
please see Section 12.7.2 and Table 12-1 .CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: [ADDRESS_694928] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 3 of 6
1.1 Acute coronary syndrome
If an event of acute coronary syndrome (ranging from unstable angina pectoris to myocardial 
infarction) is observed during the trial the following additional information must be reported if 
available: 
!Duration of symptoms
!Changes in ECG
!Collection of cardiac biomarkers
!Cardiac imaging
!Cardiac stress testing
!Angiography
!Use of thrombolytic drugs
!Revascularisation procedures 
1.2 Cerebrovascular event
If a cerebrovascular event (e.g. TIA, stroke) is observed during the trial, the following additional 
information must be reported if available: 
!Type of event (e.g. TIA, Stroke)
!Contributing condition
!Neurologic signs and symptoms
!History of neurologic disease
!Imaging supporting the condition
!Treatment given for the condition
1.3 Heart failure requiring hospi[INVESTIGATOR_237169] (admission to an in-patient unit or a visit to an 
emergency department that results in at least a 24 hour stay) is observed during the trial the 
following additional information must be reported if available: 
!Signs and symptoms of heart failure
!NYHA Class
!Supportive imaging
!Supportive laboratory measurements
!Initiation or intensification of treatment for this condition
1.[ADDRESS_694929] be reported if 
available:
!Signs and symptoms of pancreatitis
!Specific laboratory test supporting a diagnosis of pancreatitis:CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: [ADDRESS_694930] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 4 of 6
!Imaging performed and consistency with pancreatic disease
!Treatment for and complications of the event
!Relevant risk factors for pancreatic disease
!Family history of pancreatic disease
Please see Section 8.7.1 for further details on assessments in case of suspi[INVESTIGATOR_36194].
1.5 Neoplasm
All events of neoplasms (excluding thyroid neoplasm, which will be reported under thyroid disease) 
must be reported during the trial and the following additional information must be reported if 
available:
!Type of neoplasm
!Symptoms leading to identification of event
!Diagnostic imaging
!Pathological examination results
!Treatment for the event
!Participation in screening programs
!Risk factors associated to the event
1.[ADDRESS_694931] be reported if available:
!History of thyroid disease
!Signs and symptoms leading to investigations of thyroid disease
!Specific laboratory tests describing thyroid function
!Diagnostic imaging performed and any prior imaging supporting the disease history 
!Pathologic examinations
!Treatment given for the condition
!Risk factors identified
!Family history of thyroid disease
1.[ADDRESS_694932] be reported if 
available:
!Signs and symptoms of renal failure
!Specific laboratory test supporting the diagnosis 
!Imaging performed supporting the diagnosis
!Kidney biopsy resultsCONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: [ADDRESS_694933] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 5 of 6
!Risk or confounding factors identified including exposure to nephrotoxic agents
1.[ADDRESS_694934] be reported if available:
!Signs and symptoms associated to the event
!Time of appearance after administration of trial drug
!Relevant immunological tests performed
!Treatment given for the reaction
!Previous history of similar reactions
!Risk or confounding factors identified
Please see Section 8.7.[ADDRESS_694935] be reported if available: 
!Signs and symptoms of acute gallstone disease
!Specific laboratory test supporting a diagnosis of gallstone
!Imaging performed and consistency with gallstone disease
!Treatment given for the condition
!Relevant risk factors for acute gallstone disease
!Family history of gallstones
1.[ADDRESS_694936] be reported: 
!Trial product(s) involved 
!Classification of medication error
oWrong drug(s) administered
oWrong dose administered
!Whether the subject experienced any hypoglycaemic epi[INVESTIGATOR_36192]/or AE(s) as a result of the 
medication error 
!Suspected primary reason for the medication error CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: [ADDRESS_694937] 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 6 of 6
For definition of medication error, see Section 12.1.
1.11 Lactic acidosis
!If an event of lactic acidosis is observed during the trial the following additional information 
must be reported if available:
!Signs and symptoms of lactic acidosis
!Specific laboratory test results describing the event 
!Possible cause(s) of the event
1.12 Creatine kinase (CK) > 10x UNL
!If an event of CK > 10x UNL is observed during the trial the following additional information 
must be reported if available:
!Signs and symptoms associated to the event 
!Recent physical activity
!Possible cause(s) of the event
Please see Section 8.7.[ADDRESS_694938] > 10x UNL and total bilirubin ≤ 2x UNL
oHepatotoxicity leading to trial product discontinuation
If one of the above events is observed during the trial the following additional information must be 
reported if available:
!Signs and symptoms associated to the event 
!Risk factors
!Relevant laboratory test results 
!Diagnostic imaging performed 
!Possible cause(s) of the event 
Please see Section 8.7.4 for further details on assessments in case of increased levels 
aminotransferases.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 10 November 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN:U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: [ADDRESS_694939] 2015
Trial ID:NN9924-4222
PI[INVESTIGATOR_15597] 3 - vs. DPP-4 inhibitor
Efficacy and long-term safety of oral semaglutide versus sitagliptin
in subjects with type 2 diabetes
Trial phase: 3a
Applicable to all countries
Amendment originator:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment
CONFIDENTIALDate: 10 November 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN:U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 2 of 11
Table of Contents   
Page
Table of Contents.............................................................................................................. ................................2
1 Introduction including rationale for the protocol  amendment .............................................................3
1.1 Section 2 Flowchart ......................................................................................................... ..............3
1.2 Section [IP_ADDRESS] Supportive s econdary endpoints ...........................................................................[ADDRESS_694940] and Follow-up (visits 16A and 
17A) ........................................................................................................................... ....................3
1.4 Section 8.4.4 Electroca rdiogram – 12 -lead................................................................................... 3
1.5 Section 8.4.7 An tibodies.................................................................................................... ............3
1.6 Sections 8.7.4 Assessments in case of increased levels of aminotransferases, 12.1 
definitions, Appendix B Section 1 Adverse Events requiring additional data collection and 
Appendix B Section 1.13 Hep atotoxicity events ...........................................................................3
1.7 Section 9.4 Drug accountability  and destruction ...........................................................................4
1.8 Section 12.2 Reporting of adverse events.................................................................................... ..4
1.9 Sections 17 Statistical considerations, 17.3.1 Primary analysis for the primary estimand, 
[IP_ADDRESS] Efficacy endpoints and [IP_ADDRESS] Safety endpoints...........................................................4
2 Changes ....................................................................................................................... ...............................5
2.1 Section 2 Flowchart ......................................................................................................... ..............5
2.2 Section [IP_ADDRESS] Supportive s econdary endpoints ...........................................................................[ADDRESS_694941] and Follow-up (visits 16A and 
17A) ........................................................................................................................... ....................5
2.4 Section 8.4.4 Electroca rdiogram – 12 – Lead................................................................................5
2.5 Section 8.4.7 Antibodies.................................................................................................... ............6
2.6 Section 8.5 Laboratory  assessments .......................................................................................... ....6
2.7 Section 8.7.4 Assessments in case of incr eased levels of aminot ransferases ................................6
2.8 Section 9.4 Drug accountability  and destruction ...........................................................................6
2.9 Section 12.1 Definitions .................................................................................................... ............7
2.10 Section 12.2 Reporting of adverse events................................................................................... ...8
2.11 Section 17 Statistical considerations...................................................................................... ........9
2.12 Section 17.3.1 Primary analysis for the primary estimand ..........................................................10
2.13 Section [IP_ADDRESS] Efficacy endpoints ........................................................................................ ....10
2.14 Section [IP_ADDRESS] Safety endpoints.......................................................................................... ......11
2.15 Appendix B: Section 1 Adverse Events  requiring additional data collection..............................11
2.16 Appendix B: Section 1.13 Hepatotoxicity events ........................................................................11CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 10 November 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN:U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: [ADDRESS_694942] been corrected.
1.1 Section 2 Flowchart
In the flowchart the timing of visit 16A (V16A) and the visit window of +3 days has been added for 
clarity. 
An ‘x’ at visit 2 (Randomisation) for drug accountability has been added as the site should enter the 
date of dispensing the trial product in the interactive web response system (IWRS).
1.2 Section [IP_ADDRESS] Supportive secondary endpoints
Time to rescue medication will only be analysed at the end of the trial and the text describing 
different time points for assessment has  been deleted.
1.[ADDRESS_694943] and Follow-up (visits 16A 
and 17A)
The timing of V16A and visit window of +3 days has been added for clarity. 
1.4 Section 8.4.4 Electrocardiogram – [ADDRESS_694944]-baseline ECGs suggestive of a new myocardial 
infarction (MI), as assessed by [CONTACT_534968]. The rationale for this confirmatory ECG is 
to confirm that the ECG findings suggestive of a new MI are valid.
1.[ADDRESS_694945]. 
Binding antibodies should be seen as all antibodies binding to the drug (semaglutide), a fraction of 
these antibodies may be neutralising.
1.6 Sections 8.7.4 Assessments in case of increased levels of aminotransferases, 12.1
definitions, Appendix B Section 1 Adverse Events requiring additional data collection 
and Appendix B Section 1.13 Hepatotoxicity events
The cut off level for repeat testing of increased levels of aminotransferases has been updated from 
ALT/AST >10x UNL to >5x UNL in section 8.7.4. The rationale is to prompt follow-up of potential 
clinical significant aminotransferase levels.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 10 November 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN:U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 4 of 11
Definition of elevated liver enzymes to be reported as adverse events (AEs) requiring additional 
data collection has been updated in section 12.[ADDRESS_694946] and events fulfilling Hy’s law 
are included underneath the defined seriousness criteria in section 12.1 to clarify that these are 
specific AEs that always fulfil the seriousness criteria. 
The definition of Hy’s law in section 12.1 has been updated to align with the FDA guidance 
document “ Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation” .
1.[ADDRESS_694947] as well.
1.8 Section 12.2 Reporting of adverse events
Figure 12-1 has been updated as the previous AE flow did not contain the full AE process flow as 
described in the protocol text.
1.9 Sections 17 Statistical considerations, 17.3.1 Primary analysis for the primary 
estimand, [IP_ADDRESS] Efficacy endpoints and [IP_ADDRESS] Safety endpoints
The text regarding stratification factors in the statistical section [ADDRESS_694948] been corrected and irrelevant data removed from Table 17.1.
For the primary analysis to the primary estimand, missing data will not be imputed based on the 
stratification factor, but only treatment and treatment adherence/rescue status  i.e. [ADDRESS_694949] in the 
ANCOVA analysis.
The text below the time to event endpoint has been removed from the statistical section as well, 
since the endpoint will only be analysed at the end of the trial.
In Section [IP_ADDRESS] treatment emergent h ypoglycaemic events are defined twice by [CONTACT_86966], thus the 
second paragraph on the definition is deleted.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 10 November 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN:U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 5 of 11
2 Changes
In this protocol amendment:
!Any new text is written in italics.
!Any text deleted from the protocol is written using strike through.
2.1 Section 2 Flowchart
For V16A: 
Visit window (days): +[ADDRESS_694950]
For V2:
‘x’ in Drug accountability.
2.2 Section [IP_ADDRESS] Supportive secondary endpoints
[…]
Time to event endpoint
!Time to rescue medication
This endpoint will be evaluated after week 26, after week [ADDRESS_694951] and Follow-up (visits 16A 
and 17A)
Subject who discontinue trial product prematurely should attend visit 16A, scheduled to take place 
shortly after discontinuation of trial product (+3 days visit window).
2.4 Section 8.4.4 Electrocardiogram – 12 – Lead
12-lead ECGs will be performed as per flowchart (see Section 2) and the assessment must be 
reviewed as described in Section 8.1.[ADDRESS_694952] the ECGs to the central ECG reader as soon as 
possible.
If the central ECG evaluation of a baseline ECG is suggestive of a prior myocardial infarction 
(MI), the investigator will be notified. The investigator should consider if an update of the History 
of cardiovascular disease form is required.
If the central ECG evaluation of a post-baseline ECG is suggestive of new myocardial infarction 
(MI), the investigator will be notified and a confirmatory ECG should be performed., uUnless
already done, the investigator should report this as AE or SAE at investigator’s discretion (see 
Section 12.1).CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 10 November 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN:U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 6 of 11
2.5 Section 8.4.7 Antibodies
Samples which are positive for anti-semaglutide neutralising binding antibodies […]
2.[ADDRESS_694953] >3x UNL and total bilirubin >2x UNL,
the event must be reported as an SAE (see Section 12.1). 
2. ALT or AST >10 5x UNL and total bilirubin ≤2x UNL, 
the event should be reported as an AE requiring additional data collection (see Section 12.1 and 
Appendix B).
For both events prompt repeat testing (at central laboratory) including ALT, AST, ALP and total 
bilirubin should be done and discontinuation of trial product considered. Thereafter, repeat testing 
(at central laboratory) of ALT, AST, ALP and to tal bilirubin should be done regularly until the 
abnormalities return to normal or baseline state. Additional clinical information such as related 
symptoms, risk factors and contributing conditions (e.g. viral hepatitis, autoimmune hepatitis, 
alcoholic hepatitis, hepatobiliary or pancreatic disorders) should be gathered to seek a possible 
cause of the observed laboratory test abnormalities.
2.[ADDRESS_694954] (used/partly used or unused including empty packaging material) can be 
stored at room temperature and must be stored separately from non-allocated trial product. Non-
allocated trial product (expi[INVESTIGATOR_5697], damaged and available) must be accounted as unused at the latest 
at closure of the trial site.
Drug accountability is performed by [CONTACT_36300]. Only dispensed DUNs returned by [CONTACT_423] 
(used/partly used or unused) are accounted for. Drug accountability should be done on tablet level.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 10 November 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN:U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: [ADDRESS_694955] be documented and recorded in IWRS including 
destruction confirmation.
2.9 Section 12.1 Definitions
Serious adverse event
An SAE is an experience that at any dose results in any of the following:
!Death.
!A life-threateningaexperience.
!In-patient hospi[INVESTIGATOR_36220].
!A persistent or significant disability or incapacityc.
!A congenital anomaly or birth defect.
!Important medical events that may not result in death, be life threateninga or require 
hospi[INVESTIGATOR_36221] - based on appropriate medical judgement 
- they may jeopardise the subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in the definition of SAEd. 
Suspi[INVESTIGATOR_534946]. 
[…]
Trial specific serious adverse event
The following laboratory abnormalities must be reported as an SAE:
!ALT or AST >3x UNL and total bilirubin >2x UNL
Additional assessments should be made for events meeting the above criterion (see Section 8.7.4).
The following adverse events must always be reported as an SAE using the important medical event 
criteria if no other seriousness criteria are applicable:
!suspi[INVESTIGATOR_36225]
!risk of liver injury defined as alanine aminotransferase (ALT) or aspartate aminotransferase 
(AST) >3x UNL and total bilirubin >2x UNL, where no alternative aetiology exists (Hy's law).
[…]CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 10 November 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN:U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: [ADDRESS_694956] a special focus (e.g. required by [CONTACT_93420]). The AEs requiring additional data 
collection are:
[…]
!Hepatotoxicity events:
oALT or AST > 10 5x UNL and total bilirubin ≤ 2x UNL
oALT or AST > 3x UNL and total bilirubin > [ADDRESS_694957] discontinuation 
2.10 Section 12.2 Reporting of adverse events
[…]
AEs requiring additional data collection must be reported using both the AE form and the specific 
event form. A specific event form is a form tailored to collect specific information related to the 
individual event (see Appendix B for details about the event sspecific forms and the additional 
information to report).
[…]
An AE is observed 
and reported 
Fulfilling seriousness 
criteria?It is an SAEcomplete:
!AE form ≤ 24 hours
!SIF ≤ 5 calendar days
It is a non-serious AE
complete:
!AE formRequiring 
additional data 
collection?Requiring 
additional data 
collection?Complete:
!Specific event form ≤ 14  calendar daysYes
Complete: 
!Specific event formYes
NoYes Complete:
!Adjudication form ≤ 14 calendar daysYes
AE: adverse event
SAE: serious adverse event
SIF: safety information formAll timelines are from the investigator’s
first knowledge of the event
Events for adjudication are described in chapter 12.7.2Is the event to 
be adjudicated?
Is the event to 
be adjudicated?Complete:
!Adjudication form  ≤ 14 calendar daysYes
Figure 12-1 Initial reporting of AEsCONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 10 November 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN:U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 9 of 11
AE identifiedIs additional data 
collection required?Is the AE to be 
adjudicated and/or 
is the outcome fatal?
AE form≤  24 hours
SIF ≤5 calendar days
Specific event form (AEs 
and SAEs)
SAEs ≤14 calendar days
Is the AE serious or 
non-serious?
AE form
Adjudication form
≤14 calendar days
Source data ≤4 weeks
Non-seriousSerious
NoYes Yes
Queries and follow-up 
requests to be resolved 
≤14 calendar days
AE: adverse event
SAE: serious adverse event
SIF: safety information form 
AEs for adjudication are described in the protocol section 12.7.[ADDRESS_694958] knowledge of the event
No additional action
 No additional actionNo
Figure 12-1 Initial reporting of AEs
2.11 Section 17 Statistical considerations
General considerations
[…]
The randomisation is stratified based on pre-trial therapy at screening (metformin or 
metformin+SU) and descent (Japanese subjects/non-Japanese subjects). In the statistical analyses 
descent is a part of region and pre-trial therapy at screening is referred to as stratification factor.
In statistical analyses where stratification is included, tThe two combinations (metformin;
metformin+SU) in the stratification factor will be included based on the actual information
collected through the eCRF. In case of missing eCRF information the information collected from 
IWRS system will be used.
Table 17–[ADDRESS_694959] (TE) . -0.5% -0.3% -0.1% -3.0 kg -2.0 kg -1.0 kg
Adjusted TE, non-inferiority -0.395% -0.255% -0.055% -2.52 kg -1.67 kg -0.82 kg
Adjusted TE, superiority -0.425% -0.255% -0.085% -2.55 kg -1.70% kg -0.85% kg
Standard deviation 1.1% 1.1% 1.1% 4.0 kg 4.0 kg 4.0 kgCONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 10 November 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN:U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 10 of 11
2.12 Section 17.3.1 Primary analysis for the primary estimand
The primary estimand will be estimated based on the FAS using week 26 measurements from the
in-trial observation period. The primary statistical analysis will be a pattern mixture model using
multiple imputation to handle missing data assuming that the missing data mechanism is missing at
random (MAR). Imputation of missing data at week 26 will be done within 16 8groups of subjects
defined by [CONTACT_36333], stratification factor and whether subjects at week 26; (i) have
discontinued treatment or initiated rescue medication or (ii) still on treatment and have not initiated
rescue medication. It is hereby [CONTACT_534969] 26 are similar in
terms of randomised treatment arm and treatment adherence/rescue status.
Missing values for each group will be imputed as follows:
!An analysis of covariance (ANCOVA) with region and stratification factor as a categorical 
fixed effect sand baseline HbA1c measurement as a covariate will be fitted to observed 
values of the change from baseline in HbA1c at week 26.
!The estimated parameters for location and dispersion will be used to impute [ADDRESS_694960] with missing week 26 data based on region, stratification factor and baseline 
HbA1c. Thus, 100 complete data sets will be generated including observed and imputed 
values.
Analysis used for confirming superiority versus sitagliptin at week 26:
For each of the 100 (now complete) imputed data sets the change from baseline to week 26 will be
analysed using an ANCOVA with treatment, region and stratification factor as categorical fixed 
effects and baseline HbA 1cas covariate. The results obtained from analysing the datasets will be 
combined using Rubin’s rule to draw inference.
2.13 Section [IP_ADDRESS] Efficacy endpoints
[…]
For evaluation of the primary estimand the analysis will be performed separately for week 26, [ADDRESS_694961] or initiated rescue medication
prior to week 26 or at or after week 26. This will result in imputation of missing data within 16 32  
groups of subjects instead of the 16 8groups as described for the week 26 evaluation in
Section 17.3.1. The frequency of missing data is expected to be slightly larger at week 52 and week
78 compared to week 26. The rate of missing data is expected to decline over time.
[…]
Time to event endpoint
!Time to rescue medicationCONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 10 November 2015 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN:U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: [ADDRESS_694962] ratios between each dose levels and sitagliptin will be presented together with
95 % confidence intervals and two-sided p-values for test of no difference. This endpoint will be
evaluated after week 26, after week 52 and after week 78. Furthermore, the endpoint will be 
presented by a Kaplan-Meier plot.
2.14 Section [IP_ADDRESS] Safety endpoints
Classification of Hypoglycaemia:
Hypoglycaemic epi[INVESTIGATOR_36238]-treatment observation period 
only.
Treatment emergent: hypoglycaemic epi[INVESTIGATOR_534943]-treatment observation period (see definition of observation periods 
in Section 17.2).
A treatment emergent hypogl ycaemic epi[INVESTIGATOR_67662] a hypoglycaemic epi[INVESTIGATOR_534944]-treatment observation period (see definition of observation periods in Section 17.2).
2.15 Appendix B: Section 1 Adverse Events requiring additional data collection
!Hepatotoxicity events:
oALT or AST > 510x UNL and total bilirubin ≤ 2x UNL
oALT or AST > 3x UNL and total bilirubin > 2x UNL
oHepatic event Hepatotoxicity leading to trial product discontinuation 
2.16 Appendix B: Section 1.[ADDRESS_694963] > 510x UNL and total bilirubin ≤ 2x UNL
oALT or AST > 3x UNL and total bilirubin > 2x UNL
oHepatic event Hepatotoxicity leading to trial product discontinuation CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 1 of 19
Protocol Amendment
no 2
to Protocol, final version 3
dated 12 November 2015
Trial ID: NN9924-4222
PI[INVESTIGATOR_15597] 3 - vs. DPP-4 inhibitor
Efficacy and long-term safety of oral semaglutide versus sitagliptin
in subjects with type 2 diabetes
Trial phase: 3a
Applicable to all countries
Amendment originator:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 2 of 19
Table of Contents   
Page
Table of Contents.............................................................................................................. ................................2
Table of Figures............................................................................................................... .................................3
Table of Tables................................................................................................................ ..................................3
1 Introduction including rationa le for the protocol  amendment .............................................................4
1.1 Additional eye examinations and additional data collection on diabetic retinopathy....................4
1.2 Investigator’s responsibility in ensuring evaluation and management of certain risk factors 
and complications .............................................................................................................. ............[ADDRESS_694964] to follow-up..............................5
1.4 Other minor adjustments, clarifications  and correction of typographical errors............................5
2 Changes ....................................................................................................................... ...............................7
2.1 Section 2 Flow chart ........................................................................................................ ..............7
2.2 Section [IP_ADDRESS] Supportive s econdary endpoints ...........................................................................7
2.3 Section 5.3.2 B ackground medication ......................................................................................... ..8
2.4 Section 6.4 Rescue criteria................................................................................................. ............8
2.5 Section 6.6 Withdrawal criteria ............................................................................................. ........8
2.6 Section 8.1 Visit procedures ................................................................................................ ..........9
2.7 Section 8.1.4 End-of-treatment (visit 16) and Follow-up (visit 17)...............................................[ADDRESS_694965] and follow-up (visits 16A and 
17A) ........................................................................................................................... ....................9
2.9 Section [IP_ADDRESS] Lost to follow-up .................................................................................................10
2.10 Section 8.4.1 Physical examination ......................................................................................... ....10
2.11 Section 8.4.3 Eye examination.............................................................................................. .......11
2.12 Section 8.4.7 An tibodies................................................................................................... ...........11
2.13 Section 8.5 Laboratory  assessments ......................................................................................... ...11
2.14 Section 8.7.1 Assessments in case of suspi[INVESTIGATOR_534947]..........................................11
2.15 Section 12.1 Definitions ................................................................................................... ...........12
2.16 Section 12.2 Reporting of adverse events................................................................................... .12
2.17 Section 12.7.2 Event ad judication committee..............................................................................13
2.18 Section 17.2 Definiti on of analysis sets................................................................................... ....14
2.19 Section 17.3.1 Primary analysis for the primary estimand ..........................................................14
2.20 Section [IP_ADDRESS] Efficacy endpoints ........................................................................................ ....14
2.21 Section [IP_ADDRESS] Safety endpoints.......................................................................................... ......15
2.22 Section [IP_ADDRESS] Oral Semaglutide .......................................................................................... ....16
2.23 Section 27 References...................................................................................................... ............16
2.24 Reference numbers .......................................................................................................... ............17
2.25 Appendix B, Section 1 Adverse events  requiring additional data collection...............................17
2.26 Appendix B, Section 1.14 Diabetic retinopathy and related complications ................................18
3 References .................................................................................................................... ............................19CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 3 of 19
Table of Figures   
Page
No table of figures entries found.
Table of Tables   
Page
No table of figures entries found.CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 4 of 19
1 Introduction including rationale for the protocol amendment
This protocol amendment introduces:
1. Additional eye examinations and additional data collection on diabetic retinopathy
2. Investigator’s responsibility in ensuring evaluation and management of certain risk factors 
and complications
3. Clarification of the criteria for completion, withdrawal and lost to follow-up
4. Other minor corrections and clarifications
1.1 Additional eye examinations and additional data collection on diabetic retinopathy 
Protocol sections updated: 2, [IP_ADDRESS], 8.4.3, 12.1, 12.2, 17.2, [IP_ADDRESS], [IP_ADDRESS], 27; Appendix B 
section 1 and 1.14 (new).
Transient worsening of diabetic retinopathy is a recognised complication in selected patients with 
diabetes after initiation of intensive antidiabetic treatment1-3. Risk factors for these events include 
long-standing poor glycaemic control and presence of proliferative retinopathy, and initial large 
improvements in blood glucose may be an additional aggravating factor. In a recently completed
cardiovascular outcomes trial with s.c. semaglutide, results indicate an increased risk of events 
related to diabetic retinopathy in subjects treated with semaglutide compared to placebo4.T h e  
majority of the related adverse events were moderate in severity and did not lead to premature 
discontinuation of trial product. , additional eye examinations 
have been implemented in all trials in the PI[INVESTIGATOR_36181]. Also, to further understand this 
safety signal, additional information will be collected for all diabetic retinopathy events reported 
during the trial. As recruitment has been completed, the information will be collected for all 
subjects retrospectively as well as going forward, to the extent that the information is available. 
Furthermore, information to the investigators and subjects related to diabetic retinopathy has been 
added to the protocol (see Section 18) and the subject information. 
1.2 Investigator’s responsibility in ensuring evaluation and management of certain risk 
factors and complications
Protocol sections updated: 8.4.1, [IP_ADDRESS], 27.
, text is added to highlight the investigators responsibility in relation 
to further evaluation of potential incidental thyroid nodules discovered at the physical examination.
In addition, text is added to highlight the investigator’s responsibility in ensuring evaluation and 
management of cardiovascular risk factors and microvascular complications such as diabetic kidney 
disease and diabetic retinopathy.CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: [ADDRESS_694966] to follow-up
Protocol sections updated: 6.6, 8.1, 8.1.4, 8.1.5, [IP_ADDRESS] (new).
The criteria for subject completion, ‘withdrawal’ and ‘lost to follow-up’ respectively are clarified 
and have been made consistent across sections. Lost to follow-up is considered a subcategory to 
withdrawal from trial. In addition, it is emphasised that as soon as contact [CONTACT_1639] a subject is lost, efforts 
must be made to regain contact [CONTACT_36358]. 
Only if contact [CONTACT_36359]. 
Because this trial is not an outcome trial the terminology ‘health status’ is replaced with “relevant 
safety information” - the purpose of which is to follow up on any adverse events or pregnancy, and 
not to determine if a subject completes the trial or not.
1.4 Other minor adjustments, clarifications and correction of typographical errors
Laboratory analysis
Protocol sections updated: 8.4.7, 8.5, 8.7.1.
The protocol is updated to reflect that on suspi[INVESTIGATOR_534948].
The protocol currently specifies that the in vitro neutralising antibody assays will be performed by 
[CONTACT_3454], however it may be decided by [CONTACT_135572] (Celerion) will perform the assay.
Statistical considerations
Protocol sections updated: 17.3.1, [IP_ADDRESS].
For the pattern mixture model using multiple imputation, the number of imputations will be 
increased from [ADDRESS_694967] model used for the time to event endpoint has been clarified.
Adverse events for Adjudication
Protocol sections updated: 12.7.2.
Table 12-2 has been aligned with Table 12-1 reflecting that unstable angina pectoris (UAP) requires
hospi[INVESTIGATOR_36265].CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 6 of 19
Initial reporting of AEs
Protocol sections updated: 12.2.
Figure 12-[ADDRESS_694968] the legislation of “within” timelines 
which is now interpreted as “less than”.
Background medication
Protocol sections updated: 5.3.2.
Section has been updated to specify that dose changes of background medication is allowed in case 
of a safety concern.
Rescue criteria
Protocol sections updated: 6.4.
The section has been updated to specify that rescue medication should be offered until end of 
treatment and not end of trial as previously specified. After end of treatment, the protocol section 
5.4 applies.CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 7 of 19
2 Changes
In this protocol amendment:
!Any new text is written in italics.
Any text deleted from the protocol is written using strike through.
2.1 Section 2 Flow chart
For V12, V16 and V16A: ‘ x’ in ‘Eye examination’
Footer Description
X5Dilated fundoscopy/fundus photography performed within [ADDRESS_694969] examination.
Dilated fundoscopy/fundus photography must be performed again:
!at V12 or within 5 weeks prior to or after V12 (applicable for all subjects)
!at V16 or within 5 weeks thereafter (for subjects completing treatment)
!at V16A or within 5 weeks thereafter, and again within 5 weeks prior to V16 
(for subjects who have prematurely discontinued trial product)
2.2 Section [IP_ADDRESS] Supportive secondary endpoints
Supportive secondary safety endpoints
!Number of TEAEs during exposure to trial product, assessed up to approximately 83 weeks*
!Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_534932], assessed up to approximately 83 weeks*
!Treatment emergent severe or BG confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_534949], assessed up to approximately 83 weeks (yes/no)
Change from baseline to week 26, 52 and 78 in:
!Haematology
!Biochemistry
!Calcitonin
!Pulse
!Systolic blood pressure
!Diastolic blood pressure
!Electrocardiogram (ECG) category
!Physical examination (week 52 and 78 only)
!Eye examination category (week 52 and 78 only)CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 8 of 19
2.3 Section 5.3.2 Background medication
After inclusion (V1), subjects must continue anti-diabetic pre-trial background medication (i.e. 
metformin alone or in combination with SU) throughout the entire trial. The background medication 
must be maintained at the stable, pre-trial dose and at the same frequency during the whole 
treatment period unless rescue medication is needed (see Section 6.4) ,or if the subject has 
unacceptable hypoglycaemia on a background of SU in which case the dose of SU can be reduced 
or if another safety concern related to the background medication arises.
2.[ADDRESS_694970] of treatment on 
glycaemic parameters, rescue criteria will be applied from week 8 and onwards. If any of the FPG 
values (including fasting SMPG) exceed the limits outlined below and no intercurrent cause of the 
hyperglycaemia can be identified, a confirmatory FPG (at central laboratory) should be obtained by 
[CONTACT_36282] a re-test:
!14.4 mmol/L (260 mg/dL) from week 8 to end of week 13
!13.3 mmol/L (240 mg/dL) from week 14 to end of week 25
!11.1 mmol/L (200 mg/dL) from week [ADDRESS_694971] should be offered 
rescue medication (i.e. intensification of existing anti-diabetic background medication and/or 
initiation of new anti-diabetic medication). 
In addition, subject should be offered rescue medication if:
!HbA 1c (at central laboratory) > 8.5% (69.4 mmol/mol) from week [ADDRESS_694972]’s request to withdraw from the 
trial must always be respected.
A subject who does not complete the trial is also considered withdrawn from the trial. Hence, a 
subject is considered withdrawn from trial if the following applies:
!Subject withdrew consent
!Subject is lost to follow up (only to be used if there is no contact [CONTACT_534970]’s last scheduled visit, see Sections 8.1.4 - [IP_ADDRESS])
!Other (subject deceased or closure of trial site)CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 9 of 19
2.6 Section 8.1 Visit procedures
[…]
If a subject is unable or unwilling to attend all subsequent visit(s) the investigator should at least 
aim to have the subject attend the V8, V12 and the End-of-treatment visit (V16) as these visits 
should be performed for all subjects (except subjects who withdraw informed consent, see 
Section 8.1.6).
The following sections describe the assessments and procedures. These are also included in the flow 
chart (see Section 2). Informed consent must be obtained before any trial related activity, see 
Section 18.2.
2.7 Section 8.1.4 End-of-treatment (visit 16) and Follow-up (visit 17)
At V16 the subject should be reminded about the importance of attending the follow-up visit (V17). 
If the subject, nonetheless, does not attend V17, the site should make efforts to obtain contact [CONTACT_36361].
A trial completer is defined as a subject who attends, or are in contact [CONTACT_36362], at the subject’s 
last scheduled visit. For subjects who complete treatment, the last scheduled visit is V17. (For 
subjects who discontinue trial product, see Section 8.1.5).
In case the subject cannot be reached (by [CONTACT_36286]) at the scheduled visit [ADDRESS_694973] (e.g. 
close relatives), relevant physicians, medical records and locator agencies (if allowed according to 
local law) to collect health status. If no health status can be collected, the subject should be 
considered lost to follow.
2.[ADDRESS_694974] and follow-up (visits 16A 
and 17A)
Subjects who discontinue trial product prematurely should attend visit 16A, scheduled to take place 
after discontinuation of trial product (+3 days visit window). Visit 17A should be scheduled 5 
weeks (+3 days visit window) after the last date on trial product. A treatment discontinuation 
session must be performed in the IWRS at visit 16A (see Section 10).
Subjects should continue with the originally scheduled site contacts after visit 17A and up to and 
including visit 16. If necessary, in order to retain the subject in the trial, site visits can be replaced 
by [CONTACT_36287] V17A. However, as a minimum, these subjects should be asked to attend 
the scheduled V8 at week 26, V12 at week 52 and End-of-treatment (V16) at week 78. if a subject 
is unable or unwilling to attend all subsequent visit(s), the investigator should at least aim to have 
the subject attend V8 (week 26), V12 (week 52) and End-of-treatment (V16) (week 78) as these CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 10 of 19
visits should be performed for all subjects, if at all possible (except subjects who withdraw consent, 
see Section 8.1.6) . 
In case the subject cannot be reached (by [CONTACT_36286]) at the scheduled visit [ADDRESS_694975] (e.g. 
close relatives), relevant physicians, medical records and locator agencies (if allowed according to 
local law) to collect health status. If no health status can be collected, the subject should be 
considered lost to follow up. 
A subject who prematurely discontinues trial product is still considered a trial completer if the 
subject attends or is in contact [CONTACT_36362], at the subject’s last scheduled visit.
For subjects who prematurely discontinue trial product, the last scheduled visit is V16 (or V17A if it 
is scheduled after V16). (For subjects completing treatment, see Section 8.1.4). The site should in 
due time prepare for establishing contact [CONTACT_534971] 
V8, V12 and V16 respectively, if the subject has agreed to attend these visits.
2.9 Section [IP_ADDRESS] Lost to follow-up
In case contact [CONTACT_36365], the site should immediately undertake efforts to 
re-establish contact. If the subject cannot be reached (by [CONTACT_36286]) and the 
subject has consented to it, the site should consult the contacts provided by [CONTACT_423] (e.g. close 
relatives), relevant physicians, medical records and locator agencies (if allowed according to local 
law) in an attempt to regain contact [CONTACT_36366]. Efforts to regain contact [CONTACT_36367]’s last scheduled 
visit: V17 for subjects who have completed treatment, whereas for subjects who have discontinued 
trial product prematurely the last scheduled visit is V16 (or V17A if it is scheduled after V16). Only 
if contact [CONTACT_534972]’s last 
scheduled visit, can the subject be considered lost to follow up (see Section 6.6).
2.10 Section 8.4.1 Physical examination
A physical examination will be performed by [CONTACT_36291] (see 
Section 2 and 8.1.7 ). A physical examination must include:
!General appearance
!Head, ears, eyes, nose, throat, neck
!Thyroid gland*
!Respi[INVESTIGATOR_2133]
!Cardiovascular system
!Gastrointestinal system including mouth
!Musculoskeletal systemCONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 11 of 19
!Central and peripheral nervous system
!Skin
!Lymph node palpation
*Please note that the diagnostic evaluation of thyroid nodules should be in accordance with the 
American Thyroid Association Management Guidelines or any updates hereof62, and adapted to 
local treatment guidelines if applicable.
2.11 Section 8.4.3 Eye examination
Dilated fundoscopy/fundus photography will be performed as per flow chart (see Section 2) by [CONTACT_36369]. Fundoscopy requires pharmacological dilation of both 
pupi[INVESTIGATOR_8324]. Results of the dilated fundoscopy/fundus photography will be interpreted by [CONTACT_093] 
(see Section 8.1.7).
2.[ADDRESS_694976], IgE anti-semaglutide antibodies and PK samples will be 
analysed by a special laboratory and orNovo Nordisk A/S (see Sections 8.4.7, 8.6.[ADDRESS_694977] be used.
2.14 Section 8.7.1 Assessments in case of suspi[INVESTIGATOR_36194]
[…]
In case of suspi[INVESTIGATOR_36194], the trial product should promptly be interrupted (NO 
treatment discontinuation call should be made in IWRS before diagnosis of acute pancreatitis is 
confirmed). Appropriate additional examinations must be performed, including local or central
measurement of amylase and lipase.CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: [ADDRESS_694978] a special focus (e.g. required by [CONTACT_93420]). The AEs requiring additional data 
collection are:
!Acute coronary syndrome (myocardial infarction or hospi[INVESTIGATOR_36193])
!Cerebrovascular event (stroke or transient ischaemic attack (TIA))
!Heart failure requiring hospi[INVESTIGATOR_11956]
!Pancreatitis 
!Neoplasm (excluding thyroid neoplasm)
!Thyroid disease (including thyroid neoplasm)
!Renal event 
!Hypersensitivity reactions
!Acute gallstone disease
!Medication error (concerning trial products):
oAdministration of wrong drug. 
Note: Use of wrong DUN is not considered a medication error.
oWrong route of administration.
oAdministration of an overdose with the intention to cause harm (e.g. suicide attempt).
oAccidental administration of a higher dose than intended. A higher dose is a dose of 
at least one tablet more than the intended dose; however the administered dose must 
deviate from the intended dose to an extent where clinical consequences for the trial 
subject were likely to happen as judged by [CONTACT_093], although they did not 
necessarily occur.
!Lactic acidosis
!Creatine kinase (CK) > 10x UNL
!Hepatotoxicity events:
oALT or AST > 5x UNL and total bilirubin ≤ 2x UNL
oALT or AST > 3x UNL and total bilirubin > [ADDRESS_694979] discontinuation 
!Diabetic retinopathy and related complications
2.[ADDRESS_694980] to event
adjudication [Note: In this document only the additional event is shown, all other events are 
unchanged]CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 13 of 19
Event Specific event form Event adjudication
Diabetic retinopathy and related complications Yes No
[Note: In the below figure all “ ≤” are substituted with “<”. The text in boxes will align once the 
update is done]:
AE identifiedIs additional data 
collection required?Is the AE to be 
adjudicated and/or 
is the outcome fatal?
AE form ≤<  24 hours
SIF ≤<5 calendar days
Specific event form (AEs 
and SAEs)
SAEs ≤<14 calendar 
days
Is the AE serious or 
non-serious?
AE form
Adjudication form
≤<14 calendar days
Source data ≤<4 weeks
Non-seriousSerious
NoYes Yes
Queries and follow-up 
requests to be resolved 
≤<14 calendar days
AE: adverse event
SAE: serious adverse event
SIF: safety information form 
AEs for adjudication are described in the protocol section 12.7.2All timelines are from investigators first knowledge of the event
No additional action
 No additional actionNo
Figure 12-1 Initial reporting of AEs
2.17 Section 12.7.2 Event adjudication committee
Table 12-2 Adverse events for adjudication [Note: Only shown is the event with updated event 
description, all other events are unchanged]
Events Description Adjudication outcome
Acute Coronary Syndrome !Acute Coronary Syndrome conditions include: 
!ST-elevation acute myocardial infarction 
(STEMI)
!Non-ST elevation acute myocardial infarction 
(NSTEMI)
!Silent MI 
!Unstable angina pectoris (UAP ) requiring 
hospi[INVESTIGATOR_11956]!Acute myocardial 
infarction (STEMI or 
NSTEMI), silent MI
!Unstable angina pectoris 
requiring hospi[INVESTIGATOR_534950]. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 14 of 19
2.18 Section 17.2 Definition of analysis sets
On-treatment: This observation period is a subset of the in-trial observation period and represents 
the time period in which a subject is considered exposed to trial product. For adjudicated events, 
ECGs, eye examination category, anti-semaglutide antibodies a nd AEs including hypoglycaemic 
epi[INVESTIGATOR_534951] (i) the follow-up visit V17, (ii) the follow-up prematurely discontinuation visit V17A, (iii) 
the last date on trial product +38 days or (iv) the end-date for the in-trial observation period will be 
used.
2.19 Section 17.3.1 Primary analysis for the primary estimand
Missing values for each group will be imputed as follows:
!An analysis of covariance (ANCOVA) with region, stratification factor as categorical fixed 
effects and baseline HbA 1cmeasurement as a covariate will be fitted to observed values of 
the change from baseline in HbA 1cat week 26.
!The estimated parameters for location and dispersion will be used to impute [ADDRESS_694981] with missing week 26 data based on region, stratification factor and 
baseline HbA 1c. Thus, 100 1000 complete data sets will be generated including observed and 
imputed values.
Analysis used for confirming superiority versus placebo at week 26:
For each of the 100 1000 (now complete) imputed data sets the change from baseline to week 26 in 
HbA 1cwill be analysed using an ANCOVA with treatment, stratification factor and region as 
categorical fixed effects and baseline HbA 1cas covariate. The results obtained from analysing the 
datasets will be combined using Rubin’s rule55to draw inference.
2.20 Section [IP_ADDRESS] Efficacy endpoints
Continuous efficacy endpoints 
[…]
For evaluation of the primary estimand the analysis will be performed separately for week 26, [ADDRESS_694982] or initiated rescue 
medication prior to week 26 or at /or after week 26. This will result in imputation of missing data 
within [ADDRESS_694983] available data in one of the 12 groups, the imputation 
will be made within the 8 groups specified for the primary evaluation. The frequency of missing 
data is expected to be slightly larger at week 52 and week 78 compared to week 26. The rate of 
missing data is expected to decline over time.
[…]CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 15 of 19
Handling of missing data for the response status of the above categorical endpoints will be 
determined from the imputed continuous responses. A total of 100 1000 imputed data sets will be 
created based on the same models as used to analyse HbA 1cand body weight. For the secondary 
estimand the MMRM based analysis will be implemented in a MI setting. The imputed complete 
data sets will be analysed using a logistic regression model with treatment, stratification factor and 
region as categorical fixed effects and baseline response as covariate (i.e. baseline HbA 1c for binary 
HbA 1c endpoints, baseline weight for binary weight endpoints and both baseline HbA 1c and body 
weight for the binary endpoint that combines both parameters). Inference comparing treatments will 
be drawn using Rubin’s rule55.
Time to event endpoint
!Time to rescue medication
Subjects completing the study without need for rescue medication will be censored at the time point 
of actual date of last trial product. Start time is date of first trial product. Time to rescue medication 
will be described and compared for each of the oral semaglutide dose level versus sitagliptin [ADDRESS_694984] ratios between each dose levels and sitagliptin will be presented 
together with 95 % confidence intervals and two-sided p-values for test of no difference. 
Furthermore, the endpoint will be presented by a Kaplan-Meier plot. 
2.21 Section [IP_ADDRESS] Safety endpoints
Other safety endpoints
[…]
Other safety endpoints
Change from baseline to week 26, 52 and 78 in:
!Amylase
!Lipase
!Pulse
!Systolic blood pressure
!Diastolic blood pressure
[…]
Change from baseline to week 26, 52 and 78 in:
!Haematology 
!Biochemistry (except for amylase and lipase)
!Calcitonin
!ECG evaluationCONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 16 of 19
!Physical examination (week 52 and 78 only)
!Eye examination category (week 52 and 78 only)
2.22 Section [IP_ADDRESS] Oral Semaglutide
Diabetic retinopathy complications
A transient worsening of diabetic retinopathy is a recognised complication in selected patients with 
diabetes after initiation of intensive antidiabetic treatment63-65. Risk factors for these events include 
long-standing poor glycaemic control and presence of proliferative retinopathy, and initial large 
improvements in blood glucose may be an additional aggravating factor. Several studies have, 
however, documented long-term beneficial effects of intensive glycaemic treatment in reducing 
retinopathy progression66,67even in intensively treated patients who experienced early worsening64. 
In a cardiovascular outcomes trial with s.c. semaglutide, results indicate an increased risk of events 
related to diabetic retinopathy in subjects treated with semaglutide compared to placebo68. As a 
precaution in this trial, all subjects are required to have a fundus photography or dilated 
fundoscopy performed before enrolment into the trial; moreover, subjects with proliferative 
retinopathy or maculopathy requiring acute treatment will be excluded. As part of good diabetes management the investigator is encouraged to ensure adequate monitoring and treatment of 
diabetic retinopathy in subjects enrolled into the trial
69.
General precautions 
All subjects will be included after a thorough evaluation with regards to in- and exclusion criteria 
defined in order to ensure that subjects are eligible for trial treatment. There are also strict 
glycaemic rescue criteria in place to ensure acceptable glycaemic control during the trial. If rescue 
medication is required, it should be in accordance with ADA/European Association for the Study of 
Diabetes25,26(excluding GLP-1 RAs, DPP-4 inhibitors, amylin analogues and SGLT-2 inhibitors). 
It is the responsibility of the investigator to ensure the best possible care of the subject. This 
includes adequate glycaemic control, appropriate risk factor modification such as optimal 
treatment of hypertension, dyslipi[INVESTIGATOR_36268], as well as regular 
monitoring and treatment of diabetic kidney disease and diabetic retinopathy69.
2.23 Section 27 References
62. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 
American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133.
63. Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid 
tightening of blood glucose control leads to transient deterioration of retinopathy in insulin CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 17 of 19
dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed). 1985;290(6471):811-
5.
64. The Diabetes Control and Complications Trial Research Group. Early worsening of 
diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 
1998;116(7):874-86.
65. Varadhan L, Humphreys T, Walker AB, Varughese GI. The impact of improved glycaemic 
control with GLP-[ADDRESS_694985]. 2014;103(3):e37-9.
66. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes ([LOCATION_006]PDS 33). [LOCATION_006] 
Prospective Diabetes Study ([LOCATION_006]PDS) Group. Lancet. 1998;352(9131):837-53, Erratum 
1999; 354: 602.
67. The Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye 
Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On 
(ACCORDION) Study Group. Persistent Effects of Intensive Glycemic Control on 
Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) Follow-On Study. Diabetes Care. 2016;39(7):1089-100.
68. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and 
Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016.
69. American Diabetes Association. Standards of medical care in diabetes - 2016. Diabetes 
Care. 2016;39 (Suppl. 1).
2.[ADDRESS_694986] be 
completed in the eCRF in addition to the AE form:
!Acute coronary syndrome (myocardial infarction or hospi[INVESTIGATOR_36193])
!Cerebrovascular event (stroke or TIA)
!Heart failure requiring hospi[INVESTIGATOR_11956]
!Pancreatitis
!Neoplasm (excluding thyroid neoplasm)
!Thyroid disease (including thyroid neoplasm)
!Renal event
!Hypersensitivity reactions
!Acute gallstone disease
!Medication error (concerning trial products):CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 18 of 19
oAdministration of wrong drug. 
Note: Use of wrong DUN is not considered a medication error.
oWrong route of administration.
oAdministration of an overdose with the intention to cause harm (e.g. suicide 
attempt).
oAccidental administration of a higher dose than intended. A higher dose is a dose of 
at least one tablet more than the intended dose; however the administered dose must 
deviate from the intended dose to an extent where clinical consequences for the trial 
subject were likely to happen as judged by [CONTACT_093], although they did not 
necessarily occur.
!Lactic acidosis
!Creatine kinase (CK) > 10x UNL
!Hepatotoxicity events:
oALT or AST > 5x UNL and total bilirubin ≤ 2x UNL
oALT or AST > 3x UNL and total bilirubin > 2x UNL
oHepatic event leading to trial product discontinuation
!Diabetic retinopathy and related complications
2.[ADDRESS_694987] be reported, if available:
!Signs and symptoms associated with the event
!Results of the eye examination 
!Treatment for and complications of the event
!Contributing conditionsCONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 14 November 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 19 of 19
3 References
1. Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid 
tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed). 1985;290(6471):811-5.
2. The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic 
retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116(7):874-86.
3. Varadhan L, Humphreys T, Walker AB, Varughese GI. The impact of improved glycaemic 
control with GLP-[ADDRESS_694988]. 2014;103(3):e37-9.
4. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and 
Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016.CONFIDENTIAL
Local Amendment FR n°1
CONFIDENTIALDate: 22 January 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 1o f  6
Local Amendment
no 1-FR
Trial ID: NN9924-4222
PI[INVESTIGATOR_15597] 3 - vs. DPP-4 inhibitor
Efficacy and long-term safety of oral semaglutide versus sitagl iptin
in subjects with type 2 diabetes
Applicable to FRANCE
Amendment originator:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Acc ess to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Local Amendment FR n°1
CONFIDENTIALDate: 22 January 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 2o f  6
Table of contents   "Double click to update Table of Content" 
Page 
1 Introduction including rationale for the local amendment ...... ............................................................. 3  
2 Changes ....................................................... ............................................................... ................................ 4  CONFIDENTIAL
Local Amendment FR n°1
CONFIDENTIALDate: 22 January 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 3o f  6
1Introduction including rationale for the local amendment
The rationale for issuing this substantial amendment is to add 2 new sites  and to delete one site that 
withdrawn its participation. 
New sites : 
Deletion of site form Nantes: 
Attachment II and List of investigators are updated accordingly . 
In this protocol amendment: 
xAny new text is written in italics.
xAny text deleted from the protocol is written using strike thro ugh.CONFIDENTIAL
Local Amendment FR n°1
CONFIDENTIALDate: 22 January 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 4o f  [ADDRESS_694989] of investigators to NN9924-4222: 
Attachment II –Addition of new sites 
Investigator: Name:
[CONTACT_1641]:
Address:
Tel:
Fax:
E-mail:
Investigator: Name:
[CONTACT_1641]:
Address:
Tel:
Fax:
E-mail:CONFIDENTIAL
Local Amendment FR n°1
CONFIDENTIALDate: 22 January 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 5o f  6
Deletion of site: 
Investigator: Name:
[CONTACT_1641]:
Address:
Tel:
Fax:
E-mail
1.List of Investigators –Addition of a new sub-investig ator at site  2 new sites ( and 
and deletion of site  CONFIDENTIAL
Local Amendment FR n°1
CONFIDENTIALDate: 22 January 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 6o f  6CONFIDENTIAL
Local Amendment FR n°2
CONFIDENTIALDate: 03 March 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 1 of 6
Local Amendment
no 2-FR
Trial ID: NN9924-4222
PI[INVESTIGATOR_15597] 3 - vs. DPP-4 inhibitor
Efficacy and long-term safety of oral semaglutide versus sitagliptin
in subjects with type 2 diabetes
Applicable to FRANCE
Amendment originator:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Local Amendment FR n°2
CONFIDENTIALDate: 03 March 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 2 of 6
Table of contents   "Double click to update Table of Content" 
Page
1 Introduction including ration ale for the loca l amendment ...................................................................3
2 Changes ....................................................................................................................... ...............................4CONFIDENTIAL
Local Amendment FR n°2
CONFIDENTIALDate: 03 March 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 3 of 6
1 Introduction including rationale for the local amendment
The rationale for issuing this substantial amendment is to add 1 new site, to modify the Investigator
of one site and to add sub-investigators at one site.
- New site :
- Modification of the Investigator for the site from  (site  due to change in local
organisation and the existing Investigator become an investigator from satellite’s site:
and addition of a satellite site :  
- Addition of a new sub-investigator :
Attachment II and List of investigators are updated accordingly.
In this protocol amendment:
!Any new text is written in italics.
!Any text deleted from the protocol is written using strike through.CONFIDENTIAL
Local Amendment FR n°2
CONFIDENTIALDate: 03 March 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 4 of 6
2 Changes
The following changes to Attachment II to NN9924-4222:
1.Attachment II – Addition of a new site and change of Investigator to another site with new
satellite site associated
Investigator: Name:
[CONTACT_1641]/
qualification:
Address:
Tel:
Fax:
E-mail:
Modification of the PI [INVESTIGATOR_534952]:
Investigator:Name:
[CONTACT_1641]/
qualification :
Address:
Tel:
Fax:
E-mail:CONFIDENTIAL
Local Amendment FR n°2
CONFIDENTIALDate: 03 March 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 5 of 6
Investigator: Name:
[CONTACT_1641]/
qualification:
Address:
Tel:
Fax:
E-mail:
Satellite site:
Name:
[CONTACT_1641]/
qualification:
Address:
Tel:
Fax:E-mail:CONFIDENTIAL
Local Amendment FR n°2
CONFIDENTIALDate: 03 March 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 2.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: [ADDRESS_694990] of Investigators – Addition of 1 new sub-investigator at site , modification of the 
Investigator at site  addition of 2 new sub-investigators at site and addition of a new 
siteCONFIDENTIAL
Local Amendment FR n°3
CONFIDENTIALDate: 02 May 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 1 of 4
Local Amendment
no 3-FR
Trial ID: NN9924-4222
PI[INVESTIGATOR_15597] 3 - vs. DPP-4 inhibitor
Efficacy and long-term safety of oral semaglutide versus sitagliptin
in subjects with type 2 diabetes
Applicable to FRANCE
Amendment originator:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Local Amendment FR n°3
CONFIDENTIALDate: 02 May 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 2 of 4
Table of contents   "Double click to update Table of Content" 
Page
1 Introduction including ration ale for the loca l amendment ...................................................................3
2 Changes ....................................................................................................................... ...............................4CONFIDENTIAL
Local Amendment FR n°3
CONFIDENTIALDate: 02 May 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: 3 of 4
1 Introduction including rationale for the local amendment
The rationale for issuing this substantial amendment is to add sub-investigators at 4 sites.
- Addition of a new sub-investigators : 
o  
o  
 
o
 
o   
 
List of investigators is updated accordingly.
In this protocol amendment:
!Any new text is written in italics.
!Any text deleted from the protocol is written using strike through.CONFIDENTIAL
Local Amendment FR n°3
CONFIDENTIALDate: 02 May 2016 Novo Nordisk
Trial ID: NN9924-4222 Version: 1.0
UTN: U1111-1168-4339 Status: Final
EudraCT No.: 2015-001351-71 Page: [ADDRESS_694991] of Investigators – Addition of 1 new sub-investigator at sites   and .CONFIDENTIAL